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Abstract 
Abstract 
Cardiovascular disease (CVD) is one of the main causes of death in western society. 
Platelet activation, thrombus formation and plaque rupture are all central events in the 
pathogenesis of acute coronary syndromes, therefore therapies targeted at controlling 
platelet numbers and aggregation are likely to be beneficial in the treatment of CVD. 
Megakaryocytes (MKs) which are the precursors to platelets are an ideal target for 
these therapies, however the intrinsic factors that regulate the production and shedding 
of platelet precursors are poorly understood. Recent studies identified that MKs 
express functional NMDA-type glutamate receptors similar to those found in the CNS 
and that antagonism of these receptors prevents normal MK differentiation and platelet 
function. This thesis investigates glutamate signalling within MKs further, focusing on 
the glutamate release capability of MK cells and the mechanisms involved. Using 
molecular and cellular techniques it was demonstrated that MK cells expressed 
numerous regulatory proteins required for vesicular glutamate release, including core 
SNARE proteins, VAMP, SNAP-23 and syntaxin; specific glutamate-loading vesicle 
proteins, VGLUTI and VGLUT2; and glutaniate transporters, EAATI and EAAT2. 
Active vesicle recycling was observed in MK cells using a fluorescent reporter and an 
enzyme-linked fluorimetric assay confirmed that MK cells constitutively released 
glutamate and that glutamate release levels increased significantly following MK 
differentiation. Transient transfection of the human cell line MEG-01 with tetanus 
toxin, which disables vesicle recycling, induced a 30% decrease (P<0.001) in released 
glutamate compared to empty vector controls. In contrast, over-expressing VGLUTI 
caused a 41% increase (P<0.001) in glutamate release activity of MEG-01 cells 
compared to controls. 
These data demonstrate that MK cells regulate glutamate exocytosis through specific 
vesicular proteins , indicating that glutamate signalling may 
be a potential target for 
CVD therapies. Also the observations that MKs both release and recycle glutamate 
indicates an important role for glutamate signalling from these cells in autocrine and 
paracrine interactions within the bone marrow microenvironment. 
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Chapter 1: Introduction 
LI Cardiovascular disease 
1.1.1 Prevalence and Mortality statistics 
Statistics released by the British Heart Foundation in 2006 (\vNv"\-. heartstats. oI-, -') 
indicate that diseases of the heart and circulatory system, cardiovascular discýiscs 
(CVD), remain the main cause of death in the UK. Approximately four in everv ten 
people die from CVD, and in 2004 it accounted for more than 216,000 deaths. The t\\. o 
main forms of CVD are coronary heart disease (CHD) which accounts for 
approximately half of all deaths by CVD, and stroke which accounts for about a 
quarter of all deaths from CVD. 
CHD is the most common cause of death in the UK and it is estimated that more than 
one in six women and one in five men die from the disease. In total there were just 
over 147,000 deaths caused by heart disease in the UK in 2003, CHD by itself was 
responsible for over 114,000 of these deaths and approximately 33.500 deaths were 
caused by other forms of heart disease (Figure 1.1). Although there is a higher 
incidence of CVD in the elderly, it is also one of the main causes of premature death in 
the UK (death before the age of 75), leading to over 65,000 premature deaths in the 
UK in 2003. 
Since the early 1970s the UK has seen a decrease in the death rates from CVD. and in 
the past 10 years they have fallen by 37% for people under 75 years. Since the late 
1970s death rates from CHID have also fallen. and in the last 10 years have decreased 
1)ý- 44% for people under 65 years. However in recent years CHID death rates have 
hccii falling slo\\-cr in the younger age groups, and fastest in the 55-64 year age group 
(Figtit-c L-2). In the last 10 years the death rate due to stroke has seen a decrease also. 
thet-c has been a 2231) o 
decrease in mortality under the age of 65 years. In recent \Cal'. s 
death 1-atcs due to stroke have declined at a slo\\ci- rate than previously, particularly in 
the vouiwcr a(le oroups as sceii with CHID. ý' CIN 
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Figure I. I: Causes of death in the lJnited Kingdom in 2003. Coronary heart disease (CHD). 
stroke and other forms of cardiovascular disease (CVD) are the main causes of death un the 
United Kingdom for both males and females. 
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Figure 1.2: Male and female death rates per 100,000 population from coronar, *, heart 
disease (CHD) in the United Kingdom, from 1968 until 2003. UK death rates from CHD 
remain higher in males than in females, although death rates in younger males are decreasing 
more than those in females of a similar a2e. Since the late 1970s death rates from ClID have Cý 
fallen, and in the last 10 years have decreased by 44% for people under 65 years. However in 
recent years CHD death rates have been falling sloxver in theyounger age groups. and fastest 
in the 55-64 year age group. 
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In the t-,, K death rates from CHD remain higher in males than in females. althOL1011 
death rates in younger males are decreasing more than those in females of a similar 
age. Also, as well as differences bemeen sexes. there are also variations between 
regions. CHID mortality rates are highest in the North of England and Scotland. IoNvest 
in the South of England, and intermediate in Wales and Northern Ireland. 
The World wide death rate from CHD is generally on the decrease Lis mirrored by the 
statistics for the UK. However despite recent improvements, the death rate from CHD 
in the UK is still among the highest in the developed woi-ld. In Eastern and Ccntral 
Europe, where death rates have been rising rapidly recently, the death rates are 
generally higher than in the UK, but among developed countries only Ireland and 
Finland have a higher rate than the UK (Figure 1.3). 
1.1.2 Current therapies 
The number of operations carried out to treat CHD has increased dramatically oN'cr the 
last twenty years. In the UK alone approximately 415,000 inpatient cases are treated 
for CHD in NHS hospitals each year, with around 58,000 percutaneous transluminal 
coronary angioplasties (PTCA) and '10,000 coronary artery bypass surgeries (CABG) 
taking place per annum. These procedures are extremely invasive, therefore there has 
been extensive research into drugs to treat and prevent CVD. In the last twenty NVM*s 
according to statistics released by the British Heart Foundation, diuretics have been 
the most commonly prescribed drug used in the prevention of CVD. However, there 
has also been an increase in the number of prescriptions for drugs aimed at prc\ýeiiting 
clotting in the blood, namely. antiplatelet, and anticoagulant drugs. Megakaryocytes. 
among the rarest of haernatopoletic cells. differentiate and produce platelcts \'Ia 
intermediate cytoplasmic extensions known as proplatelets (Shivdasanj, 2001, Italiaiio. 
. Jr. ýind 
ShiN-dasani, 22003) (for a more in-depth review of platelets and megakai-\-()c\ tes 
sce Inti-odLiction 1.2). Platelets have an important, but sometimes under-estiniated role 
in cardiovascular disease (Willotigliby et al.. 2002a). PlaqLic rupture exposes collagen 
', ind \, on Willebrand factor (NNN'f) resultHig in platelct adhesion, platelet ýictl\-ation. 
clottino ýictlvation and agoi, coation leading to occlusive thrornbtis formation. and the 
patliogenesis ofýicute coronary s\ ndrornes (ACS) such as stable an(-, ina pectoris aiiý] 
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acute myocardial infarction (A. %ll) (Harding et al.. 2002a. Willoughby et al.. 2002b) 
and ischaernic complications followiiiu, percutaneous coronary intervention (PCI). 
In the UK over the last twenty years there has been a forty fold increase in the 
prescription of antiplatelet drugs. Antiplatelet drugs are predominantly directed al'al st Cý 11 
platelets and function by inhibiting platelet aggregation via inactivation of tile 
glycoprotein (GP) Ilb/Illa receptors on platelets (Harding et al.. 2002b). 
Aspirin is currently the most widely used antiplatelet drug for the treatment of CVD. 
Aspirin exerts its antithrombotic effects via the irreversible acetylation of the platclet 
cyclo-oxygenase (COX-1) enzyme inhibiting the conversion of arachidonic acid (.. \A) 
to prostaglandin G2 and H2 (PGG/H2). The end result is a reduction in the production 
of Thromboxane A2 (TXA2'), a compound with vasoconstrictor and platelet 
aggregation properties, which is produced from PGG/H) (Figure 1.4) (Awtrýý and 
Loscalzo, 2000a). However, aspirin has several adverse side effects such as gastric 
ulcers, impaired platelet function with resultant haernorrhagic complications, and renal 
failure. Studies have also suggested that there is an increased risk of haemorrhagic 
stroke in patients treated with aspirin in the setting of an AMI or acute ischemic 
stroke. Additionally, aspirin affects only one of many pathways leading to platelet 
activation and therefore is only a relatively weak antiplatelet drug, and a minority of 
patients appear to be "aspirin resistant" (Pawar et al., 1998; Awtry and Loscalzo, 
2000c. Harding et al., 2002c; Vane and Bottflio. 2003)). These limitations have led to 
the development of novel antiplatelet agents. such as Ticlopidine (a thienopyridine 
derivative), phosphodiesterase inhibitors (dipýridamole) and GP Ilb/Illa inhibitors. 
Thienopyridines prevent platelet aggregation by blocking ADP(P, Yl, )-receptors. 
phosphodiesterase inhibitors elevate intracellular cyclic AMP levels and inhibitillu, 
platelet function, and GP Ilb/Illa-blockers function by interfering with fibrinogen 
(Fb)- and NAW (von Willebrand factor) -mediated platelet aggregation (Born and \1111s, 
1969, .; \wti-y and Loscalzo, 2000b. 
Harding et al., 2002d) (Figure 1.4). Further details 
about platelet function and their involvement in vascular disease is discussed iii 
section 1_4- 
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1.2 Megakaryocytes and Platelet Production 
The term megakaryocyte was first introduced by ýVAV. Howell in 1890. who 
described the "occurrence, structure and formation of the gnant cclls of the maiTow" 
(Howell, 1890). 
In 1906 J. H. Wright recognised megakaryocytes as the precursors to blood platelcts. 
commenting on the *detachment of platelet-like fragments or segirnents from 
pseudopods' of megakaryocytes (Wright. 1906). Wright hypothesised that pseudopod 
projections from the surface of mature megakaryocytes penetrated into the bone 
marrow sinusoids to shed platelets (Wright, 1910). Ho\\-e\-er it was not until the 1970. s. 
with advances in molecular biology and in vitro methods. that this hypothesis was 
confirmed. Since the 1970s, which have been described as the modern era of 
megakaryocyte and platelet research, insights into the stages of normal and abnormal 
megakaryocyte development and its regulation by numerous cytokines and (-n-o\\tII 
factors have been achieved. One of the most important advanccs in this area oI 
research was the identification of the C-mpl proto-oncogene as the receptor tor 
megakaryocyte development and platelet production, and the subsequent isolation and 
cloning of the c-mj-)I ligand, thrombopoictin (TPO) (Wendling et al., 1994b; Lok ct al., 
1994b-, Kaushansky et al., 1994b-, de Sauvage et al., 1994b). 
1.2.1 Mega ka ryocytopoiesis 
Megakaryocytes are the precursors to platelets and are primarily located in the bone 
marrow, where they represent approximatel. v 0.1% of the niarroý\ cell population 
(Nurden et al., 1997d). The production of an adequate number of platelets is vital m 
evvi-N-day life to repair minute vascular damage. to initiate thrombus formation in 
response to vascLilar iii'urv and to aid wound healing. Megakai-voc%tes produce 
approximately 1011 platelets eacli day and in response to pkitclet c1ciiiand can inci'cal-lc 
production of circulating platelets by moi-c than 10-fold ((Ic\\Irtz ct al., 1995b, 
Kaushanskv, 21003. Kaushanskv. 2005). 
() 
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Within the bone marrow megakaryocytes are derived from common haernatopoletic 
stem cells (HSCs) (see Figure 1.5). HSCs are responsible for producing all of the 
circulating blood cells required for haernostasis (Ogawa, 1993). HSCs give rise to the 
early common myeloid progenitors (CMPs). Megakaryocyte and erythroid lineages are 
produced by a common megakaryocyte-erythroid progenitor (MEP) that is derived 
from the CMPs. In response to transcription factors such as GATA-1 which driN'e 
differentiation of MEP, cytokines and growth factors (see section 1.2.2 for further 
details) MEP develop into BFU-MK (burst-forming units of megakaryocytes) and 
CFU-MK (colony-forming units of megakaryocytes), which have the ability to 
proliferate, but are committed to the megakaryocyte lineage (Briddell et al., 1989). 
Alternatively, MEP can progress down the early or late erythroid lineage giving rise to 
BFU-E or CFU-E (Schulze and Shivdasani, 2004c). During megakaryocyte 
development, proliferating diploid megakaryocyte progenitors (megakaryoblasts) stop 
dividing and give rise to mature polyploid megakaryocytes by a process of cell 
endoreduplication and cytoplasmic maturation (Nurden et al., 1997c-, Shivdasani, 
200 1; Ravid et al., 2002a) (see section 1.2.1.1 and Figure 1.6 for more details). Mature 
megakaryocytes have a large abundant cytoplasm, and a unique set of organelles 
including alpha granules, dense bodies and a distinctive demarcation membrane 
system (DMS). 
1.2.1.1 Megakaryocyle endomilosis 
The main hallmarks of megakaryocyte maturation are the formation of a polyploid 
nucleus and the expansion of cytoplasmic mass. A cell is described as being polyploid 
when it has a greater than diploid content of DNA, and is thought to occur in 
megakaryocytes by endomitosis. Endomitosis is a cell cycle in which the number of 
normal haploid chromosomes in the cell is multiplied (e. g., 2N in diploid cells, 4N or 
greater in polyploid cells) (for review see Ravid et al., 2002b and Figure 1.2.2). 
Polyploidy has also been identified in other mammalian cells including hepatocytes 
(Kudryavtsev et al., 1993), cardiac myocytes (Sandritter and Scomazzoni. 1964). and 
arterial smooth muscle cells (Barrett et al., 1983) all of which become polyploid at 
some point during their normal life cý, cle. Polyploidisation has also been observed in 
10 
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cancerous turnours, caused by a process called aneuploidy. in which specific 
chromosomes are deleted or replicated (Barlogie. 1984a). Analysis of aneuploid cells 
can be used in the prognosis of prostate, colon and breast cancers (Barlogie, 1984b). 
Several studies have demonstrated that the endomitotic cell cycle in megakaryocýles is 
composed of repeating rounds of DNA replication separated by short gaps (Zhang et 
al., 1996). Due to the rarity of megakaryocytes in the bone marrow, and the relatively 
short gap period during their endomitotic cell cycle, in the past it was difficult finding 
sufficient numbers of polyploidy megakaryocytes in which to study the endomitosis 
process ftilly (Odell, Jr. and Jackson, 1968; Wang et al., 1995). However in early 
studies it was observed that megakaryocytes did enter the mitotic phase of the cell 
cycle, including chromosome condensation, but that the later stages of this phase were 
missing (Winkelmann et al., 1987). In recent years the development of recombinant 
TPO as a tool for producing polyploid megakaryocytes in vitro has lead to a greater 
understanding of the endomitotic cell cycle in megakaryocytes. Nagata and coworkers 
(Nagata et al., 1997c) examined large numbers of primary murine megakaryocytes, 
cultured in the presence of TPO, for features of mitosis and observed that several of 
these polyploid cells had condensed chromosomes, spindles originating from multiple 
spindle poles, and multiple centrosomes. The breakdown of the nuclear membrane was 
also observed in these cells, but they did not show features of late mitosis including 
the outward movement of the spindle poles. These observations suggested that during 
the megakaryocytic cell cycle the cells enter mitosis, proceeding as far as anaphase A, 
but do not proceed in to anaphase B, telophase, and cytokinesis (Figure 1.6). A similar 
study conducted by Vitrat and colleagues (Vitrat et al., 1998b) examined the 
morphological features of human megakaryocytes cultured with TPO, in the presence 
of nocodazole, which the authors' claimed maintained approximately 20% of the 
megakaryocytes in "pseudometaphase" allowing them to observe a larger number of 
mitotic phase cells. Vitrat and coworkers observed DNA condensation, nuclear 
membrane breakdown, and the formation of a spherical mitotic spindle in the 
megakaryocytes as seen in the previous study by Nagata et al. (Nagata et al., 1997b). 
However. they also observed chromatid separation and movement towards the spindle 
poles, suggesting that polyploidy megakaryocytes complete anaphase but lack 
cytokinesis. contradicting the hypothesis by Nagata et al. that megakar,, -ocvtic 
endomitosis is due to a block at the metaphase-anaphase transition. The precise everits 
13 
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surrounding the mitotic events of polyploid megakaryocytes are still debatable, 
however it is clear that these cells undergo a process of abortive mitosis, possibly 
caused by alterations in the regulation of mitotic exit (Nagata et al.. 1997a; Vitrat et 
al., 1998a). 
1.2.2 Platelet formation 
Platelet formation is a complex process and due to the extreme rarity of the 
megakaryocytes in normal bone marrow (<O. I% of total cells) the mechanisms 
underlying this process are poorly understood. The current model for platelet 
production from megakaryocytes is based on the observation that megakaryocytes 
extrude long cytoplasmic projections (proplatelets) which contain swellings 
encompassing platelet organelles that are later delivered into the blood circulation as 
platelets (see Figure 1.7) (Italiano, Jr. et al., 1999d; Hartwig and Italiano, Jr., 2003). 
Platelets are small anucleate particles that are found in close proximity to blood vessel 
walls during laminar flow. In response to vascular injury, platelets undergo 
morphological changes allowing them to aggregate and cover the site of injury (see 
section 1.2.4 for a more detailed review of platelet activation and thrombus 
formation). Platelets are assembled along intermediate pseudopodial extensions called 
proplatelets that are created from the escape and evagination of the extensive internal 
membrane system of mature megakaryocytes (Radley and Haller, 1982). Proplatelet 
formation generally commences from one site on the megakaryocyte, where one or 
more pseudopodial extensions form. These extensions continue to elongate and widen 
for 4 to 10 hours, forming proplatelets of approximately 2 to 4 ýM in diameter. 
Proplatelets continue to form from the original site until the entire megakaryocyte 
cytoplasm is transformed into a complex network of proplatelets (Italiano, Jr. et al., 
1999c). 
The reorganisation of microtubules, which are polymers of ap-tubulin dimers, are 
essential for proplatelet elongation (Tablin et al., 1990). Microtubules consolidate in a 
mass underneath the plasma membrane in the area where the proplatelet is to be 
formed. Microtubules then align into bundles and fill the cortex of the first blunt 
process to be formed by the megak-aryoc)-te. The proplatelet shaft is thickened and 
extended by the merger of microtubules into linear bundles. Platelet-sized swellings 
14 
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Figure 1.7: Platelet production from megakaryocytes. 
Initially the immature i-negakaryocyte undergoes endornitosis. followed by organelle and 
granule synthesis, centrosomal microtubule array and cytoplasmic maturation. Prior to 
proplatelet formation centrornes disassemble and microtubules move to the cell cortex, 
leading to the formation of thick pseudopods. Proplatelet formation iI I is driven by the sliding of 
over-lapping rnicrotubules at the cell cortex, organelles and granules are trafficked to the tips 
of these proplatelet structures where nascent platelets develop. Finally the entire 
rnegakarýyocyte cytoplasni is convertcd into a mass of proplatelets and released from the cell. 
Tile nucleus is then extruded from the mass of proplatelets and platelets are released from the 
ends of tile proplatelet structures (figure adapted from Patel et al. 2005). r_- 
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develop along the length and at the ends of the proplatelets. These swellings along the 
proplatelet have been identified as regions where microtubule bundles with in the shaft 
diverge for a short distance before reconvening to thicken the proplatelet. At the free 
end of the proplatelet, microtubule bundles form loops which give rise to the platelet- 
sized bulbous tips of the proplatelets. Coiling of microtubules onlý' occurs at the tips of 
the proplatelet extensions, indicating that this is the primary site for platelet formation 
(Topp et al., 1990; Italiano, Jr. et al., 1999b; Schwer et al., 2001a). The importance of 
microtubule assembly in platelet formation has been highlighted in experiments using 
transgenic mice lacking PI-tubulin. These mice develop thrombocytopenia (15 to 30% 
reduction in platelet numbers) and form spherocytic circulating platelets, due to 
defective marginal band formation and poor assembly of microtubules within the 
proplatelets (Schwer et al., 200 1 b). 
While the physical properties of proplatelet formation are well established, the 
underlying intracellular factors and conditions involved in this process are not yet well 
understood. Recent studies into megakaryocytic signalling pathways and transcription 
factors have implicated protein kinase C, serine/threonine phosphatases, NF-E2 and 
GATA-1 in proplatelet formation and normal platelet production (Shivdasani et al., 
1995b; Leven et al., 1997; Shivdasani et al., 1997c; Lecine et al., 1998c; Rojnuckarin 
and Kaushansky, 2001; Raslova et al., 2006). Other proteins regulated by NF-E2, such 
as Rab27b, caspase-12,3P-hydroxysteroid dehydrogenase, and PI-tubulin (as 
discussed previously), are also thought to play an important role in the regulation of 
proplatelet formation and/or platelet release (Lecine et al., 2000; De Botton et al., 
2002; Nagata et al., 2003; Tiwari et al., 2003; Kerrigan et al., 2004). 
The actual process of platelet release in vivo has not yet been identified due to the 
rarity of megakaryocytes within the bone marrow; however, it has been proposed that 
in vivo the proplatelets extend into the bone marrow vascular sinusoids, where they 
can be released in to the blood stream (Italiano, Jr. et al., 1999a). However, evidence 
is accumulating to suggest that the bone marrow stroma contributes to proplatelet 
development and platelet release. In recent studies chemokine SDF-I and the growth 
factor FGF-4 have been shown to be necessarý' for megakaryocyte recruitment to 
sinusoid endothelial cells (Avecilla et al., 
2004). Studies have also shown fibrinogen. 
supports proplatelet development in vitro and 
in vivo is localized to the vascular 
sinusoids (Larson and Watson. 2006b). 
Further it has been demonstrated that 
16 
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fibrinogen regulates proplatelet formation via integrin allbP3 in vitro a flinding 
supported by the use of thrombopoietin-stimulated allbP3 knockout mice. where the 
absence of allbP3 lead to reduced platelet counts (Larson and Watson. 2006a). Other 
matrix proteins such as vitronectin and collagen have also been shown to promote 
proplatelet formation (Leven and Tablin, 1992; Sabri et al.. 2004). 
1.2.3 Regulation of megakaryocytopoiesis 
Megakaryocytes are derived from haernatopoietic stem cells (HSCs) via a tightly 
regulated process involving specific cytokines, haernatopoietic growth factors and 
interactions with the bone marrow microenvironment. The primary function of 
megakaryocytes is to produce blood platelets, which play a vital role in haemostasis 
and thrombosis. 
Thrombopoietin (TPO) is the major hormone controlling megakaryocyte development. 
It was first identified as the as the ligand for the c-mpl proto-oncogene receptor, which 
is present on the surface of both megakaryocytes and platelets. The importance of TPO 
in megakaryocytopoiesis and thrombopoiesis was confirmed using mice deficient in 
the TPO gene and the c-mpl receptor. These mice showed an 85% reduction in 
peripheral platelet, marrow and spleen megakaryocytes, however the megakaryocytes 
and platelets that remained were functionally normal. Therefore TPO seems to be 
important in the development of an adequate number of megakaryocytes and platelets, 
but other factors are also involved (see Figure 1.8) (Gurney et al., 1994a; Kaushansky. 
1995c; de Sauvage et al., 1996b). 
There are several haernatopoietic growth factors which regulate proliferation, 
polyploidisation and maturation of megakaryocytes in vivo and in vitro (Figure 1.8). 
These include cytokines, such as interleukin- I (IL- 1), IL-3, IL-6, IL- 11, granulocyte 
macrophage-colony stimulating factor (GM-CSF), and stem cell factor (SCF). It has 
been reported that SCF acts on the late stages of megakaryocytopoiesis by inducing 
polyploidisation and improving the maturity of the final megakaryocytes. IL--3 and 
GM-CSF are stimulators of megakaryocyte colony formation, however IL-3 is more 
potent than GM-CSF as it promotes the production of a greater number of colonies 
containing a higher number of megakaryocytes. IL-6 has been shown to promote 
niega-k-aryocyte maturation by increasing the cell size. pol)-ploidisation. number and 
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synthesis of platelet proteins and proplatelets, and IL- II induces the maturation of 
early megakaryocytes by increasing megakaryocyte ploidy and size (Gordon and 
Hoffman, 1992; Wendling and Han, 1997). 
Lineage differentiation of megakaryocytes is governed by many transcription factors, 
megakaryocytic and erythroid lineages, as discussed in section 1.2.1. are derived from 
a common precursor and share many early lineage-restricted transcription factors 
including GATA- 1, FOG- I (Friend Of Gata- 1), Fli- I (Friend leukaemia integration- 1). 
and the nuclear factor 2 (NF-E2) (see Figure 1.8) (Shivdasani and Orkin, 1996; 
Shivdasani, 2001). 
Ets genes are a large family of transcriptional regulators consisting of a conserved 
winged helix-loop-helix DNA binding (ETS) domain that recognises purine-rich DNA 
sequences with a GGA(A/T) consensus, named the Ets binding sequence (EBS) 
(Oikawa and Yamada, 2003; Seth and Watson, 2005). Fli-I (Friend leukaemia 
integration-1), a member of the Ets transcription family, is preferentially expressed in 
haernatopoietic lineages and vascular endothelial cells where it has a vital role in 
maintaining normal development and oncogenesis (Truong and Ben David, 2000). 
Evidence is accumulating to suggest that Fli-I is a positive regulator of 
megakaryocytopoiesis (Hart et al., 20OOc-, Spyropoulos et al., 20OOc-, Kawada et al., 
2001d; Jackers et al., 2004a). Fli-I expression is increased in the megakaryocytic cell 
line, K562, after phorbol-ester induced differentiation promoting the expression of 
megakaryocytic markers CD41 and CD61 (Athanasiou et al., 1996; Holmes et al., 
2002a; Eisbacher et al., 2003b). Targeted disruption of the Fli-I gene in mice leads to 
severe dysmegakaryopoiesis and vascular defects, embryos of these homozygous 
mutants (Fli-I -/-) showed hemorrhage from the dorsal aorta into the lumen of the 
neural tube and ventricles of the brain beginning on embryonic day II and were dead 
by embryonic day 12 (Hart et al.. 2000b. Spyropoulos et al., 2000b; Kawada et al.. 
2001c). Analysis of cultured cells from day 10 embryos revealed an absence of 
megakaryocytes and aberrant red blood cell development (Kawada et al., 2001b). 
These results indicate that Fli-I has a vital role in haernatopoiesis and embryonic 
development. 
Significantly. Fli-I is a transcriptional activator of several megakaryocytic-specific 
genes including GATA-1. thrombopoietin receptor (c-mpl). glycoprotein-Ilb (GP-11b). 
GP-Vl. GP-IX. and GP-Ib (Watson et al., 1992: Lemarchandel et al.. 1993. Seth et al.. 
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1993; Zhang et al., 1993; Deveaux et al., 1996; Wang et al.. 2002: Holmes et al.. 
2002b; Eisbacher et al., 2003a). 
The zinc-finger proteins GATA-1 and GATA-2 have been shown to have important 
roles in erythro-megakaryocyte transcription (Martin and Orkin, 1990: Romeo et al.. 
1990). GATA-1 has a vital role in both the early and late stages of megakaryocyte 
differentiation and regulates megakaryocyte proliferation (Shivdasani et al.. 1997b). 
Mice lacking the GATA-1 gene in megakaryocytes and humans with critical point 
mutations have platelet counts 15% less than that of normal, with increased platelet 
size, spherical platelets instead of discoid, and increased bleeding times (Shivdasani et 
al., 1997a; Nichols et al., 2000; Freson et al., 2001). GATA-I mutations in humans 
lead to severe diseases involving both megakaryocytes and erythroid cells (Schulze 
and Shivdasani, 2004b; Muntean and Crispino, 2005a). GATA-1 mutations, which 
produce a truncated form of GATA-I (GATA-1s), precede the transition to 
megakaryocyte-lineage acute leukaemia (AMKL) in patients with Down's syndrome 
(trisomy 21), indicating a role for GATA-I in the proliferation of megakaryocyte 
progenitors (Wechsler et al., 2002; Crispino, 2005). 
FOG- I (Friend of GATA-1) is a zinc finger transcription factor, initially discovered as 
a GATA binding protein, whose expression pattern mirrors that of GATA- I in both 
erythroid and megakaryocytic cells. The interaction between GATA-1 and FOG-1 is 
vital for embryonic haernatopoiesis and megakaryocyte development (Shimizu et al., 
2004). Patients with GATA mutations that interfere with this interaction have severe 
thrombocytopenia and dyserythropoietic anaemia, indicating that the GATA-I/FOG-1 
interaction is clinically significant in megakaryocytopoiesis (Muntean and Crispino, 
2005b). Targeted disruptions in FOG-1 have a phenotype similar to that observed in 
GATA-1 null mice. however FOG-1 knockout mice lack megakaryocytes indicating 
that FOG-1 has a critical role in early megakaryocyte development (Tsang et al.. 
1998). 
The transcription factor NF-E2. a heterodimeric basic-leucine zipper, comprises of a 
megakaryocytic-erythroid specific 45-kDa subunit and a non-specific p18 Maf family 
subunit which control megakaryocyte maturation. proplatelet formation and platelet 
release (Shivdasani. 1996, Lecine et al.. 1998a. Schulze and Shivdasani. 2004a). NF- 
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N2 regulates the transcription of megakaryocytic genes, including Rab27b, P-tubulin. 
and thromboxane synthase. (For more information about the role of NF-N2 target 
genes in megakaryocyte differentiation please refer to a recent review by Schulze and 
Shividasani, 2005 (Schulze and Shivdasani, 2005)). NF-N2 knockout mice, either 
lacking the megakaryocytic-erythroid specific 45-kDa subunit or both the alternative 
pl 8 subunits, have severe thrombocytopenia (<5% of normal). These megakaryocytes 
have hallmarks of maturity, including an enlarged cytoplasm, and polyploidy DNA. 
but also have disorganised internal membranes, reduced granule numbers and fail to 
produce proplatelets in culture (Shivdasani et al., 1995a; Shivdasani, 1996; Lecine et 
al., 1998b; Shiraga et al., 1999; Onodera et al., 2000). These findings indicate that 
NF-N2 functions at the point where megakaryocytes prepare to produce proplatelet 
extensions and release platelets. 
Recent studies have provided evidence that the Rho/ Rho Kinase (ROCK) pathway, a 
regulator of actin cytoskeleton, is a negative regulator of proplatelet formation (Chang 
et al., 2007a). Rho is expressed at high levels during all stages of megakaryocyte 
differentiation and is activated by TPO. Overexpression of spontaneously active or a 
dominant negative RhoA leads to a decrease or increase in proplatelet formation 
respectively, indicating that Rho activation inhibits proplatelet formation. Inhibition of 
ROCK leads to an increase in proplatelet formation, indicating that the inhibitory 
effect of Rho is mediated through ROCK (Chang et al., 2007b). 
1.2.4 Role of megakaryocytes and platelets in vascular disease 
Platelets are activated in response to vascular injury, acting to control bleeding and 
maintaining normal haemostasis. Platelets are normally heterogeneous with respect to 
their size, density and reactivity. Changes in these characteristics may be involved in 
the pathogenesis of vascular diseases such as acute myocardial infarction, unstable 
angina and sudden cardiac death (Thompson et al.. 1982; Falk, 1983). During normal 
haemostasis, platelet activation and adhesion to the blood vessel XN-all is initially 
controlled by two adhesion receptors. glycoprotein (GP) lb-IX-V and GPVl "xhich 
bind to von Willebrand factor (N, Wf) and collagen respecti, %, ely under conditions of 
high shear stress (Kroll et al.. 1996b: Jackson et al.. 2003: Nieswandt and Watson. 
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2003a: Andrews et al.. 2004; Famdale et al.. 2004. GakN-az. 2004). Platelet adhesion is 
also mediated by several platelet integrin receptors and their ligands. The major 
platelet integrins involved in platelet adhesion are ctlIbP3 (GPIlb'llla: CD41/'CD61) 
and a2pl integrin (GPIa/lIa). which interact with vNVf and fibrino(2ell. and colla(-Yen 
respectively (Nieuwenhuis et al.. 1985: Kroll et al.. 1996a; Ruggeri. 1997b. Savagc et 
al., 1998; Xiong et al.. 2003b). 
GPVI consists of two Ig domains. a mucin-rich stalk and a cytosolic sequence coupled 
to a disulfide linked Fc receptor (F7R) 7-chain homodimer (Moroi et al., 1989. 
Clemetson et al., 1999, Nieswandt et al.. 2000, Nieswandt and Watson, 2003b). The 
FcR y-chain is required for the expression of GPVI on platelets, and the cross-linking 
of collagen with the GPVI-F7R-chain complex initiates a signalling patIlway via 
tyrosine phosphorylation of an ITAM (imi-nunoreceptor tyrosine-based activation 
motit) present on the F7R chain, resulting in the phosphorylation and activation ot' L- 
PLCy 2 (phospholipase C7 2). Activation of PLC7 -2 
leads to a subsequent increase in 
the levels of the messengers inositol 1,4.5-trisphosphate, 1,2-diacylglycel-ol, 
phosphatidylinositol 3,4,5-trisphosphate, and intracellular calcium resulting in platelet 
activation (Gibbins et al., 1996, Poole et al., 1997, Tsuji et al., 1997; Gibbins et al., 
1997; Asselin et al., 1997). 
The GPIb-IX-V complex consists of four transmembrane glycoproteins, GPINX 
(CD42bcc) disulfidelinked to GPIbP (CD42bP/CD42c), noncovalently complexed with 
GPIX (CD42a) and GPV (CD42d) in the ratio 2: 2: 2: 1, all of which are members of the 
leucine-rich protein family (Andrews et al.. 1997: Lopez et al.. 1998b, Berndt et al.. 
2001b). It is the N-terminal domain of GPlb(x that contains the bindino sites for ONT 
(Berndt et al., -2001a). 
Platelet activation, which is required for platelet ýtggi-cgation 
and subsequent thrombus formation, is stimulated by the interaction of GP lb-IX-V 
and vWf- Platelet activation leads to a conformational change in the allbý'l 
((jPllh'1lLi) receptor on the platelet surface enabling it to bind to plasma fibrinogen. 
leadii-ig, to the reorganisation of the platelet cytoskeleton and cross-linkii-ig, of this 
complex \\ith aqjacent actl\-ated platelets resulting in platelet aggregLition and the Z: 1 -- 
I, orniation of a haernostatic pltio, (Isenberg ct al., 1987, Frojjiiiovic. 1998, Shattil. 1999. 
Ruggeri. `000). Several platelet agonists including adenosine diphosphate (ADl)). 
till-onibin. collagen. thromboxane A-2 and epinephrine have been identified as 
icti\-atoi-s of platelct (Waoilei- and Miroer. 20011 ýi '). ADP and thrombiii 
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activate platelets via G-coupled purinergic receptors P2Y, and P2YI-) and G-coupled 
protease-activated receptors PARA and PAR-4 respectively, enabling allbP3 to bind 
to its ligands fibrinogen or vWf resulting in platelet aggregation and thrombus 
formation (Coughlin, 2000; Dorsam and Kunapuli, 2004). 
Under normal conditions of haemostasis platelets circulate close to the endothelial 
cells of the blood vessel lining but do not attach to it, however under pathological 
conditions platelets respond to changes in the endothelial lining, such as fat deposits 
and plaque rupture, and exposed subendothelial structures by adhering to the site of 
the lesion leading to thrombus formation and cardiovascular ischaernic events 
(Frishman et al., 1995; Body, 1996; Ruggeri, 1997a). Further studies have 
demonstrated platelet hyperaggregatibly in stable angina pectoris, unstable angina 
pectoris, non-Q-wave myocardial infarction, and in patients with coronary artery 
disease risk factors such as smoking, hypertension, hypercholesterolaemia, 
hyperhomocysteinemia and diabetes mellitus (For review see Willoughby et al., 
2002c). 
1.2.5 Megakaryocyte and platelet disorders 
Qualitative disorders of platelets and megakaryocytes are a large group of rare 
inherited diseases which give rise to excessive mucocutaneous bleeding due to defects 
in megakaryocyte development and platelet formation and function (For review see 
Nurden, 2005a). It has been known since the mid 1970s that both cell surface proteins 
such as the glycoproteins (GP) on the platelet surface, and intracellular proteins have a 
major role in platelet function, and the pathogenesis of inherited platelet and 
megakaryocyte disorders (Nurden et al., 1997a). 
Glanzmann's thrombasthenia (GT) is the most common platelet disorder, it is an 
autosomal recessive disorder characterised by deficient platelet aggregation caused by 
an absence or non-functioning allbP3 (GPIlb/Illa) complex (George et al., 1990b, 
Caen and Rosa, 1995; Nurden, 1999). As mentioned in section 1.2.4 during normal 
platelet activation. alIbP3 binds fibrinogen and vWf allowing cross-linking of platelets 
and thrombus formation. however in GT patients this does not occur and as platelets 
fail to respond to physiological agonists, such as ADP, thrombin or collagen leading to 
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the impaired platelet aggregation. The disease is caused by mutations in the genes 
encoding GPIlb or GPIlla that result in qualitative or quantitative abnormalities of the 
proteins, to date over 70 mutations have been identified which give rise to this 
autosomal recessive disease (these can be found on an internet data base; 
http: //med. mssm. edu/glanzmanndb) (Tomiyama, 2000). GT patients are divided into 
two groups according to the amount of GPIIb/IIIa complex expressed on their platelet 
surface: type I patients have less than 5% of GPlIb/IIIa; type 11 patients 10-20% and 
type III (variant) patients 50-100% (For reviews see George et al., 1990a; French and 
Seligsohn, 2000; Bellucci and Caen, 2002). 
Another qualitative megakaryocyte and platelet disorder is Bernard-Soulier syndrome 
(BSS) which is an autosomal recessive disorder first described in 1948 by Bernard and 
Soulier (For review see Bellucci, 1997) and is characterised by prolonged bleeding 
times, moderate to severe thrombocytopenia, and enlarged (giant) platelets. BSS 
platelets aggregate normally in response to ADP and collagen but show a lack of 
platelet response to ristocetin or botrocetin (Howard et al., 1973; Lopez et al., 1998a). 
The underlying defect causing BSS is an abnormal GPIb-V-IX complex, required as 
described previous in section 1.2.4, for normal haemostasis by binding vWf, allowing 
platelet adhesion and thrombus formation at sites of vascular injury (Clemetson, 
2003). There are four distinct transmembrane proteins required for the assembly of the 
functional receptor on the cell-surface of bone marrow megakaryocytes, GPlba, 
GPlbP, GPIX and GPV (Andrews et al., 1999). GPlba, GPlbP, and GPIX are closely 
associated and the lack of a single subunit dramatically decreases the surface 
expression of the GPlb-V-IX complex (Ulsemer et al., 2001). The majority of these 
mutations are in the GPlba region and decrease the expression of GPlba on the 
platelet surface, whereas mutations of GPIX and GPIb generally decrease expression 
of the entire complex on the platelet surface leading to the abnormal functioning of the 
complex and the impaired platelet function seen in BSS patients (Lopez et al., 1998c. 
Ware et al., 2000; Poujol et al.. 2002, Strassel et al., 2003; Kato et al., 2004). 
Familial thrombocytopenias are an extensive group of bleeding disorders caused by 
quantitative and qualitative defects in megakaryocyte development and platelet 
formation. In patients suffering from this disorder the genetic defect can lead to 
profound changes being observed in platelet morphology, and other blood cells and/ or 
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organs (Geddis and Kaushansky. 2004: Drachman. 2004a). An example of a familial 
thrombocytopenia is Paris-Trousseau syndrome. \\-here lan-Te platelets witli (liant 
a-granules and an increased number of small immature me(, iakar\'oc\'tes with an 
arrested maturation are observed in the bone marrow. It is thought that a mutation ot' 
the Ets family transcription factor gene. FLIL may be the potential cause ot' 
Paris-Trousseau thrombocytopenia because of similar abnormalities observed in the 
megakaryocytes of mouse embryos in which flil has been genetically deleted, 
including immature megakaryocytes with hypolobulated nucleus. abnormal u-_(_, ranUlC 
synthesis, and an increased number of small CFU-MK colonies. To support this 
evidence it has also been shown that the FLI1 gene is present on human chromosome 
I lq24, a region deleted in Paris-Trousseau thrombocytopenia (Spyropoulos et al.. 
2000a; Hart et al., 2000a; Kawada et al., 2001 a: Jackers et al., 2004b). 
In patients suffering from congenital amegakaryocýlic thrombocytopenia, another 
familial thrombocytopenia, the numbers of megakaryocytes are low from birth, with 
aplastic bone marrow evolving with age (Drachman, 2004b: Nurden, 2005b). An 
example of this type of thrombocytopenic condition is X-linked thrombocytopellia, 
caused the substitution of a single amino acid caused by a 2-base mutatioll oil the 
X-chromosome. This substitution inhibits the interaction betweeii GATA-1 and FO(j- 
1. resulting in severe thrombocytopenia and large platelets (Mehaffcy et al., 2001 ). III 
this disorder. mutations in the c-mpl gene. wliich encodes the TPO receptor. prevent 
TPO from carrying out its normal thrombopoietic roles in megakaryocytic cells. 
Complete loss of the C-mpl receptor lead to a more severe disease v'-Ith plasma "I'PO 
IeN'els beino 10-fold less than that observed in normal cells (Ihara et al.. 1999b: 
Ballmaier et al.. 2001a, Ding et al., 2004). This is the only known mei-, akaryocý-tic 
disease thotiolit to be as a direct result of abnormal TPO/c-Mp1 signalling (Muraoka et 
al., 1997-, Ihara et al.. 1999a; Ballmaier et al.. 2001b). 
Impaired TPO signalling has been implicated only in congenital amegakar',, 'oc\-tic 
thrornbocytopenia sLi, (,,, (-, csting that other factors rna\ be involved in the pathogenc"Is of 
othcr mcgAarvocytc disorders. One such factor recentl", identified to have a k-ev role 
in n-ic, -, 
Aar%ocvte diffcrentiation and platelet production is ulutai-nate signalling, 
(Cjencvcr et al.. 1999m. Hitchcock et al.. 2200')rn). Functional ýý-rncthyl-D-aspartatc 
(NNIDA)-type tylutai-nate i-cccptoi-s xvci-e shown to be cxprcs.,, cd by bone marrow 
UN/ vtW---, 
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megakaryocytes, similar to those identified at neuronal synapses responsible for 
mediating excitatory neurotransmission in the central nervous system (CNS) (Genever 
et al., 19991), and their inhibition using an NMDA receptor antagonist MK-801. lead 
to impaired megakaryocytopoiesis and platelet production suggesting a fundamental 
role for glutamate signalling in megakaryocytes (Hitchcock et al., 20031). 
1.3 Glutamate signalling in the CNS 
The amino acid L-glutamate is the major excitatory neurotransmitter in the 
mammalian central nervous system (CNS). It is believed to be involved in aspects of 
normal brain function including learning, cognition and memory (Fonnum, 1984a: 
Ottersen and Storm-Mathisen, 1984c; Collingridge and Lester, 1989c; Headley and 
Grillner, 1990c). Glutamate is also involved in neuronal differentiation, cell migration 
and cell death, as well as formation or removal of synapses in the developing brain 
(Foster and Fagg, 1984; Mayer and Westbrook, 1987; Komuro and Rakic, 1993). 
Neurotransmission of glutamate at glutamatergic synapses can be divided into four 
stages (see Figure 1.9); the first is the passage of an action potential along the axon of 
2+ 
the pre-synaptic cell leading to the influx of Ca , the 
fusion of the synaptic vesicle 
carrying the neurotransmitter to the presynaptic membrane, and finally, the release of 
glutamate in to the synaptic cleft. During the second stage the released glutamate 
diffuses across the synaptic cleft where it is free to bind to the glutamate receptors on 
the post-synaptic cell. The third stage involves the binding of glutamate agonists to 
their receptors leading to receptor activation, leading to the influx of charged ions such 
as Ca 2+ and Na+ (or activation of coupled G-proteins) into the post-synaptic cell, 
leading to the depolarisation of the post-synaptic cell, allowing the action potential 
from the pre-synaptic cell to be continued activating of a variety of downstream 
signalling events. In the fourth stage glutamate is removed from the synaptic cleft by 
ii, lutamate transporters expressed on neighbouring astrocyte and glial cells, leading to 
the termination of synaptic transmission. 
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1.3.1 Glutamate release from pre-synaptic neurons 
Membrane trafficking in presynaptic nerve terminals in the CNS is essential for 
glutamate secretion and involves biogenesis of specialised vesicles that perfon-n a 
regulated cycle of fusion, exocytosis and regeneration, called the synaptic vesicle 
cycle (see Figure 1.10) (Sollner et al., 1993d; Calakos and Scheller, 1996b; Robinson 
and Martin, 1998a; Richmond and Broadie. ) 2002a). See section 3.1 for a more in 
depth review of exocytosis mechanisms. 
Exocytosis of neurotransmitter is a complex and highly regulated process involving 
specific protein-protein interactions. The current model involves the SNARE (soluble 
N-ethylmaleimide-sensitive factor [NSF] attachment protein [SNAP] receptor) 
hypothesis (Figure 1.11), which was first proposed in 1993 to explain vesicle docking 
and fusion in molecular terms. It proposes that vesicles have specific v-SNARE 
proteins which recognise and interact with the target protein t-SNAREs on the plasma 
membrane of presynaptic cells (Sollner et al., 1993c). This membrane protein complex 
is composed of the vesicle associated membrane protein, VAMP, a single-pass 
transmembrane protein located primarily on the vesicle membrane; syntaxin la, a 
single-pass transmembrane protein residing primarily on the plasma membrane; and 
SNAP-25 (synaptosomal-associated protein, 25kDa), which contains two SNARE 
domains bordering a region of palmitolyated cysteines which associate with the 
plasma membrane. These proteins interact with each other in a structurally conserved 
parallel 4-helix bundle which brings the vesicle and plasma membranes into close 
contact so that they are ready to fuse (Sollner et al., 1993b; Chapman et al., 1994e; 
Bennett, 1995a; Hanson et al., 1997b; Chen and Scheller, 2001b). 
There are numerous SNARE-interacting proteins that regulate SNARE complex 
assembly and disassembly (Figure 1.11). SNARE assembly is triggered by the binding 
of calcium to a putative calcium sensor, synaptotagmin. This induces the fusion of 
synaptic vesicles docked at the active zone close to calcium channels. Following 
membrane fusion, disassembly of the SNARE complex is regulated by two proteins, 
the ATPase NSF (N-ethylamide sensitive fusion protein) and an adapter protein 
a-SNAP (soluble NSF attachment protein). SNARE formation is also regulated by 
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syntaxin-interacting proteins such as Munc-18, GTPases Rab 33. Rab 3) binding 
proteins Rabphilin 3, which are involved in exocytosis via hydrolysis of GTP. and 
vesicular adapter proteins Doc-2 and Mint, which regulate Munc-18/sYntaxin 
interactions (Malhotra et al., 1988, Clary et al., 1990b; Calakos and Scheller. 1996a: 
Betz et al., 1997a; Novick and Zerial, 1997b; Sassa et al., 1999b; Biederer and Sudhof, 
2000; Mochida, 2000; Nakajima et al.. 2001; Richmond et al., 2001; Gerst. 200,33). 
Section 3.1 provides a more in depth review of SNARE and associated proteins. 
1.3.2 Glutamate receptors 
The glutamatergic system in the CNS is composed of glutamate receptors (GluRs) and 
transporters. The majority of neuronal and glial cells have GluR on their plasma 
membranes, however glutamate signalling has also been shown to have a role in 
peripheral organs and tissues (see section 1.4 for details) (Hosli and Hosli, 1993a; 
Vernadakis, 1996a; Steinhauser and Gallo, 1996a; Conti and Weinberg, 1999a; 
Shelton and McCarthy, 1999b; Bergles et al., 2000b). 
The GluRs, which are responsible for glutamate uptake in neuronal cells, can be 
divided into two categories: the ionotropic GluRs (iGluRs) and the metabotropic 
GluRs (mGluRs) (see Figure 1.12) (Monaghan et al., 1989; Hollmann and Heinemann, 
1994; Schoepfer et al., 1994; Borges and Dingledine, 1998; Nakanishi et al., 1998; 
Ozawa et al., 1998a; Dingledine et al., 1999e). 
1.3.21 lonotropic Glutamate Receptors 
The iGluRs are ligand-gated ion channels. which when activated undergo a 
conformational change allowing an influx of ions into the postsynaptic cell directly 
through the receptor (Hollmann and Heinemann, 1994; Ozawa et al.. 1998b; 
Dingledine et al., 1999d). leading to the production of the intracellular second 
messengers cAMP, -ins (1.4.5)P-3 and DAG (For reviews see Hollmann and 
Heinemann, 1994; Dingledine et al., 1999f). The iGluRs can be subdivided into three 
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groups based on their structural and pharmacological similarities: N-methyl-D- 
aspartate (NMDA), ct-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) 
and kainate (KA) receptors, these receptors are named after their pharmacological 
agonist that activates them (Monaghan et al., 1984a; Hollmann and Heinemann, 1994). 
The AMPA and KA receptors are found to be ubiquitously expressed throughout the 
CNS at varying levels (Monaghan et al., 1984b; Represa et al., 1987) whereas the 
NMDA receptor are primarily located in the forebrain (Monaghan et al., 1989). All 
three iGluRs consist of an extracellular N-terminal and intracellular C-terminal. three 
transmembrane domains (M 1,3 and 4), and a re-entrant loop (M2) that faces the 
cytoplasm but does not transverse the membrane. The amino acids comprising the re- 
entrant loop are proposed to control the ion permeability of each receptor type. The 
agonist-binding sites for the iGluRs are located in the SI region, located before M 1. 
and the S2 region, located after M3 (Figure 1.12). In the CNS the iGluRs are involved 
in mediating long-term potentiation (LTP), the mechanism responsible for the 
formation of memory and learning (Bliss and Collingridge, 1993a; Meyer and Shen, 
2000; Liu and Cull-Candy, 2000). 
1.3.2.1.1 AMPA receptors 
AMPA receptors are thought to mediate the majority of rapid excitatory transmission 
in the CNS (Hollmann and Heinemann, 1994; Dingledine et al., 1999a). AMPA 
receptors have a rapid response to their agonists and desensitise quite rapidly. It has 
been proposed that AMPA receptors may play an important role in synaptic plasticity, 
and modulating membrane trafficking and synaptic targeting of receptors mediated by 
their direct phosphorylation by protein kinases and phosphatases (Lynch and Baudry, 
1984-, Raymond et al., 1993, Soderling and Derkach, 2000). 
AMPA receptors are tetrameric heteromeric complexes of four homologous subunits 
GluRl, -2, -3 and -4, which combine to produce 
distinct receptor subtypes with 
different stoichiometries (Hollmann and Heinemann, 1994; Dingledine et al.. 1999b). 
Multiple cloning of the AMPA receptor protein cDNA revealed that more than one 
isoform of these proteins was present in neuronal tissues. These alternative isoforms 
are formed bý, alternativelý- spliced exonic sequences of 38 amino acids near the M4 
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transmembrane domain of the GluRI-4 subunits in either a "flip" or -f1op- 
configuration (Sommer et al., 1990a). AMPA receptors containing the flip isoform of 
the GluRI-4 subunits are found in prenatal and post-natal brain neurons during 
neuronal development and form non-desensiti sing receptors. whereas the flop isoform. 
of the AMPA receptor subunits are only observed in postnatal brain maturation and 
receptors containing these subunits exhibit an increased desensitisation rate to 
glutamate-induced activation (Sommer et al., 1990b; Monyer et al., 1991). 
AMPA and KA receptors are primarily permeable to Na+ and K+, and generally show 
relatively low unitary conductances (Cull-Candy and Usowicz, 1987, Jahr and 
Stevens, 1987; Trussell et al., 1988). The majority of the AMPA receptors are 
2+ 2+ impermeable to Ca , these receptors contain the GluR2 subunit which confers Ca 
impermeability, however, a small population of neuronal cells in the retina, 
cerebellum, cerebral cortex and hippocampus contain AMPA receptors which form 
ion channels permeable to Ca 2+ (lino et al., 1990; Gilbertson et al., 199 1; Burnashev et 
al., 1992a; Burnashev et al., 1992b; Jonas et al., 1994). The majority of AMPA 
receptors in the hippocampal pyramidal cells consist of GluRI - GluR2 and GluR2 - 
GluR3 complexes, where as in Purkin e cells AMPA receptors mainly consist of just 
GluR2 - GluR3 heteromers. 
1.3.21.2 Kainate receptors 
KA receptors have many similar characteristics to the AMPA receptors, however 
unlike AMPA receptors, which are thought to play a role in glutarnatergic synaptic 
transmission in the majority of excitatory synapses in the brain, the roles of KA 
receptors are still a matter of uncertainty. KA receptors are ligand-gated channels 
permeable to cations, activated by low concentrations of kainate and display rapid 
synaptic transmission and desensitization characteristics (EgebJerg et al., 1991; Kohler 
et al.. 1993. for a review see Pinheiro and Mulle, 2006). KA receptors are thought to be 
involved in slow glutamatergic neurotransmission regulating presynaptic 
neurotransmitter release (Malva et al., 1995, ChittaJallu et al., 1996; Vignes and 
Collingridge, 1997). 
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There are five KA receptor subunits GluR5,6,7, KAI and KA2. which can be 
arranged in different ways to form a tetramer, a four subunit receptor. The mRNAs 
encoding the KA receptors are subject to post-translational modifications and/or 
alternative splicing as seen in the AMPA receptor subunits. All splice variants differ in 
their cytoplasmic C-domain apart from GluR5 which has an alternative 15-amino acid 
exon in the N-terminal domain. There are three main splice variants for GluR5, two 
main splice variants for the GluR6 subunit, and 2 additional splice variants for the 
GIuR7 subunit, increasing the receptor diversity (for review see Hollmann and 
Heinemann, 1994). 
1.3.2.1.3 NMDA receptors 
NMDA receptors mediate excitatory neurotransmission in the CNS in different ways 
from AMPA and KA receptors. They are not believed to function as mediators of 
rapid synaptic transmission, unlike the AMPA and KA receptors, due to their slow 
response to glutamate (Lester et al., 1990). NMDA receptors also have high 
conductances, require glycine as a co-agonist and display a high permeability to Ca 2+ 
(MacDermott et al., 1986; Mayer and Westbrook, 1987). The slow response of these 
receptors is thought to be due to the fact that they are inhibited by Mg 2+ present in the 
extracellular environment of neuronal cells (Nowak et al., 1984; Mayer et al., 1984). 
NMDA receptors have a higher affinity for glutamate than the AMPA receptors, so a 
small population of these receptors are maintained in a partially activated state. 
However, full activation of the NMDA receptors requires the removal of Mg2+ from 
the glutamate binding site. The blockage of NMDA receptors by Mg2+ is voltage- 
dependent, therefore when glutamate is released into the synaptic cleft activating the 
KA and AMPA receptors, the subsequent depolarisation of the postsynaptic cell leads 
to the removal of Mg2+ and the activation of the NMDA receptors. 
Seven NMDA receptor subunits have been identified, one NRI, four NR2 (A-D) and 
two NR3 (A, B) subunits. The majority of native NMDA receptor complexes are 
heterotetramer ic, consisting of two glycine binding NRI subunits and two glutamate 
binding NR2 subunits (Das et al.. 1998, Rosenmund et al., 1998; Hawkins et al., 
1999). Howev er, expression studies in frog oocytes, where both NRI and NR2 were 
co-expressed, indicated that it is the NRINR2 heterodirners that are the functional 
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unit in these receptors (Nakanishi et al.. 1992c: Seeburg. 199')a: Mori and Mishina. 
1995b: Furukawa et al.. 2005: Chen and 'WvIlle. 2006). Eight soforms of the NRI 
subunit (, `ýRl a- h) exist, derived from alternati\e splicing of the exonic sequences. 
however it is unknown whether more than one of these variants exist within one 
NMDA receptor complex (Anantharam et al., 1992: SLI(-, ihara et al.. 1992: Nakanishi ct 
al., 1992a; Durand et al.. 1993: Hollmann et al.. 1994: KoItchine et al.. 1996). 'NR2 
subunits are regarded as modulatory subunits. whereas NRI acts as an essential 
subunit for the formation of the heteromeric NMDA receptors (For revieWs see 
references Nakanishi et al., 1992b, Seeburg, 1993b: Mori and Mishina, 1995a). 
1.3.2.2 Metabotropic Glutamate Receptors 
The mGluRs (mGluRI-8) are G-protein-coupled receptors wliicli can be divided into 
three classes, group 1,11 and III based on sequence similarity. pharmacology and 
intracellular signalling mechanisms (Figure 1.12). The members of the same subgroup 
share approximately 70% amino acid sequence identity, while the homology between 
different subgroups is approximately 45%. The different mGluR subtypes have similar 
structures, possessing a seven-transmembrane spanning domain with an extracellular 
N-teri-ninus consisting of approximately 550 amino acid residues, and an intracellular 
C-terminal domain, the length of which depends on subtype (Hollmann and 
Heinemann, 1994, Dingledine et al., 1999c). The group I mGluRs (mGluRI and -5) 
are positively coupled to phospholipase C. and are activated by (±) I -amino- 
cyclopentane-tr(ins-1,33-dicarboxylic acid (trans-ACPD) leading to the activatioii of 
colocallsed NMDA receptors via mechanisms involving protein kinase C-mediated 
tyrosine phosphorylation. In contrast group 11 (mGluR2 and -3) and group III 
(mGILR4, -6, -7 and -8) are negatively coupled to adenyl cyclase (Conn and Pin, 1997: 
Schocpp et al., 1999; Pin et al., 1999a; Bordi and Ugolim, 1999b; Brauner-Osborne et 
al.. 2000; Schoepp, 2001a; Benquet et al., 2002). Group 11 receptors are also actl\. atcd 
hv o-tins-ACPD, \\-Iille group III is activated by L (+)-2-amino-4-phosphonobutý-ric 
acid (I. -AN). All three classcs of the mGluRs are enriched in the hippocampus, and 
the OluR2. -3 and -5 receptors can be found iii the cortex. nuclcLis accumbens and 
amygdal (I'ottilii et al.. 1994. Pin and Mivoisin. 1995. BILInicke Ct al.. 1996: 
I., lin-, emoto et al.. 1997: Bordi and Ugolmi. 1999a: Pin ct al.. 1999b: 'Spooreil Ct al., 
, Sclioepp, 
2001b). 
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1.3.3 Glutamate transporters 
Specific. high affinity transport systems are required by all amino-acid 
neurotransmitters to complete the synaptic actions of the transmitter after recePtor 
activation and to recycle the molecules invol%, ed. L-2lutamate. as discussed 
previously. is the major excitatory transmitter of the mammalian C'N'S. and 
transportation of glutamate is vital as high (Ylutamate concentrations in the synaptic 
milieu can cause excitotoxicity leading to neuronal in jLiry. Glutamate transporters plaN 
an important role in maintaining the local inteority of excitatory synaptic transmission 
(Marcaggi and Attwell. 2004a). 
Five high-affinity glutamate transporter subtypes have been identified in the CNS, 
EAAT-l (GLAST), EAAT-2 (GLT-1), EAAT-3 (EAAC-1), FAAT-4 and EAAT-5 
(Storck et al., 1992; Pines et al.. 1992a, Kanai and Hediocr, 1992b, Fairman et al., 
1995; Arriza et al., 1997b). The different acronyins (EAAT, excitatory amino acid 
transporter; GLAST, glutarnate-asparate transporter; GLT, glutamate transporter, 
EAAC, excitatory amino acid carrier) used to described the glutamate transporters al-C 
used to describe the glutamate transporters in different species, for example EAAT-l 
is the name for human subtype whereas GLAST is the name for the equix, alent subtype 
in the rat, they do not reflect the functional differences among the transporters. EAATs 
are members of a unique family of proteins, called the solute carrier family I (SLCI) 
(For reviews see Kanai and Hediger, 2003a, Kanai and Hediger, 2004a) and disphiy 
considerable homology. sharing 50-60% sequence identity with each other at the 
arnino-acid level, and '10-40% homolo(, N- with ASCTI and ASCT2 (alanine-serinc- 
cysteine transporters) which are also members of the SLCI familý- of proteins (Kanai 
and I lediocr, 2004b). 
All fivc of the glutarnate transporter subtypes catalyse Na+ and K+ coupled transport of 
L-glUtarnate. maintaining a largc concentration gradient across the cell membrane 
(Danbolt, -'001d-, 
Kanai and Hediger. 2003b, Shigen et al., 1-004). It has been Cý - 
"s -wested 
by sc\cral studies that I'AA-rs have a dual function as both a glutai-nate u( 
tran"Portcr (I. C. SUbstratc recognition. binding. transport and ion cmiplimg) and i 1 1011 
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channel (i. e. chloride flux) (Slotboom et al.. 2001: Amara and Fontana. Kaimei- 
and Borre, 2002; Ryan et al.. 2004 
EAATs express distinct molecular and pharmacological characteristics. and are 
observed in distinct localisations at both the cellular and regional level. EAATl is 
expressed by glial cells throughout the CNS and is found at high concentrations in 
Bergmann glia of the cerebellum (For reviews see Danbolt. 2001c. 
Kanai and Hediger, 2004c; Beart and O'Shea, 2007a). EAAT2 is found predominantly 
in glial cells, and its expression can be observed abundantly throughout the CNS (For 
reviews see Danbolt, 2001b; O'Shea, 2002c, Kanai and Hediger. 2004d; Beart and 
O'Shea, 2007b). EAAT3 and EAAT4 are found almost exclusivek- in neurons. 
EAAT3 is widespread throughout the CNS, whereas EAAT4 is expressed mainly bý 
cerebellar Purkinje cells (For reviews see Danbolt, 2001a, O'Shea, -1002a. Kanai and 
Hediger, 2004e, Beart and O'Shea, -2007c). 
but is also expressed at lowel- levels in the 
forebrain (Dehnes et al., 1998, Massie et al., 2001). EAAT5 is expressed 
predominantly in the retina where it is present in rod photoreceptor and bil)olar ccils 
(Arriza et al., 1997a; Pow and Barnett, 2000). 
1.3.4 Vesicular Glutamate transporters 
Specific transporters expressed on the vesicle membrane determine the transmitter 
caroo that Nvill be packaged, carried and subsequently released following fusion mth 
the plasma membrane. 
The vesicular transport system for excitatory amino acids in the CNS has only recelitly 
been discovered. Research carried out by Ni et al. in 1994 (Ni et al., 1994c) discovered 
a iimel gciic wlilcli \\as upregulated in prfiiiai-y cultures of rat cerebellar granule 
iicurons after exposure to subtoxic IcN-els of the N-ii-lethyl-D-aspartate (NNIDA) 
receptor apoillst NMDA- lilicction of this gciic into XcIlopus oocytes resulted ill 
Na+-dependent phosphate transport similar to that observed in native oi- recombinamly 
expressed Wiley Na'-dependent cotransporters. The gene was 560 amino zicids 
(61 kDa). and was predicted to liavc six to eight transi-nembrane domains. with L_ 
ated phospliorylation sites for protein kinase (PKC). t\rosine kinase and postulL 
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calmodulin-dependent kinase 11 on the intracellular loops (Ni et al.. 1994d). Analysis 
of the iiiR\A revealed its expression was restricted to the brain. and was shown to 
have 32% identity to a rabbit kidney type I Na_/phosphate cotransporter. therefore it 
was named brain specific Na+-dependent inorganic phosphate cotransporter (BNPI) 
(Ni et al., 1994c). The discovery that BNPI mRNA expression was restricted to 
neuronal cells which use glutamate as a neurotransmitter. including cortical cells. 
granule cells of the dendate gyrus. cerebellar granule cells, and hippocarnpal 
pyramidal cells (Ni et al., 1995) strongly suggested a specific function for BNPI iii 
glutarnatergic neurons (see Table 1.1). Further studies by Bellocchio et al. (1998. 
2000), and Takamori et al. (2000) independently confirmed that BNPI functions to 
load L-glutamate into recycling intracellular vesicles, and due to this BNPI was 
renamed vesicular glutamate transporter I (VGLUTI) (Bellocchio et al.. 1998e, 
Takamori et al., 2000c; Bellocchio et al., 2000c). Glutamate transport by VGLUTI 
was inhibited by the H+ ionophore, indicating that an electrochemical H+ gradient is 
the driving force responsible for transport (Bellocchio et al.. 2000b: Takamori et al., 
2000b). 
Evidence that VGLUTI was absent from many excitatory synaptic pathways that were 
thought to use glutamate as a neurotransmitter, indicated that there may be more than 
one vesicular glutarnate transporter (Bellocchio et al., 1998d). Recently a second 
brain-specific Na+/phosphate cotransporter was identified, a 582 amino acid (64.4kDa) 
protein with 82% amino acid homology to VGLUTI (Aihara et al., 2000c; Hisano et 
al.. -2002e). This novel transporter 
known as differentiation-associated Na+/phosphate 
cotransporter (DNPI) was cloned during a differential display technique to identify the 
ocnes expressed during rat pancreatic AR42J cell differentiation. The gene which was 
upregulated durino differentiation was identified as a Na+/phosphate cotransporter as 
expression of the cDNA in Xenopus oocytes, like VGLUTL enhanced Na+-dependent 
phosphate transport (Aihara et al.. 21000b). DNPI has been predicted to have eight 
transmembrane domains from its amino acid sequence, with putative glycosylation 
Sites t-)ct\\-ccii the first two putative transmembrane helices (Varoqui et al., 2002c). 
DNPI has been shown to be highly expressed in sviiaptic vesicles. where it has been 
sl, oN\ii to tunction ýis a vesicular (-Autarnate transporter \-N-ith properties similar to 
\'GLU 1 1. and \\-, is therefore renamed vesicular g1titaniate transporter 2 (VGLUT2) 
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Region 
VGLUTI 
mRNA Protein 
VGLUT2 
mRN. A Protein 
N'GLUT3 
mRNA Protein 
Accumbens nuceus 
Amygdala 
Cerebellar cortex 
Dorsal thalamic nuclei 
Habenula 
Hippocampus 
Hypothalamus 
Midbrain 
Neocortex 
Olfactory bulb 
Piriform cortex 
Retina 
Septum 
Striatum 
Subthalamic nucleus 
Table I. I: Regional distribution of VGLUT isoforms in rat brain. Expression 
levels: High (***), Medium (**) and Low (*) (Herzo(-, et al., 2004, Hisano et al., 
2002). 
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(Herzog et al.. 2001 a: Takamori et al.. 2001 b: Frerneau. Jr. et al.. -'()()If. 
Varoqui et al.. 
2002c). Glutamate transport by VGLUT2 N\as shoxvn to be dependent oil If- 
electrochemical gradient. like VGLUTI. as well as electric potential (Varoqui et al.. 
2002b). 
Although these transporters share high sequence identity. and have highly similar 
substrate specificity, kinetics and pharmacology. these VGLUT proteins do differ in 
their expression profiles. VGLUTI and VGLUT2 are predominantly expressed in tile 
adult brain, expressing complementary expression patterns (Table 1.1). 
mRNA has been shown to be predominately expressed in several discrete regions 
including the cerebral cortex, hippocampus. cerebellar cortex, and amygdale (Ni et al., 
1994b), where as VGLUT2 mRNA is preferential ly expressed in the spinal cord. 
brainstem, and the diencephalic structures, including the thalamus, of both human and 
rat brain (Aihara et al., 2000a; Herzog et al., 2001a; Fremeau, Jr. ct al., . '00 1 e, 
Varoqui et al., 2002a, Hisano et al., 2002d). In the cortex at both the mRNA and 
protein level, terminals in all layers label for VGLUTL apart from fourth Liver which 
principally labels for VGLUT2 (Takamori et al.. 2001a; Fremeau, Jr. et al., 2001d). In 
the denate gyrus and the hippocampus. granule and pyramidal cell layers label for 
VGLUT2 (Fremeau, Jr. et al., 2001c), however all the terminals in the dendritic field 
stain for VGLUTI (Bellocchio et al.. 1998c). Although the majority of glutarnatergic 
iieurons in the brain express one of the VGLUT isoforms several studies Ilavc 
sLiooested that cerebellar mossy fibres, pinealocytes, primary sensory neurons, 
cerebellar unipolar brush cells, and certain pancreatic islet cells coexpress both 
VGLUTI and VGLUT-2 (Hisano et al., 2002c- Hioki et al., 2003: Hayashi et al., -1003. 
Li ct al., -20033, 
Nunzi et al.. 20033: Morimoto et al.. 2003a; Bai et al.. 2003d). 
A third vesicular olutan-iate transporter. VGLUT'), has been discovcrccl wilich has 
more than 70() o structural identity to VGLU-rI and VGI-t'T-'. and shares the glutamate 
transport characteristics similar to those of VGI, ('-I-l and \I'GLU. "I--' (Reimcr et A. 
1998: 1 Aarnon ct al., 200-1, Hisano et al.. -'()()-'b. Frerneau, Jr. et al.. 2002b. Gras et 
has a vcrv different distribution to -, ()()-"b, Bai et al.. 200)c). HoNNc\ci-. VGLUT3 
c*ther V(T LL' I'l or VOLUT. sincc it is restrictcd to non-glLitarnatcn-11c neurons and 
\\ýis ofien found to colocalisc with other neurotransmitter ti-misportei-, (Fable 1.1 ). 
I'-' mR\A and protein is expi-csscd by a proportion of the (iABAcr(-, tc 
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interneurons in the cortex, hippocarnpus and interpeduncular nucleus, and cholinergic 
interneurons in the striaturn and nucleus accumbens. This isoform has also been shown 
to be expressed in serotoninergic neurons of the raphe nuclei (Schafer et al., 2002a, - 
Gras et al., 2002a; Somogyi et al., 2004; Herzog et al., 2004). These results suggest 
that VGLUT3 in conjunction with other neurotransmitters is involved in the co-release 
of two neurotransmitters by neurons in the adult brain. Recently experiments have also 
identified a role for VGLUT3 in glutamate release from astrocytes (Montana et al.. 
2004). The precise number of amino acids composing VGLUT3 is not definite, as 
studies by Gras et al. (2002) suggest that rat VGLUT3 is 589 amino acids (64.7 kDa) 
where as another study by Fremeau et al. (2002) have reported rat VGLUT3 be 530 
amino acids (Fremeau, Jr. et al., 2002a; Gras et al., 2002c). However, a 601 amino 
acid (65kDa) secondary structure for mouse VGLUT3 has been reported which is 
predicted to have eight to ten transmembrane domains (Schafer et al., 2002b). As seen 
with VGLUTI and VGLUT2 glutamate transport was shown to be driven by a H+ 
electrochemical gradient (Varoqui et al., 2002d). 
1.4 Non-neuronal glutamate signalling 
Evidence is accumulating for the expression of components required for glutamatergic 
signalling in non-neuronal tissues. Functional glutamate receptors have been identified 
in several peripheral tissues and organs including the heart, intestine, kidney, pancreas, 
placenta, mammary gland and bone (for reviews see Skerry and Genever, 2001b; 
Hinoi et al., 2004a). Table 1.2 summaries the expression of the glutarnatergic system 
in peripheral tissues. 
Glutamate signalling in other tissues 
The pancreas consists of several types of endocrine cells, predominantly found in the 
islets of Langerhans. including glucagon-secreting alpha (a) cells, and insulin- 
secreting beta (P) cells. The P-cells are the most abundant, accounting for two thirds of 
the islet cells, where as the ct-cells are less abundant. accounting for only a fifth of the 
islet cells. Subunits of AMPA. KA, NMDA and metabotropic glutamate receptors 
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(mGluR2A, -4, -5, -8, GluRl. -2. -_'3. -4. -6. -7. K. A-2. NR2A! (', D and NNRI) have been 
shown to be expressed by the Islets of Langerhans In the pancreas. modulating both 
insulin and glucagon secretion (Bertrand et al.. 1992: Bertrand et al.. 1993. Bertrand et 
al., 1995; Inagaki et al., 1995: Weaver et al.. 1996a; Liu et al.. 1997b. Brice ct al.. 
2002; Tong et al.. 2002: Bai et al.. 200-")b). SLIUgesting, that glutarnate may be all 
iiitracellular signal mediator in the islet. It has therefore been suggested that in P-cclls 
glutamate transporters may be directly involved in controlling insulin release 
(Maechler and Wollheim.. 1999). Glutamate transporters similar to EAAT--' have been 
cloned from the pancreas, and immunocytochernical studies have shown that EA.. \T--' 
is present in P-cells, but not by the a-cells (Manfras et al., 1994, Gammelsxter et al.. 
1999). 
VGLUTs similar to VGLUTI and -2 found in the CNS havc also been identified in 
pancreatic (x- and P-cells (Bai et al.. 2003a), however no other cloned (. Ylutamate 
transporters have been shown to be expressed by islet cells so far. The cells have been 
shown to express receptors for other neurotransmitters including acetý'Icholine and 
GABA (Molnar et al., 1995; Weaver et al., 1996b: Liu et al.. 1997a). The expression 
of the inhibitory neurotransmitter GABA in pancreatic cells. suggests that a synapse- 
like organisation may be present in the pancreas. 
In the gastrointestinal tract, glutamate has been shown to modulate hi stamine- induced 
ýicid secretion in the rat stomach (Tsai et al.. 1999). as well as contractility in the 
(Yastric fundus, jejunum, ileum and large intestine (Shannon and Sawyer, 1989, Sinsky 
and Donnerer, 1998, Li et al.. 2005). VGLUT2 has been shown to be abundant in the 
antrurn and pylorus of the stomach, and in the intestine two types of glutarnate 
transporters have been identified. VGLUT2 which is abundant in the ileum and 
I'AAT-3' has been found in the intestine (Kanai and Hediger. 1992a). 
Glutarnate signalling has been shown to have an important, but poorly understood. 
function in the metabolism ol' heart imocNtcs (Dinkelborg, et al.. 1996). is 
cxprcsscd in myocardial mitochondria \\hcrc it has been shoxvn to function as a 
makitc aspartýitc shuttle. aiding nictabolism (Ralplic et al.. 2004). Other (-, lutarnatc 
Chapter I 
iGluRs mGluRs 
issue/cell GluTs VGluts NNIDA ANIPA KA Group Group 11 Group 
Table 1.2: Expression of the glutamatergic system in peripheral tissues 
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transporters and GluRs have been identified in human and rat heart including GLAST. 
EAAT-3, GluR- 1, -2,, -3, -4, -5, -6 and -7, KA- I and -2, and mGluR- I a, -2. -33 and -5, 
which are thought to improve the mechanical function of the ischaemic or hypoxic 
myocardium. (Nakayama et al., 1996; Gill et al., 1998; Gill et al., 1999). 
Glutamate signalling has also been documented in the skin, human keratinocytes have 
been shown to express functional NMDA receptors (NRI, NR-2A and -2B), AMPA 
receptors (GluR-2 and -3), mGluRs (-la, -2 and -3) and glutamate transporters 
(EAAT-2 and -3) (Morhenn et al., 1994; Genever et al., 1999a; Nahm. et al., 2004). 
Expression/function profiling has identified some components of glutamate signalling 
in cells derived from haematopoietic stem cells (HSCs) including monocytes, 
macrophages, megakaryocytes (discussed in Chapter 1.5), platelets (discussed in 
Chapter 1.5), B and T lymphocytes, implicating glutamate-mediated intercellular 
signalling in the control of haemostasis and blood cell function (Kondo et al., 1997; 
Akashi et al., 2000; Hao et al., 2001; Manz et al., 2002). 
Functional glutamate transport systems have been identified in macrophages derived 
from human blood monocytes including those mediated by high-affinity glutamate 
transporters similar to those found in embryonic neurons and neonatal astrocytes 
(EAATs), and sodium independent cysteine/ glutamate antiporters, which transport 
extracellular cysteine in exchange for intracellular glutamate (Bannai, 1986; Rimaniol 
et al., 2000b). Interestingly, these transporters are only functional in the presence of 
inflammatory factors such as TNFa and liposaccharide, which increase cysteine 
uptake suggesting that glutamate transport is regulated locally by inflammation and 
acts to increase antioxidant activity. Monocyte-macrophages have been reported to 
remove excess glutamate from the medium of neuronal cells cultured in the presence 
of high concentrations of this amino acid, leading to the suggestion that EAATs on 
macrophages protect neurons against the damaging effects of glutamate-mediated 
excitotoxicity during inflammation. It has been suggested that monocyte-macrophage 
cysteine/ glutamate transporters play important roles in the regulation of glutathione 
(GSH) synthesis (a ubiquitous antioxidant synthesised from cysteine, glutamate and 
glycine), increasing intracellular GSH levels and reducing oxidative stress in response 
to elevated extracellular glutamate (Rimaniol et al.. 2000a, Rimaniol et al., 2001). In 
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HIV infection. neuronal damage is caused by micoglial activation. involvini-) oxidatiVe 
stress. glutarnate-med1cated excltotoxicit), and apoptosis. In healthy Individuals. 
astrocytes normally act to maintain low extracellular alutarnate concentrations in the 
brain preventing neurotoxicity. This neuoroprotective ftinction is impaired followill, -, 
HIV infection. Fxpression of EAAT1 on brain macrophages may compensate for 
impaired astrocyte function by restoring glutamate transport activitv. removill(u, excess 
extracellular glutamate and locally increasing GSH and antioxidants levels (Gras et 
al.. 2003; Vallat-Decouvelaere et al.. 2004). Other experiments have demonstrated that 
factors secreted from HIV-1-infected monocyte-macrophages havc the abilitN to 
activate NMDA receptors comprised of NRla and NR213 subunits in the brain. 
implicating a role for these cells and NMDA receptors in the neuronal degeneration 
observed during HIV associated dementia (Xiono et al., 2003a). On a similar vc1n, 
secretory factors derived from amyloid stimulated monocyte-macrophagcs found ill 
patients with Alzheimer's disease have been shown to directly actiN, atc NMDA 
receptors which may contribute to the pathooci-icsis of the disease (Xiong et al., 21004). t7 
Together, these data indicate that monocýle-macrophages play an important role in 
modulating glutarnate signalling in the CNS. and raise the possibility that they also 
i, c(, Lilate glutarnatergic pathways within the bone marrow from where they are derived. 
In recent studies it has been demonstrated that resting peripheral blood lymphocytes 
(PBL) and Jurkat T cells express genes for NMDA receptors including NRI and 
NR213. PBL induced to proliferate with phytohema(, (Ylutinin (PHA) were demonstrated 
to express elevated IeN, els of NRI in addition to NR2A and NR2D, suggesting T-cell 
acti\*ation causes the up-regulation of gene transcription for NRI and these additional 
subunits (Miglio et al., 2005a). These data confirm previous observations that restin r_1 9 
rat F-cells express the NRI subunit (Boldyi-eN- et al.. 2004). Functional effects of 
NNIDA receptor signalling in T-cells has been investigated using MK-801 and D-AP-5. 
a cornpetitiN, e antaoonist. Both compounds \Ncrc sliown to inhibit PIJA-induced T-cell 
proliferation, but did not cause Cell Cycle arrest and had no effect on cell \, iability. 
sLi, _,, _, cstin, _, 
NNMDA receptor activation docs not influence these factors. Howe\, cr 
inhibition of' the cxpression of ('D-'--;. a ccll-surl1icc marker of T-cell acti\-ation by 
these antagonists suggcstccl that NAIDA receptor signallin(-, rna,, control the cark- 
phascs of cell activation (Miolio et al.. -2005b). It, 
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1.4.2 Glutarnate signalling in bone 
The cylindrical cavities of bones are filled with a network of thin. calcified trabeculae 
and bone marrow. Bone marrow contains a diverse population of cells including botli 
haernatopoletic and non-haernatopoietic stem cells. which are the precursors to 
osteoclasts and osteoblasts respectively. 
The identification of glutamate signalling in bone originated from attempts to identify 
potential targets for therapeutics to manipulate bone mass to treat bone disorders 
(Mason et al., 1997f). A technique known as differential RNA display was used to 
investigate the changes that occur in osteocyte gene expression after mechanical 
loading of rat bone in vivo. One of the genes found to be down regulated by this 
process was GLAST (EAAT-1 in humans). Immunohistochernical studies using 
neonatal rat tibiae, confirmed the expression of GLAST in old as well as i-icN\-Iy 
incorporated osteoblasts and osteocytes (Mason et al.. 1997e). A novel splice variant 
of EAAT-L EAAT-la, has also been cloned from bone which is identical to the 
neuronal EAAT-I but lacks exon 3. The deletion of exon 3 is thought to alter the 
membrane topology of the transporter leading to the cellular efflLIx of glutamate 
instead ol'its accumulation (Huggett et al., 2000). More recent studies have identified 
that osteoblasts den-ionstrate functional glutamate uptake in vitro, and these findings 
havc been confirmed by the identification of a number of glutamate transporters 
including EAAT-1, -2 and -31 (Takarada et al., 2004). 
Molecular and cellular biological techniques have identified functional GluRs on bone 
forming osteoblasts (GluR-'), KA-I and -2. NR-I. -2A/B/D, mGluR-1, -4 and -8). and 
bone rcsorbim osteoclasts (NR-1, -2A/B/D) in vivo and in vitro, where they thOU. JIt 
to modulate cellular function (Mason et al., 1997d, Chenu et al.. 1998a; Gu and 
Publicover. 2000. Itzstein et al.. 2001; Hinoi et al.. 22001: Blian(-'Li et al.. 2001c: Him 
et al., 22002. 
Kalariti and Koutsilleris, 2004). NMDA receptor anta(-, onists, \IK-801 Z: ' 
and AIA' lia\, c bccii sliowii to inhibit ostcoblast differentiation and bone formatim 
(Birch ct al.. 1997. Skcrry. 1999). as \\cll as bone resorption in osteoclasts (Chenu et 
al., 1998b. It/stcin et al.. 2000a). Sustained exposure to NMDA antagonists was 
showil to inhibit the expression of CBFA-l. a bone dit'tCrentiation transcription factor. 
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at both the mRNA and protein level in osteoblasts (Hinoi et al.. 2003). and reduced the 
number of resorption pits on cortical bone slices inhibiting the fori-nation of the 
adhesion- Induced sealing zone between osteoclasts and the bone required for bone 
resorption (Chenu et al.. 1998c: Itzstein et al.. 2000b). These reports strongly stio(lest 
that NMDA receptor antagonists affect osteoclastogenesis possibl\ through osteoblast- 
derived growth factors (Peet et al.. 1999: Taylor. 2002). 
Recent studies have identified components essential for regulated glutarnate 
exocytosis in presynaptic neurons in osteoblasts (Bhan(, u et al., 1001b). Nlolectilar 
techniques including RT-PCR, northern blot analysis and western blot analysis have 
shown expression of the target membrane-SNARE proteins SNAP-25 and syntaxin 4 
and the vesicular-SNARE protein VAMP. the minimum molecular requirements for 
core exocytotic complex formation in osteoblasts. Immunofluorescent localisations 
revealed peripheral SNAP-25 expression on osteoblastic cells, particularly at 
intercellular contact sites, colocalising with immunoreactive glutamate and tile 
synaptic vesicle-specific protein, synapsin 1. Osteoblastic expression of SNARF 
accessory proteins, including muncl8, rSec8, DOC2, syntaxin 6. and synaptophysin. 
required for glutamate exocytosis in the CNS have been identified. mRNA for the 
putative Ca 2 +-dependent regulators of ,,, esicle recycling activity, synaptotagmin I and 
the GTP-binding protein Rab3A are also identified by northern blot analysis. I Nidence 
for vesicular glutamate exocylosis from osteoblasts has also been supported by the 
observation that osteoblasts express the vesicular transport protein VGLUTI, which is 
involved in the packaging of glutamate into synaptic vesicles with in the synapse 
(Bhangu ct al., 2001a) and the identification of vesicles which are able to undergo 
repetitive recycling at peripheral sites, a process central to glutamate exocytosis in 
glutaniatergic neurons, in osteoblasts by FMI-43 labelling, a fluorescent-based 
technique developed to study intracellular trafficking (P. G. Genever and P. S. Bhangu. 
personal communications). It has also been demonstrated that osteoblastic cells 
actively release olutarnate spontaneously in a differentiation-dependent manner 
(Bhanpu et A.. 2001d, Genever and Skerry, 2001e). These data provide evidence that CN - 
ostcoblýists ýirc able to dii-cct olutarnate releýisc by re('Lllated vesicular cxocytosis, 
mimickmg, pi-csynaptic 21LItarnatcrgic ncurons. indicating that a process \Nith 
sinjilarities to that obscr\ ed in s% iiaptic neUrotraiisinission occurs in bone. 
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For a recent review of NNIDA signalling in bone the reader is directed to a review by 
Spencer et al. (Spencer et al.. 2007) and Fil.! LII'C 1.1 ýý which summaries glutainate 
signalling with in the bone microenvironment. 
1.5 Glutamate signalling in megakaryocytes andplatelets 
1.5.1 Glutamate release and uptake in platelets 
Previous reports have identified functional NMDA-type glutamate receptors oil human 
platelets. In neuronal cells NMDA receptors bind MK-801 at high alutamate or t__ 
glycine concentrations (Ransom and Stec, 1988). HoxN-ever, in platelets MK-801 failed 
to bind to the NMDA receptors in the presence of either olutarnate or glycitic 
Suggesting that in platelets these receptors are functionally distinct from those found iii 
neuronal cells. NMDA receptors have an anti -aggregation activity \N-ithin platelets. 
Activation of NMDA receptors causes glutarnate to antagonise the aggregation 
properties of arachidonic acid (AA), platelet acti\'ating factor (PAF) and adenosine 5, - 
diphosphate (ADP) (Franconi et al.. 1998a). Also, stimulation of the NMDA receptors 
has been shown to prevent platelet aggregation by inhibiting the synthesis of 
thromboxane A2, a platelet aggregation promoter. from AA (Francom et al., 1996b). 
Molecular and morphological studies have shown the presence of three major 
olutarnate transporters, EAATI, EAAT2 and EAAT' 1, in human platelets similar to 
those found in the CNS (Zoia et al.. 2004c, Rainesalo et al.. 2005. Hoogland et al.. 
2005c). Zoia et al have shown that the EAAT I and EAAT3 3 inhibitor SOS significantly 
reduced olutainate uptake by platelets. while the specific EAA-F-') inhibitor DHK. did 
not si(-, iiifi clylutamate uptake, suggesting EAAT2 does not seem to play a icantly affect -1- 
major role in platelet olutamate uptake activity (Zoia et al.. 21004b). However, studies 
by I-loodland ct al concluded that F-AAT-1 was the predominant (-Ylutamate transporter 
in pkitclets, rcsponsible for platelet glutamatc uptake (Hoogland ct al.. 2005b). Their 
, Studies lia\'c slioN\ ri that I AA-F'- is responsible for the Hicrease M sodium-dependent 
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glutamate uptake in human platelets activated with thrombin, and EAAT2 
immunoreactivity was found to be predominately in a-granules, suggesting thrombin 
stimulates glutamate transport from a-granule EAAT2 to the cell membrane. The 
functional significance of thrombin-stimulated glutamate uptake by blood platelets is 
yet to be determined (Hoogland et al.. ) 2005a). Biochemical and molecular studies 
have also revealed that EAATI and glutamate uptake is down regulated in ageing 
patients, and that a further glutamate uptake reduction is observed in Alzheimer's 
disease patients (Ferrarese et al., 2000; Zoia et al., 2004a). These results indicate that 
platelet glutamate transporters may be able to be used as markers to identify the 
significance of glutamate in patients with neurophychiatric disorders. 
Interestingly, recent studies have established that platelet exocytosis occurs through 
the formation of SNARE complexes involving t-SNAREs SNAP-23, and syntaxin 2 
or 4 (Polgar and Reed, 1999; Reed et al., 2000; Chung et al., 2000; Shirakawa et al., 
2000; Lemons et al., 2000; Chen et al., 2000b), and the v-SNARE cellubrevin/VAMP- 
3 (Bernstein and Whiteheart, 1999a). Cellubrevin/VAMP-3 is the only v-SNARE to 
be described in platelets (Bernstein and Whiteheart, 1999b), botulinum toxin-based 
studies indicate that one v-SNARE is required for a-granule exocytosis, however it is 
unclear whether it is VAMP-3/cellubrevin (Flaumenhaft et al., 1999). Platelets also 
contain the general accessory proteins a-SNAP, y-SNAP, and NSF (Lemons et al., 
1997). Dense core granule secretion is mediated by the SNARE complex accessory 
proteins such as a-SNAP and NSF, and in vitro exocytosis assays have determined 
that the t-SNAREs SNAP-23 and syntaxin 2, but not syntaxin 4 or 7, are involved in 
dense core granule exocytosis from platelets (Chen et al., 2000a). Sec/Munc (SM) 
proteins, such as Munc 18, have a critical role in platelet granule secretion, selectively 
interacting with platelet syntaxins leading to platelet granule exocytosis (Houng et al., 
2003). 
Recent studies have shown that human platelets express the vesicular transport 
proteins VGLUTI and VGLUT2, and have the ability to release glutamate following 
aggregation (Tremolizzo et al., 2006). The role of glutamate in platelets is currently 
unknown but considering that human platelets express NMDA-like receptors, a role 
for glutamate in platelet activation and aggregation has been proposed (Franconi et al., 
1996a, Franconi et al., 1998b). 
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L-5.2 Identification of functional NMDA receptors in mega ka ryocytes 
As previously discussed megakaryocýles represent less than 0.5% of the rare myeloid 
cell population in the bone marrow and are responsible for the production and releas-C 
of I/ 10 '' platelets into blood and the systemic circulation each day. Megakarvocytes 
are \'Ital to the maintenance of haemostasis (blood clotting and wound healing) (131-1.1110 
and Hoffman, 1998: Italiano, Jr. et al.. 1999e) although there is no\\- acCUMulating, 
evidence that megakaryocytes have additional roles within their bone marro\\ 
microenvironment including the regulation of haematopoietic and mesenchymal stem 
cell differentiation, through the local release of growth factors and cytokines. It has 
also been demonstrated that megakaryocytes express numerous factors involved in 
bone remodelling and bone cell function, including NFKB ligand (RANKL) 
(Kartsogiannis et al., 1999), osteonectin, osteocalcin (Kelm, Jr. et al., 1992: Thiede et 
al., 1994), TGF-P and their receptors, calcium-sensing receptors (House et al., 1997), 
oestrogen receptors (Bord et al., 2001) and NMDA-type glutamate receptors (Genever 
et al., 1999k). Functional roles for megakaryocytes in the regulation of bone 
remodelling have been suggested based on the phenotypic analysis of transgenic mice, 
\ý, -hich display skeletal abnormalities and from pharmacological studies. Mouse models 
over-expressing thrombopoletin (TPO). the major hormone controlling 
nicoakaryocytopolesis display osteopetrosis (Yan et al., 1996). and TPO itself has L_ 
been shown to inhibit osteoclastogenesis (Wakikawa et al., 1997). These data indicate 
that megakaryocytes haN,, e direct effects on remodelling, affecting the osteoblastic 
factors inN, olved in both bone formation and resorption. 
Using Northern blot analysis and reverse -transc ri ptase polymerase chain reaction (R'I'- 
PCR) it has been slioN\ii that rat bone marrow cells. human megakaryoc-Ytes and the 
nicoakarNoblastic cell line, MEG-01. expressed the mRNA for the NMDA receptor 
Subunits, NNIDARI (NRI) and NNIDAR2 (NR2) (Geiiever et al., 1999j: Hitchcock et 
al., 200-3k). In vk-o radioligand bindnig, of ['3H]-MK-80I. confirmed that tile 
megAaryocytic NNIDA subtiiiits coordinated into a functional open-channel forming 
NNIDA-typc glutaniate receptor. and that antagonism of these receptors \\ith MK-801 
had 111'OfoUnd 111111bItOl-V CffCcts oii MTO-01 differentiation (Genever et al.. 19991). 
NN, Ijcjj I, -cjted with phorbol-inyristatc acetate (I'MA) Nil. (y-01 cells differentiate into a 
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megakaryocyte- like phenotype., increasing expression of CD41 (GPIlb'llla) and 
producing platelet-like particles (Takeuchi et al.. 1991b). Treatment of cells with 
MK-801 (50-150ýtM) in the presence of PMA significantly inhibited CD41 expression 
ý 4-- by 30-55%. In more recent studies it has been demonstrated by RT-PCR that CD-1 
derived human megakaryocytes express mRNA for NRIA and NR22D receptor 
subunits. in addition to the NMDA receptor accessory proteins. Yotiao and post- 
synaptic density protein 95 (PSD-95). NMDA receptor antagonism has been 
demonstrated to inhibit TPO-induced megakaryocytic differentiation of CD-')4'- I IsCs. 
as determined by reduced expression of the megakaryocyte markers CD61. CD41a and 
CD42a. Treatment of mature CD34+-derived megakarvocytes with MK-801 has also 
been shown to inhibit proplatelet formation, without affecting cell proliferation ol- 
apoptosis and when examined by transmission-electron microscopy (TEM) these cells 
lack a-granules, multi-lobed nuclei and demarcated membranes, which \\-cre abundant 
in untreated mature megakaryocyte controls (11itchcock et al., 2003j). These findings 
support a functionally significant role for NMDA receptor signalling in 
megakaryocytopolesis and platelet production. 
Therefore the observations that bone cells express the glutamate/aspartate transporter. 
GLAST (GLT-1) (Mason et al. 1997), and that NMDA-týlpe glutamate receptors are 
found on bone marrow megakaryocytes suggest a role for glutamate signalling in 
paracrine intracellular communications withiii the bone marrow microenvironment. 
1.6 Primary aims 
Work from our laboratory has demonstrated that megakaryocytes express functional 
neuroi-cceptors with similarities to the NMDA-tvpe glutamate receptors in the central 
nervous systern (CNS) and that antagonism of these receptors prevents normal 
nieg, ak-arvocyte differentiation and platelet function (Geiiever et al., 1999h, Hitchcock 
et al., 20031). This \\as the first evidei-ice of glutamatc shynalling in mcoakar%ocytes 
and identified a potcritially novel mechanism for regUlatii-ig, inegakaryocytopoicsis and 
platelet release. I lo\\I-c\-er the cellular source of glLitai-nate within bone niarro\\ has vct 
tk) be determined. Preliminary evidence from our laboratory suggests that 
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megakaryocytes are able to both send and receive glutamate signals (Genever et al.. 
1999g; Hitchcock et al., 2003h). Therefore the aims of this PhD project are to: 
determine the expression patterns of SNARE and related exocytotic proteins in 
megakaryocytes 
measure glutamate release from megakaryocytes in the presence and absence 
of appropriate stimuli 
identify the functional effects of activation and inhibition of glutarnate release 
on megakaryocyte differentiation and platelet production in vitro. 
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General Materials and Methods 
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Chapter 2: 
2.1 Cell Culture 
General Materials and Methods 
Plasticware and cell culture reagents 
The plasticware and reagents used for cell culture were purchased from Litc 
'Iechnologies (Paisley, UK) unless otherwise stated. Cells were maintained in a 
humidified atmosphere at 37'C in 5%CO2. All medium Nvas supplemented Nvith 
IOOU/ml penicillin, 100ýtg/ml streptomycin and 2 mmol/l L-glutamine unless stated 
otherwise. 
2.1.2 Cell line cultures 
MEG-01 and human erythroleukaernia (HEL) megakaryoblastic cell lines were 
maintained as suspension cultures in RPMI 1640 medium (without L-glutamate) with 
10% fetal bovine serum (FBS). For the experiments investigating cell viability, the cell 
lines were incubated in RPMI 1640 medium (without L-glutamate) without phenol 
red. Medium was changed every 3 days, passaged by centrifugation (440g for 5 
minutes at room temperature) and re-plated at IxIO cells/ml. Megakaryocytic 
differentiation was induced by treating both cell lines with IOOnM phorbol myristate 
acetate (PMA; dissolved in ethanol) for 72 hours. For non-PMA treated samples, an 
equi\'alent \'olume of ethanol vehicle was added. 
2.1.3 Extraction and expansion of mouse megakaryocytes 
Primary mouse i-negakarvocytes %\ci-c extracted and expanded using a technique, 
dcscribed by Prof. Kenneth Kaushansky. San Dicuo (personal COMMUnication). 
The t, emora and tibmc \\ci-c removed from fivc adult B6('ba micc. tile ends of tile 
bones removed and the bone marrow flushed out with Iscove's modified Dulbecco's 
and -'rifl, tibia) in to a 50ml falcon medium (INIDNI. Sionia) plus -'Oo 
FBS Onfl/ tenlui 
S 
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tube. The suspension was passed twice though a 22-gauge needle to break up cell 
clumps, and then passed through a 70 - 100 ýim filter to remove debris. The cell 
suspension was centrifuged (-140g for 5 minutes) and the supernatant removed 
carefully. The cell pellet was then resuspended in 95ml Optimem (Invitrogeii) 
supplemented with lOOU/ml penicillin, 10(), Lt(-'/Ml streptomycin. rnmold L- 
glutamine, and 5ml BHK-TPO conditioned media (see section 2.1 -3.1 
for details). The 
cells were then cultured for 3 days in a T175 culture flask in a humidified atmosphere 
at 37'(' in 5%CO2. After 72 hours the cells were centrifuged at 160g for 5 minutes 
and resuspended in 8ml IMDM containing 2% FBS, the megakaryocytes N\cre then 
purified on a BSA gradient (as described by Drachman et al., 1997) for 30 minutes to 
allow the larger megakaryocytes to settle to the bottom. The lower 7ml was siphoned 
off into a 15ml universal and centrifuged at 160g for 5 minutes and resuspended in :: 71 
Iml Optimem supplemented with lOOU/mI penicillin, lOOpg/ml streptomycin and 
2mol/l L-glutamine for use in other experiments. 
2.1.3.1 TPO conditioned media 
BHK-TPO cells (Baby Hamster Kidney cells engineered to constitutively release 
thrombopoletin (TPO), a kind gift from Prof Kenneth Kaushansky, San Diego) were 
Cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) with 10% FCS in 
a hUrnidified atmosphere at 37'C in 5%CO2. The medium was changed every 72 
hours until the cells were 70% confluent. The medium was removed from the adherent 
cells hy gentle aspiration and they were washed with 5ml IxPBS, and incubated for 5 
minutes with 22ml trypsin/ 
EDTA at 37'C to remove the cells from the flask. DMI. 'AI 
with 10% FBS was added to the cells and they were centrifuged at 400g for 5 minutes. 
The cell pellet was re-suspended in DMEM with 10% FBS and growii until 70% 
confluent. The cells were then divided into 4 petri dishes and cultured until 70% 
confluent, the medium was then removed and the cells were washed twice with Ix 
phosphate buffered saline (PBS). The cells were then cultured for another 24 hours in 
DNIFNI containiii(g, 10o FBS. Aftci- this incubation the conditioned medium \\as 
i-ci-noved fi-orn the cells. filtered through a 0.2ýim filter. split into 5nil aliquots and 
stored at --'O\'('. 
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2.1.4 Isolation of CD34+ cells from umbilical cord blood 
The purification and culture of CD34 positive (CD)4') umbilical cord blood cells was 
carried out as previously described by NIathur et al. (Mathur et al.. 2004). ý'mbihcal 
cord blood was withdrawn from the umbilical cord and placenta from pre-term 
mothers giving birth by caesarean section. Informed consent was given by all tile 
mothers at least 12 hours before donating cord blood. Approximately 50-100nil of 
blood was extracted from each placental preparation and collected into heparillised 
50ml centrifuge tubes. The umbilical cord blood was diluted I N-olume to 3 \-olumes 
with Hanks buffered saline solution (HBSS) and overlaid on ficoll-paque (Fischer). 
The preparation was centrifuged at 440g for 35 minutes in a bench top centrifuge 
equipped with a swing-out rotor. and the mononuclear cells were removed from the 
ficoll interface. The cells were washed twice in I Oml cold "buffer A" (PBS containing 
2% bovine serum albumin (BSA) (Sigma) and 5mM EDTA), centrifuging at 440g for 
10 minutes at 4'C to pellet cells, the mononuclear cells were then re-suspended in 
300[tl buffer A. The CD34+ cells were isolated using a magnetic labelling protocol 
(Miltenyi Biotec, Germany). To 1 X108 mononuclear cells IOOVI of blocking reagent 
and 100ýtl of magnetic anti- human CD34+ fluorescein isothiocyanate I (FITC) 
conjugated antibody were added, incubated for 30 minutes at 4'C and washed in 
buffer A. The cells were resuspended in 500ýtl of buffer A and passed through a 
MiniMACs magnetic column attached to the magnetic base unit (Miltenyi Biotec). 
The magnetic column was washed three times with 500ýtl buffer A to remove the 
CD34-negative (CD-')4-) populations. The column was then removed from tile 
magnetic source, and the CD34+ population collected by flushing Iml of buffer . -\ 
through the column. This process was then repeated with a second magnetic column. 
I l'o determine the purity of the CD334+ population, 25ý0 of cells ý, ý'ere taken from both 
CD'14 + and CD34- cell populations for analysis by flow cytometry using the 
DakoCytomation CyAn analyser and the fluorescein isothiocyanate (FITC) filter. The 
a\ cragc PUMN'of the CW4+ cells was approximately 86() o (see Figure 2.1). 
CD34+ cells \\ci-c cultured in ýNIK basal culture medium (NIKB\I): INIDNI (Sigma, 
I 
_ý) 
ý, 90) supplemented with 0. lo BSA (Sigma). 22 mM glutamine, lmM sodium 
pyruvatc. MEM ilon-essemial arnino acids (0ibco BRL. diluted 1: 100). MEM 
(Gibco BRL diluted 1: 100). 0.1 rn\ I 2-mercaptoethanol. I OOU, ml penicillin 
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and 0.1 j-i-iu,, "ml streptomycin. The medium was also supplemented with 1010 cord 
blood plasma and 40ng/ml thrombopoletin (TPO) (R &D systems. UK). To Obtain 
cord blood plasma. undiluted umbilical cord blood was centrif I uged at 18OOg for '5 
minutes at 4'C, and the plasma fraction removcd. 
GD34+ cells were plated at 1.5x 105 cells/ml in -14-%N-ell plates and incubated for 4 days 
in a humidified atmosphere at 37'C in 5%CO2. After the incubation period tile 
nonadherent cells were transferred to a 50 ml tube and the cells counted. The cell 
suspension was then adjusted to a density of 1.5xlO cells/ml by addition of fresh 
MKBM supplemented with 10% umbilical cord blood plasma and 40ng/ml TPO and 
incubated for 12 days for use in further experiments. After 14 days of culture, CD'14 
expression had reduced to 2.56% whereas CD61 and CD41 expression \vas 
approximately 90%, indicating megakaryocyte differentiation (see Figure 2.1 ). 
2.2 Statistical analysis 
Statistical significance in the various assays was initially assessed by determinim" 
whether the data was normally distributed using a Kolmogorov-Smirnov test (using 
Minitab statistical software). Data which followed a normal distribution pattern was 
further assessed by a Levene's test (using SPSS statistical software) to determine the 
equality of variances. If the data was not normally distributed or the variances were 
not equal the data would have been analysed by a Mann-Whitney U test. Ho'ýN'ever. the 
data in this thesis was found to be normally distributed with equal variances, therefore 
it was analysed by one-way ANOVA. a parametric test, and differences betweeil test 
0 -s test (using Minitab). P values <0.05 -ere ,, FoUpS \\, ere 
determined using a TukeN 
considered statistically significant. 
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Figure 2.1: Flow cytometry data from differentiated CD34' umbilical cord blood 
(UCB) cells. (A) Purity analysis of isolated CD34' haernatopoietic cells following 
MACS separation from UCB. CD-14* cells were labelled with a mouse anti-human 
CD34-FITC antibody (Miltenyl Biotech) after MACS separation. During the separation 
process both the CD34- and CD34' floxv--through were collected and tested for purity by 
flow C-Vrtometry. CD34-positivity typically ranged from 85-92% (Pink filled peak) II 
compared to CD34- (blue peak). (13) Analysis of megakarvocytic differentiation of 
CD34' UCB cells after 14 days exposure to 40ng/ml thrombopoietin (TPO). The 
differentiated cells were labelled with mouse anti-human CD-34-FITC. mouse anti-human 
CD41 -FITC (Caltag laboratories). mouse anti-human CD45-FITC (Caltag laboratories), 
mouse anti-hunian CD61 -Fl-rc (Caltag laboratories). Results show increased expression 
of the inegakarvocytic markers CD41. CD61, CD45 and a reduction in expression of 
CD34. 
2.56% 
60 
Chapter 
Chapter 3 
Megakaryocytic expression of 
SNARE complex and accessory 
proteins 
Expression ofthe SNARE complex protein SNAP-23) by, differentiated MEG-01 cells after 72 hours 
incubation with I 00nM PMA. Green fluorescence shows positivity, for SNAP-23, blue fluorescence 
indicates the nuclei of the cell. 
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Chapter 3: Megakaryocytic expression 
complex and accessory proteins 
of SNARE 
3.1 Introduction 
In the CNS the release of a neurotransmitter from the pre-synaptic ccll is controlled bý 
several processes: docking of synaptic vesicles at the active site, priming of docked 
vesicles to make them fusion competent, and calcium-dependent fusion of N-csicles 
with the plasma membrane (For reviews see Jahn and Sudhof, 1999, Nlurthy and Dc 
Camilli,, 2003). The docking and fusion of syriaptic vesicles at the plasma membrane is 
mediated by soluble N-ethylinaleimide-sensitivc factor [NSF] attachment protein 
[SNAP] receptor (SNARE) proteins, which form a highly stable SN, ARE complex 
(Sollner et al.. 1993a, Sollner et al., 1993g, Sutton et al., 1998b). SNARE proteins are 
divided into two categories defined by their localisation m"ithin the iicrvc terminal. 
SNAREs present on the vesicle membrane are known as \, -SNAREs, and SN,, '\REs 
present on the target plasma membrane are knox\'ii as t-SNAREs. Syllaptic \'esicle 
cxocytosis requires three neuronal SNAREs: N, csicle associated membrane protein 
(VAMP) the main \, -SNARE, and t-SNAREs syntaxin I and 25kDa synaptosomal- 
associated protein (SNAP-25) (Trimble et al.. 1988a, Oyler et al., 1989d, Bennett et 
al., 1992c, Sollner et al., 1993f; Sutton et al.. 1998a) (See section L3.1). 
VAMPs are essential components of the exocytotic fusion machinery, and represent a 
family of small-type 11 integral membrane proteins of approximately 11-I'l kDa. 
_ý II is exposed 'Structuraliv they consist of a vartable 
N-terminal region \N, h*ch i to the 
cytoplasm, followed by one extended or two short amphipathic (1-helices predicted to 
Crom coiled-coil structures. and a C-terminal transmembrane domain. These Ct-helical 
rc, -Jons are necessary 
for SNARE proteins to form the protem-protein interactions 
required for the formation of the SNARE complex (Grote et al.. 1995: Regazzi ct al.. 
1996, Gerst. 1997. Hao et al.. 1997). There are at least four isoforms 
(c\cluding alternativc splicing) which have been identified as functioning upon 
-naptic vesicle release in mammalian sccretory grantile, dense core vesicle and sN 
ss The two isoforms which have been associated witli trafficking, cvcms fliat vstenis. 
involve rcoulated e\ocý-tosis in the mammalian C'N-, are V, \\IPI and \'., \\IP2 (For 
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review see Gerst,, 1999d). These VA. \4P proteins are a major constituent Of synaptic 
vesicles and peptidergic secretory granules in neurons (Elferin], ' et al.. 1989: Batimert 
et al.. 1989c). VAMP2 is involved in stimulus-coupled secretion in a variety of cell 
types. including neurotransmitter release from neuronal cells (Trimble et al.. 1988c: 
Baumert et al.. 1989b). VAMPI is widely expressed in nervous tissue and exists in 
two alternatively spliced forms VAMPla and VAMPlb which may be tissue- and 
organelle- specific (Mandic et al., 1997; Isenmann et al., 1998). The VA\lPla splice 
variant is similar to VAMP2 and is involved in synaptic vesicle release. A third 
ubiquitously expressed isoform, CellubrevinNAMP3. is expressed by non-neuronal 
cells and localises to numerous types of secretory organelles, including secretory 
granules in pancreatic acinar cells and GLUT4 containing vesicles in adipocytes 
(McMahon et al., 1993; Aledo et al., 1996; Sengupta et al., 1996). 
The syntaxin family of proteins are t-SNAREs which participate in membrane fusion 
(Sollner et al., 1993h). There are sixteen described members of the syntaxin familý' in 
mammalian cells, of which at least four are localised to the plasma membrane and 
participate in synaptic \'esicle exocytosis. These include syntaxinla, -lb and possiblý, 
-1c. syntaxiiil-, -3 and -4 (Inoue et al., 1992b: Bennett et al.. 1992d, Bennett et al., 
1993b; Jagadish et al., 1997a). Syntaxin I is found primarily at the plasma membrane 
of neuronal cclls and at the synapse where pools of the protein are involved in the 
fusion of transport vesicles with the plasma membrane, whereas syntaxin 4 is localised 
to the plasma membrane of a wide variety of cells, but similarly to syntaxin I it 
appears to be involved in the fusion of transport \'esicles with the plasma membrane. 
Symaxins are small integral membrane proteins of approximately 300 amino acids 
which possess a single transmembrane domain (Bennett et al., 1992c, Inoue et al.. 
1992c), and have at least three putative coiled-coil forming regions (HI, H21 and H3) 
in the N-terminal and C-terminal domains. The C-terminal domain H3 coiled-coil 
1, C01011 is invok, ed in protein-protein interactions with VAMP (Calakos et al.. 1994, '7' 
1 laý'ýislii ct al., 1994c . 
Hayashi et al., 1995. Kee et al., 1995b) and SNAP-2 5 (1 layashi 
ct al., 191)4b, Chapman ct al., 1994d, Kee et al., 1995a). 
Flic third of the '. -, NARE complex protein families is the synaptosonle-associated 
proteill. -, ý\.. \P-25 (()Nler et al.. 1989c). SNAP-2-5 is a highly conservcd protein of 
'25kDa NNI-lich NvLis originally identified in ljcl-voLis tissue. and exists as tN, \o variants 
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SN'AP-25A and SNAP-25B (Bark et al.. 1995b). However, it has also been shown to 
be expressed in other tissues such as adipose and skeletal muscle (Roth and Burgoyne. 
1994; Sadoul et al.. 1995; Jagadish et al.. 1996: Kannan et al.. 1996). SNAP-225 is 
anchored to the cvtosolic face of the plasma membrane via palmitolyated side chains 
in the middle of the molecule, and has a putative coiled-coil region located at tile 
C-terminus which associates with VAMP and syntaxin leading to the formation of tile 
SNARE complex (Hayashi et al.. 1994a: Chapman et al.. 19940. SNAP-23 
(synaptosome-associated protein of 23,000 Dalton) is a ubiquitousl\ý expressed 
isoform of SNAP-25, able to function in regulated exocytosis by associating with 
VAMP and syntaxin forming the SNARE complex (Ravichandran et al., 1996c). 
The function of the SNARE proteins is controlled by numerous positive and/or 
negative regulators at different stages of assembly and disassembly of the trans- 
SNARE complex. Syntaphilin, an expression-limited pre-synaptic protein, has beell 
shown to have a regulatory role in the assembly of the SNARE complcx by competing 
with 'SNAP-25 for binding to syntaxin I preventing the formation of the SNARE 
complex by absorbing free syntaxin I (Lao et al., 2000a). Transient overexpression of 
syntaphilin in cultured hippocampal neurons significantly reduces neurotransmitter 
rclease, suggesting that syntaphilin is a molecular clamp which regUlates synaptic 
\, cslclc exocytosis by controlling the availability of free syntaxin I for SNARE 
complex assembly (Lao et al.. 2000b). Sviitaphilin also has a function in endocytosis 
\\-here it binds to dynamin I preventing dynamin-mediated endocytosis (Das et al., 
2003). 
The priming of synaptic vesicles is a critical step in the synaptic vesicle cycle. 
ciiabling docked vesicles to fuse to the plasma membrane and undergo rapid 
cxocvtosis upon Ca ')+ influx (Klenchin and Martin, 2000). The Muncl') familv- of 
proteins, which are hornologues of the C. elegans Linc-13 family of proteins, have been 
sliomi to he involved in primmg, synaptic vesicles for exocytosis (Brenner. 1974a: 
l'okumarLi and Aupustine. 1999: Brose et al.. '000a: Martin, 1002). \Iuncl )s. of 
which there are thi-cc mammalian isoforms: NILIIIC I 'I-I. -13-21. and are 
differentialk cxpresscJ in the brain and localisc to the s\napse (Brose et al.. 1995. 
]-, -I Bctz et al. - 
1998b. ALIULIStIn et al.. 1999a. Brosc et al.. 2000b). \Iunc -) is 
periplicral mcnibranc locallsed to plasma membranes of synaptosornes. where it is 
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essential for the priming of synaptic \-esicles at 90% of the glutarriatergic _-'N-IIapse', -' 
(Augustin et al.. 1999b). Munc13 proteins contain multiple regLilatory dornLiins (Cl 
and C2 domains) that bind endogenous second-messenger diacylgdNcerol. 
phospholipid. and calcium (Maruyama and Brenner, 1991: Betz et al.. 1998a). The C 
terminus of Munc 13-1 interacts with the N-terminal putative coiled-coil domain of 
syntaxin 1. and its interaction appears to aid the assembly of the S',, \'. -\RF complex. 
suggesting Munc 13 is involved in priming synaptic vesicles (Betz et al.. 1997b). These 
activated vesicles can be released immediately on Ca 2- influx. 
Another component of the general fusion machinery involved in the priming of 
vesicular vesicles at the pre-synaptic membrane is Sec I /Munc- 18 (SM). SM proteins 
are members of a family of conserved hydrophilic proteins xvith no recognisable 
domains originally identified in yeast and C clegans (Brenner, 1974b, Novick and 
Schekman, 1979; Novick et al., 1980, Hosono et al., 1992: Halachmi and Lev, 1996: 
Jahn, 2000). There are at least seven mammalian homologues of the SM protein 
family: three of which, Munc 18 (also known as Munc I 8a. Munc- 18- 1, nSec 1, rbScc), 
Muncl8b (also known as Muncl8-2). and Muncl8c (also known as MuncI8-3), are 
involved in exocytosis (Hata et al., 19931a, Garcia et al., 1994; Pevsner et al., 1994b-, 
Tellam et al., 1995, Gengyo-Ando et al., 1996-, Bock et al., 2001). The mammalian 
SM protein involved in exocytosis of synaptic vesicles is Munc 18, which was initially 
thought to bind selectively to the t-SNARE syiitaxin I with nanomolar affinity, 
preventnig the in Oo-o formation of the SNARE complex (Hata et al., 1993b; I)C\-,, ner 
et al., 1994a). However, more recent studies using munc18-1 null mice have shown 
that in the absence of Munc 18 the stability of syntaxin I is compromised, but targeting 
ot'symaxin I to the presynaptic membrane and its assembly into the SNARE complex 
is MuncI8 independent (Toonen et al.. 2005). The lack of neurotransmitter release 
obsci-N'ed in the n7uncIN-1 null mice suggests that these S. \',, ARE complexes are non- tn 
functional or assembled in the \vroiig localisation (Verhage et al., 22000a). suggesting, 
that Munc 18 has an important role in vesicle docking and fusion, and does not act. ] ust 
as, a chaperone protein. 
I'lic Rab family of sinall monomeric GTPases, which act upstream of SNARL 
complex a,,,, ciiibl, \- aiding intracellular vcsicle transport. are potential S",, 'ARV 
rcouhtors (Bcan mid Sclicller. 1997. Novick and Zerial. 1997a). The Rab CIN 
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superfamily, of which there are four related isoforms Rab-3a, -3b, -_3c. and 3d, are 
involved in regulated exocytosis (Touchot et al., 1987; Matsui et al.. 1988; Zahraoui et 
al., 1989; Baldini et al., 1992a). Rab -3a and -3c are predominantly expressed in 
neuronal cells in the brain, where they are localised to synaptic vesicles, and are 
involved in the regulated Caý' -dependent exocytosis (Fischer et al.. 1990). Rab -3b 
and -3d are expressed in non-neuronal tissues such as adipocytes (Baldini et al.. 
1992b). The Rab 3 proteins cycle between a GDP-bound inactive and a GTP-bound 
active state, which is regulated by three types of regulator: Rab GDP dissociation 
inhibitor (GDI), Rab 3 GDP/GTP exchange protein (GEP), and Rab GAP (Takai et al., 
1996; Geppert and Sudhof, 1998; Takai et al., 2001; Zerial and McBride, 2001). Rab 
proteins associate with the membranes of synaptic vesicles in their GTP-bound state, 
and upon hydrolysis of GTP they are removed from the membrane. This cycle of 
attachment and removal of Rab 3 from the synaptic vesicle membrane is synchronised 
with exocytosis, suggesting an important role for Rab 3 proteins in neurotransmitter 
release (Fischer et al., 1991; Fischer et al., 1994a; Fischer et al., 1994b). However, 
studies using Rab 3 knock out mice have shown that deletion of Rab 3 reduces the 
probability of synaptic vesicle exocytosis without changing the basic parameters, 
indicating that Rab 3 proteins are not involved in the docking and fusion of synaptic 
vesicles but regulate neurotransmitter release by acting as modulators of the release 
machinery (Schluter et al., 2004). 
Several putative effector proteins have been identified for Rab 3, including rabphilin 
(Kishida et al., 1993; Shirataki et al., 1994; Li et al., 1994), RIM (Wang et al., 1997; 
Wang et al., 2000; Schoch et al., 2002; Calakos et al., 2004) and rabin (Brondyk et al., 
1995). Rabphilin binds to Rab 3s in a GTP-dependent manner, it co-localises with Rab 
3s on synaptic vesicles, but dissociates from Rab 3s after GTP hydrolysis during 
exocytosis (Stahl et al., 1996). Rabphilin is composed of an N-terminal Rab 
3-interacting domain, a central phosphorylation domain, and two C-terminal C2 
domains that may bind Ca 2+ (Fykse et al., 1995). In rabphilin knock out mice Rab 3A 
is targeted to synaptic vesicles normally with normal synaptic transmission and 
plasticity, suggesting that although rabphilin has the properties of a Rab 3 effector it is 
not essential for regulatory functions of Rab 3 in exocytosis (Schluter et al., 1999). 
Recent studies have suggested a role for rabphilin in regulating SNARE-dependent 
re-priming of synaptic vesicles for fusion at the plasma membrane. Rabphilin has been 
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shown to bind SNAP-25 via theC2domain regulating synaptic vesicle exoc\losis after 
the readily releasable pool has been physiologically exhausted bN- use-dependent 
depression (Deak et al. - 2006). 
Once exocytosis has taken place at the pre-synaptic membrane. the SNARE complex 
is disassembled allowing regeneration of the synaptic vesicles. The major regulator of 
this process is N -ethyl mal eimi de- sensitive factor (NSF). NSF is a hexameric protein 
that belongs to the AAA super-family of chaperone-like ATPases (Hanson et al., 
1997c; Vale, 2000- May et al., 2001: Zinsmaier and Bronk, 2001b). It is made up of 
three distinct domains: an amino acid terminal (N) and two homologous ATP-binding 
domains (DI and D2). The hexameric NSF binds to the SNARE complex through 
three molecules of a-SNAP (Soluble NSF attachment protein) to form a large 20S 
complex (Clary et al., 1990a). Hydrolysis of ATP by the DI ATPase domain leads to 
the disassembly of the SNARE complex after vesicle exocytosis has occurred at the 
synapse (Hohl et al., 1998; Wimmer et al., 2001 -, Marz et al., 2003; Furst et al., 2003). 
To investigate the expression of SNARE-complex and associated proteins in 
megakaryocytes we used i-negakaryocytic cell lines, primary megakaryocytes isolated 
from mouse bone marrow and primary megakaryocytes derived from CD34+ 
haernatopoietic stem cells from umbilical cord blood. Due to the rarity of 
inegakaryocytes with in the bone marrow the majority of research in to 
inegakaryocytic processes has been performed on megakaryocytic cell lines. The most 
commonly used are the MEG-01 and human erythroleukaernia (HEL) cells (Saito, 
1997b). These cell lines are normally derived from the bone marrow of leukaemia 
patients and have been shown to express many of the characteristics of 
iiicoakaryocytopolesis and differentiated human primary megakaryocytic cells. The 
\11'G-01 cell line N\-Lis derived from a patient suffering with chronic mycloid 
leuLicniia (CML). whereas the HEL cell line was developed from bone marrow cells 
fi-oni ýi paticnt with ýIcutc niý-clogenous leukaemia. Phorbol esters have been sll()\\"Il to 
indticc tcrimnal i-ncgaUr\'oc\tic differentiation of erythroid and me(lakar\-oblastic 
IcLkiciiiic MI lines (Sýiito. 1997a). 
I'lle N11"(1-01 CA line CNIlibit's 111Cgakarvoc ytic characteristics (CD41, CD61. CD42a 
and NAVO whilst Licking markcrs for other lincýt-ocs (0, -, ui-a et al.. 1985). NIEG-01 cells 
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can be differentiated into mature megakaryocytic cells using the phorbol ester PNIA 
which increases their CD41. CD42a and vWf expression (Ogura et al.. 1988). PNIA is 
thought to induce megakaryocytic differentiation through the activation of protein 
kinase C (PKC), translocating from the cytoplasm to the plasma membrane in 
MEG-01 cells stimulated by PMA (Long et al.. 1990b). It has been reported that 
MLG-01 cells have the ability to produce platelet-like particles that are of similar size 
and morphology to circulating platelets (Takeuchi et al.. 1991a). MEG-01 cells do not 
express the TPO receptor c-Mpl. therefore. PMA is the only known differentiation- 
promoting agent for MEG-01 cells (Matsumura et al., 1996b). 
FIEL cells in their undifferentiated state possess features common to macrophages. 
erythrocytes and megakaryocytes (Tabilio et al.. 1984, Long et al., 1990a). Stimulation 
of IIFL cells by low concentration doses of PMA, lead to an increased megakarvocytic 
phenotype recognised by the expression of the megakaryocyte-specific markers CD41 
and CD42a, as well as morphological changes such as cytoplasmic maturation and the 
formation of a polyploid nucleus. These changes are believed to be due to 
PMA-mediated activation of PKC, which controls the switch bet\\eCil megakaryocyte 
and erythrocyte lineage (Hong et al., 1996). unlike MEG-01 cells, HEL cells express 
the TPO receptor c-MpI and can therefore differentiation can also be stimulated by 
TPO (Matsumura et al., 1996a). These characteristics make the HEL cell line a useful 
model in lineage determination studies. 
Recent developments in stem cell separation techniques and the increased commercial 
ýivailability of human recombinant TPO has meant that CD34+ haernatopoietic cells 
caii iiow be promoted to form large numbers of differentiated megakaryocytes in vitro. 
The three main sources of human CD-34+ cells are umbilical cord blood (UCB), bone 
marrow and peripheral blood (Majka et al., 2001). Due to its accessibility and 
availability UCB is the most widely used source for generatiii(-, meoakarvocvtes 
t'6llo\\1n(_, CD-W separation. CD'34_*'-derivcd megakaryocytes exhibit numerous 
chýiracteristics of mature bone marrow rnegakaryocytes, including. expression of the 
mcgAarvocyte and plateict-spccific markers CD41. CD61. CD42'a and CD62P. TPO 
receptor c-MpI and PDCTF rcceptor (Ge\\irtz et al.. 1995a. Nkijka et al.. 2000). In this 
study Nvc tiscýl CD_')4_'_-dcrived rnegakarvocytcs and primary MUrine rnegakarvocyte, -, 
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isolated from the bone marrow of mice and expanded in a TPO-conditioned media 
(see Chapter 2 for details). 
The aim of this chapter is to investigate the expression the SNARE complex proteins 
and regulatory proteins involved in SNARE-dependent glutamate release in the CNS 
by megakaryocytes using these well-established cell lines, primary murine 
megakaryocytes and primary human megakaryocytes (see Chapter 2 for details). This 
would provide a greater understanding of the glutamate signalling pathways in 
megakaryocytic cells. 
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3.2 Methods 
3.2.1 RNA isolation 
Total RNA was extracted from megakaryocytic cell lines, primary megakaryocytes 
and whole mouse brain using TRIzo0'(GibcoBRL)- Cells were grown to confluency 
in 25cm 2 culture flasks, washed twice with PBS and lysed using Iml of the TRIzol" 
reagent. The whole mouse brain was snap frozen using liquid nitrogen and ground to a 
powder using a Braun dismembranator before Iml of the TRIzolý' reagent was added. 
The lysate was then transferred them to a 1.5ml eppendorf tube and incubated for 5 
minutes at room temperature. 200[d chloroform (Sigma) was added to the TRIzol' 
treated samples and vortexed before being centrifuged at 12,000g for 10 minutes at 
4'C. 500ýil of isopropanol was added to the aqueous phase and incubated at -20'C for 
15 minutes before further centrifugation. The RNA pellet was then washed with 75% 
ethanol, centrifuged at 7,500g for 5 minutes at 4'C, and re-suspended in II pI RNase 
free dH20 (Life Technologies). The quality and quantity of the RNA was determined 
by calculating the ratio of A26o and A280 using a UV spectrometer. The samples were 
then stored at -80'C. 
3.2.2 cDNA synthesis 
Genomic DNA was eliminated using the DNA-free Tm DNase treatment and removal 
reagents according to the manufacturer's instructions (Ambion). 
cDNA was synthesised from 5[tg DNase-treated total RNA using the Superscript 11 
RT-PCR system (Life technologies). IpI of oligo (dT)12-18and I ýtl I OmM dNTP mix 
were added to the RNA and made up to 12pl with RNase-free dH20. The samples 
were incubated at 651C for 5 minutes and then placed on ice. A master-mix of reagents 
was prepared containing, per reaction, 4pl 5x first strand buffer, 2PI O. IM DTT and 
I [d RNase OUT. To each reaction 7pl of the master-mix was added and incubated at 
420C for 2 minutes. I pl SuperScript 11 (or the equivalent volume of RNase-free dH20 
for the no-RT control) was added to the reaction tubes and incubated for 420C for 60 
minutes. The reaction was terminated by heating to 70'C for 15 minutes and RNA 
digested by treating with RNase H (2units) for 20 minutes at 37C. The cDNA 
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samples were diluted 1: 10 in RNase-free dHO and stored at - . '()-C until us-e. cDNA 
synthesis was confirmed by PCR usiiig glyceraldehyde-3 3-phosphate dell ydro enase 
(GAPDH) specific primers (see table 3.1). The foetal human brain cDNA used as a 
positive control NA'as obtained from Ambion (0.5ng'ýtl) and stored at -80-C. 
3.2.3 Polymerase Chain reaction (PCR) 
The PCR master-mix was prepared containing, per reaction, 5 ýt II Ox PC R buffer. 1.5 ýt I 
50mMMgCI2., Iýfl lOmM dNTP mix. 0.5ýd Platinum Taq polymerase (Life 
Technologies), Iýtl forward primer, Iýtl reverse primer (Shiiiia-Genosys, or 
1, -. urogentec) and 35[tl dH20.45VI of master-mix was then added to 411 cDNA and ruil 
ic PCR rogram designed for the indi\'idual primer set (see table 3.1 1'01' on a specifi p 
primer sequences). The PCR products (I OVI) in bromophenol blue loading buffer wcrc 
analysed by I% Tris-Acetate-EDTA JAE) agarose gel electrophoresis, using L_ 
Hyperl-adder IV (Bioline) DNA quantification marker to determine the size of the 
PCR product. 
3.2.4 Immunolocalisations 
3.2-4.1 Cytospin preparations 
A Cytospin 3 cytocentrifuge (Shandon Scientific Ltd, Runcorn, UK) was used for all 
c N'tospin preparations. The cell concentration was adjusted to Ix 10 cells/ml and 200ýtl 
ofccll suspension added to the sample chamber. Cells were spun for 5 minutes at I OOg 
onto polylysine microscope slides (BDH) with low (LO) acceleration and slide. " 
removed and fixcd in 4% paraformaldeliN-de and kept at -20'C until use. 
3.2.4.2 Fluorescent immunocytochemisfýl, 
()tospun ,I ides %\crc thawed and N\ashed 3 times in I xPBS. Cel Is k\ci-c then incubated 
in 1001o horse, sheep. or , oat serurn (Sigma). depending on the , ccondarv antibody 
'0 minutes at room temperature. -xcess serurn was removed and cyto. "pun used. for ) I' 
Cells N\cl-c incubated with primary antibody or control 1(-, Os overnight at 4'C (,, cc table 
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ý Actual 
pecies Protein Accession Forxýard Primer Product 
number Re% erse Primer Size 
Alpha Fluman/Mouse B( (), )I ý, 11 4()Q 
R-5'-AGC CACCT-TCAGCAGACAC_I_FGT-I 
Cellubrevin Human NM004781 F-5'-TGCiACAAGGTTCTCfGAAAGAGACCA-, ' 101 
(VAMI, 3) R-5'-TGAAGAGACAACCCACACGATGATGAI-G-, ' 
Cellubrcvin Mouse NM009498 F-5'-GTAATCGAAGACTCCACTCAGACACA-l' 223, 
(VAMP3) R-5*-ACACTGATCCCTATCGCCCACATCT-, ' 
(jamma SNAP I JUman NM003826 F-5'-CACCTCGCCAAAGCAGAGAAATACC-, ' 491 
R-5'-AGTGCCGCCTCATCAAACCTACG-3' 
(jammaSNAP Mouse NM028017 F-ý'-GATGCTGAAGGAGATCjCAGAAGCTG-3' 419 
R-5'-ACTGCCGTTAAAGCCTGGTATGCTG-', * 
(jAPDH II Liman/Mouse BT006893 F-5'-GCiTGAAGGTCGGWGTCAACGG-3' 520 
R-5'-GGTC ATGAGYCC T`TCCAC GAT-Y 
MUnc-13 Human BC067084 F-5'-AAGGCAGAACAGCAGGAGGA-3' 486 
GGACACTACATCACCCACAACC-3' 
Munc-13 Mouse NM_021468 F-5'-GCCTAAGT(ITGGAGGTGTGGAACAA-3' 451 
R-5'-GGCTGGGTAGTCGTGTG, CiTAAGGAG-3' 
Munc-18-1 I Iuman/Mouse BC031728 F-5'-GACCTGTCCCAGATGCTGAAGAA-3' 363 
R-5'-GAGGTGAGCCATCiTTGGTGATG-3' 
NSF HLH-nan/Mouse BC013314 F-5'-GCTCAGTTGTGTGGTTGTGGATGAC-3' 239 
R-5'-GCTGCTCTCCTGTGGCAATGTT- V 
Rab 3A I Iuman AF254795 F-5'-CGTCCTTCCTCTTCCGCTATGCT-3' 332 
R-5'-TGACACCACCCGCTCATCCTC-3' 
Rab 3A Mouse NM009001 F-5'-AAGGTCAAAACCATCTACCGCAACG-3' 313 
R-5'-CCTCAAA(; AACTCAAAGCCCACiGTG-3' 
Rab 313 11 uni ail BC005035 F-5'-GTTCACCCCCAGCCTTCGTTAGCAC- 1' 387 
R-s'-C, CCI'GCC-1-1-ACACI-GATGTTCTCCTTT-3' 
Rab 313 Mouse 13C051918 F-5'-ACCTCCI-I-C'C'TTTI-CCGCTAT(iCT(j-. 1' 416 
R-5'-TGCCTCACACTGATGTTCTCCTTG(7, -I' 
Rabp1li1fin 3A I IUIIlaIl/MOLISC BC017259 F-5'-GGAGCCAGCAAGTCCAACAAGC-3' 481 
R-5'-CCATGTCC(jGTTTCAGCCAGAG-)' 
SNAII-23 I ILI Ill an NM130798 F-5'-AGAAGATGAAATGGAA(iAGAACCTG-3' 141 
R-s'-CTGTT(YGTGTCAGCCTTGTC-3' 
SNAII-23 Mouse NM009222 1--5'-GCAAGGG(iAACAACTAAATCGCATA-3' 315 
R-5'-TCCATCTCATCTTCTCTGGCATCATT-3' 
SNAII-25 I lunian BCO 10647 F-5'-GGTATCAGGACTTTGGTTATGTTGGATG-3' 445 
R-5'-TGGTTTTGI-TGGAAI'CAGCCTTCT-3' 
SNAII-25 Mouse N M-0 11428 F-5'-GTI-A-FGTTGGAI-GAGCAAGGCGAAC-3' 392 
R-5'-ATCTGGCGATTCTGGGTGTCAAT-3' 
SN'lltaphilin I]Uniall/MOLIse BC035788 F-5'-GCGCACCTCTCCACCTGTGA-3' 250 
R-5'-GAGCC(IGTCCTGTGT(iTCCTT-3' 
Syntaxin Ia I ftlinan/Mousc NM004603 F-5'-GAGGAGGTGAAGCGGAAGCACAG-3' 384 
AGAGGCAAAGATGGCGGGGTTC-3' 
. Svntaxin 4 Human Al-026007 1---ý'-CAGGAGTTGGAGAAACAGCAGGTCA-3' 333 
R-5'-ATCAGACACCATCCCAGCATTGG-3' 
Svntaxin 4 Mouse U76932 F-5'-AGTGCiGCAGAGTGAGGTGTTTGTGT-3' 341 
R-5'-CCAATGATGACAGCCAAGATGAGAA-l' 
VAMP 1-111111all/Mousc NNI014231 F-ý'-ACCCAGGCACAAGTGGAGGAGGT-3' 229 
1 R-5'-CAATAACTACCACGATGATGGCACAGA-3' 
Table 3.1: Primer sequences, and product sizes for RT-PCR reactions 
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3.2 for primary antibodies used and concentrations). Excess primary antibody or 
control IgGs were removed. washed 3 times for 5 minutes in IxPBS and incubated 
with either FITC. or C), 3 conjugated secondarý- antibodies (Sigma. Chemicon. or Santa 
Cruz) for I hour in the dark at room temperature (see table '1.2 for secondary 
antibodies used and concentrations). Excess secondary antibodý- Nvas removed and the 
cells were washed 3 times with I xPBS for 10 minutes. The samples %\ ere mounted in 
Vectashield (Vector Laboratories) and viewed using a Leica DMLA microscope under 
UV illumination. 
3.2.5 Western Blot analysis 
3.2.5.1 Protein Extraction 
Megakaryoblastic cell lines, MEG-01 and HEL, Nvere plated at an initial concentration 
of 2xIO5 cells/ml and grown in the presence and absence of PMA for 72 hours. Cells 
were then removed and washed 3 times in I xPBS. Cells were lysed with 250ý11 cold 
lxlysis buffer (Cell Signalling. 2mM Tris (pH 7.5), 15mM NaCl, O. InIM EDTA, 
O. ImM EGTA, 0.1% Triton X-100,0.25rnM Sodium pyrophosphate, O. ImM P- 
glycerolphosphate, O. ImM Na3VO4, O. lVtg/ml Leupeptin) for 10 minutes on ice. 
lysates were transferred into a 1.5ml eppendorf tube and centrifuged at 12,000g for 10 
minutes. The supernatant was retained and the protein concentration was determined 
using the BCA protein assay (Pierce) according to the manufacturer's instructions. The 
adult human brain lysate used as a positive control was obtained from abcam 
(5111gli-ill). 
3.2.5.2 Polyacrylamide gel electrophoresis and protein detection 
40po of total cell protein and 20po of human brain IN'sate (control) was denatured at 
9ý'C' for 5 minutes in SDS loading buffer. Proteins were fractionated hN, SDý) (-, cl 
clcctroplioresis on a 15% polvacrylamide resolving ocl usino a 5% stacking Lcl in 
NOV. 100mA for I hour. -Hic electrophoresis -, -, cls \\ci-c 
then runnin,, buffer at 
cquilibrated in traiisf'cr buffer and proteins transferred onto a nitrocellulose membrane 
(Aiiiershain Biosciciiccs) at 10OV. 250iii. -\ for I hour. 
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Primary Antibody Supplier Dilution Secondarv Antibody Supplier Dilution 
Mouse anti VAMP Sigma 1: 250 Goat anti mouse -1 Signia 1.100 
FITC 
Mouse anti Syntaxin 4 BD 1: 250 Goat anti mouse - Sigma 1.100 
Biosciences FITC 
Rabbit anti SNAP-23 Synaptic 1: 50 Goat anti Rabbit - Si-ma 1: 100 
systems FITC 
Mouse anti Synaptic 1: 100 Goat anti mouse - Sigma 1.100 
Synaptotagmin systems FITC 
Table 3.2: Immunocytochemistry primary and secondary antibody suppliers and 
concentrations 
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3.2.5.3 Immunodetection 
The membrane was blocked by gentle shaking for 15 minutes and incubation 
overnight in 4% marvel in TBS-T (20iiiM Tris. 137mM NaCI. 0.1% T\Neeil 20) at 4-C. 
Following two rinses and a 15 minute incubation in TBS-T. membranes x\ci-c 
incubated with primary antibody at room temperature for I hour, %\Ith extensive 
washes in 'I BS-T between incubations of primary and secondai-\ antibodies. 
Membranes were then incubated for I hour at room temperature with the appropriatc 
horseradish peroxidase conjugated secondary antibodies (Santa Cruz Biotechnologics). 
Both primary and secondary antibodies Nvere prepared in 4% mai-vel in TBS-T, see 
table 3.3 for details of primary and secondary antibodies used. Specific antibodý- 
binding was detected by enhanced chemilluminescence using ECL chemilurninesceilt 
solution, according to the manufacturer's instructions (Amersham Pharmacia Biotech) 
and exposed onto Hyperfilm (Amersham Pharmacia Biotech) at room temperature for 
up to 5 minutes. Films were developed using a xograph automated developer. 
3.2.5.4 Membrane stripping 
Antibodies were stripped from the \\-cstern blot membrane by gentle agitation of the 
membrane in pre-warmed stripping buffer (lOOmM 2-mercaptoethanol, 2% SDS. 
62.5rnM Tris HCL pH 6.7) at 60'C for 20 minutes. Membranes were then washed 
m ice for 15 minutes in TBS-T before being blocked in 4% marvel TBS-T overnight 
prior to immunodetection as described in section 3.2.5.3. 
3.2.6 Immunohistochemistry 
3.2.6.1 Tisýsiiecollectioitaiidc-i-i, osectioiiiiig 
I Hie tibiac and femora \%crc removed from adult rats and immediately frozen in liquid 
nitrogen and store at -80'C until use. Specimens were mounted in Cryo-m-hed 
ernhedding, compound (Bright, IIK) on brass chucks and frozen using dry ice and 
ethanol. Frozen sections Nwrc collected on polylysine slides using, a Bright OTF500 
ci-Nostat (Bright) fitted with a tunosten carbide tipped knife and stored at -20-C ui-itil 
required. 
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Primary Antibody Supplier Dilution Secondary Antibody Supplier Dilution 
Mouse anti VAMP Sigma 1: 1000 Goat anti Mouse - Santa 1.1000 
I HRP Cruz 
Rabbit anti Santa Cruz 1: 1000 Goat anti Rabbit - Santa 1-1000 
VAMPI/2/3 HRP Cruz 
Rabbit anti SNAP-23 Synaptic 1: 1000 Goat anti Rabbit - Santa 1: 1000 
systems HRP Cruz 
Mouse anti Syntaxin 4 BD 1: 5000 Goat anti Mouse - Santa 1: 1000 
Biosciences HRP Cruz 
Mouse anti GAPDH Advanced 1: 800 Goat anti mouse - Santa 1: 1000 
Immunoche- HRP Cruz 
micalinc 
Table 3.3: Western blot analysis primary and seconclary antibody suppliers and 
concentrations 
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3.2.6.2 Peroxidase immunolocalisations 
Sections were fixed in 4% paraformaldehyde for 5 minutes before blocking with ')% 
hydrogen peroxide (Sigma) for 30 minutes to deplete endogenous peroxide activitv. 
The Vector Avidin / Biotin Blocking Kit (Vector Laboratories) was used according to 
the manufacturer's protocol to prevent any non-specific avidin binding to endo(_, enous 
biotin. Sections were blocked using 10% serum., chosen to match the species in which 
the secondary antibody was raised. Sections \ý-ere incubated Nvith primary antibody for 
30 minutes (see table 3.4 for concentrations of primary antibody used). follo%\-ed by 
exposure to biotinylated IgG secondary antibodies (1: 200, Vector Laboratories). 
Avidin-biotinylated-peroxidase reagent (Vectastain Elite ABC reagent, Vector 
Laboratories, 1: 50 dilution) was then applied to the specimens and incubated for 20 
minutes followed by incubation with DAB tablets (0.5mg/ml 3.3'-diaminobenzidine 
and 0.3% hydrogen peroxide; Sigma) dissolved in dH20, for 2 to 8 minutes. The 
sections were counterstained with haematoxylin before mounting in 90% \'/\' 
glycerol/PBS and viewed using a Leica DMRB microscope. Antibody negati\, c 
controls received identical treatment apart from the application of either mouse or 
rabbit IgGs (Vector Laboratories, IýLg/ml) instead of the primary antibody, depending 
on what species the primary antibody was raised in. Incubations were carried out at 
room temperature with 3x5 minute PBS washes between incubations. 
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Primary Antibody I Secondary AntibodN ; Supplier Dilution Supplier Dilution 
Rabbit anti SNAP-23 Synaptic I Rabbit - Goat anti Vector 1 -200 
systems Biotinylated laboratories 
Mouse anti syntaxin 4 BD 1: 250 Horse anti Mouse - Vector 1: 200 
Biosciences Biotmvlated laboratories 
Mouse anti VAMP Sigma 1: 250 Horse anti Mouse - Vector 1: 200 
Biotinviated laboratories 
Mouse anti Munc- 18 BD 1: 500 Horse anti Mouse - Vector 1: 200 
Biosciences Biotinylated laboratories 
Mouse anti Rat CD61 BD 1: 250 Horse anti Mouse - Vector 1: 200 
Pharmingen Biotinylated laboratories 
Table 3.4: Immunohistochemistry primary and seconclary antibody suppliers and 
concentrations 
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3.3 Results 
3.3.1 Expression of SNARE complex and accessory proteins býý 
megakaryocytic cell lines 
3.3.1.1 mRNA expression of SNARE complex and accessory protein genes kv 
megakaryocytic cells 
Identification of a single band using RT-PCR confirmed the expression of mRNA for 
the core SNARE complex proteins, the v-SNAREs VAMP2. VAMP-33 (cellubrevin), 
and t-SNAREs syntaxin Ia and syntaxin 4 by the megakaryocytic cell line MEG-0 I in 
the presence and absence of 100nM PMA, a reagent which leads to the differentiation 
of MEG-01 cells (Figure 3.1). The expression of mRNA for the t-SNARE SN., \P-215 
which is normally present in the SNARE complex in neuronal cells was not detected 
absent from megakaryocytic cells. howevei- its ubiquitously expressed homologue 
SNAP-21 was found to be expressed. 
RT-PCR was also used to identify the mRNA expression of acccssoi-y proteills 
required for SNARF-dependent glutamate release in the CNS. In MEG-01 cells. 
mRNA expression of NSF, Rab 3a, Rab 3b, Rabphilin 3a, syntaphilin, Munc-13, 
Munc- 18- 1, a-SNAP, and y-SNAP were identified in MEG-0 I cells treated with and 
without PMA (Figure 3.2). 
The mRNA for the SNARE complex and accessory proteins appeared to be more 
abundantly expressed by PMA-treated MEG-01 cells compared to control untreated 
cells. Products from MEG-01 cells were identical in size to those found in the human 
foetal forebrain positive controls and sequencing identified the products as the genes 
of interest. 
3.3.1.2 Protein expression o SNARE complex and accessory proteins in ýf 
inegaka, gocytic cells 
sNARI- complex proteins. SNAP-23i. VANIP and syntaxin 4, \\erc shown to hc 
cxpresscd at the protch, IeVel ill N111"O-01 cclls and a similar megakaryocytic cell linc 
HEL, in the presence and absence ot' PMA. by western blot analysis (Floure 
c\prcssion in MEG-01 cclls and HEI, cells identified a moiccular species at 
appro\Irnately, N(iklb. instead of the cxl)cctc, -l size of approximately I SkDa. 
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-PMA +PMA HB 
Figure 3.1: mRNA expression of SNARE complex protein genes by 
megakaryoblastic cell line, MEG-01, in the presence and absence of PMA. RT-PCR 
was used to demonstrate the n-iRNA expression of SNARE complex genes Cellubrevin, 
SNAP-23. Syntaxin I a. Syntaxin 4 and VAMP by the megakaryoblastic cell line MEG- 
01 in the presence and absence of PMA. Human foetal forebrain (HB) cDNA was used 
as a positive control and expressed all SNARE complex components. Control reactions 
(no RT) were performed in parallel. in the absence of cDNA. 
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-PMA +PMA HB 
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Figure 3.2: mRNA expression of SNARE complex accessory protein genes by 
mega ka ryoblastic cell line, MEG-01, in the presence and aýsence of PMA. RT-PCR 
was Lised to demonstrate the mRNA expression of SNARE complex accessory proteins 
NSF, sý, iitaphilin. Rab3a, Rab3b, Rabphilin3a, UNC-13, MUNC-18, (X-SNAPandy- 
SNAP by the inegakarýyoblastic cell line MEG-01 in the presence and absence of PMA. 
I 11.1nian tI octal forebrain (i HB) was Lised as a positive control and expressed all SNARE 
complex accessory proteins. Control reactions (no RT) were performed in parallel. in 
the absence of cDNA. 
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MEG-01 HEL HB 
-PMA +PMA -PMA +PMA 
dab 
ý 
GAPDH 44%Wq=NW ammo 
SNAP-23 --Oo- 
GAPDH quwqs* %% 
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Figure 3.3: Western blot analysis of SNARE complex proteins in megakar"'oblastic 
cell lines, MEG-01 and HEL, in the presence and absence of PMA. Protein 
expression of SNARE complex proteins SNAP-23. Syntaxin 4 and VAMP was 
determined by western blot analysis in i-negakary ob last' c cell lines. MEG-01 and HEL, 
in tlic presence and absence of PMA. Hurnan brain lysate was used as a positive control 
and expressed all SNARE complex components. 
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MEG-01 
Figure 3.4: Immunofluorescent localistaion of SNARE complex and accessorv 
proteins in the megakaryoblastic cell line, MEG-01 in the presence and absence of 
PMA. Protein expression of SNARE complex proteins SNAP-223. Syntaxin 4 and 
VAMP, and accessory proteins VGLUTL VGLUT2 and synaptotagmin were 
determined by ininiunocytochernistry in the i-negakaryoblastic cell line, MEG-01 in the 
presence and absence of PMA. The protein of interest is indicated by green fluorescence 
(FITO and the blue fluorescence (DAPI) shows the micleus ofthe cell. Bar indicates 
30pni- 
0, 
Ö: 
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Immunocytochemistry of %IEG-01 cell cý-tospin preparations was used to determine 
the localisation of the SNARE complex proteins in MEG-01 cell_"ý cultured in the 
absence and presence of lOOnM PMA for 7-1 hours (Figure _33.4). 
Primary antibodies 
recognising the SNARE complex proteins. VAMP. SNAP-23 and syntaxin 4. and 
accessory protein synaptotagmin were used conjunction \\ith a FITC conJugated 
secondary antibody to localise the expression of the SNARE complex proteins ill 
MEG-01 cells (green positive staining). The location of the nucleus was identified bý 
counterstaining with the nuclei dye DAPI (blue). Control samples, in which non- 
specific mouse and rabbit IgGs were used as opposed to the primary antibody exhibits 
the level of background staining. 
3.3.2 Expression of SNARE complex and associated proteins by primary 
murine megakaryocytes 
3.3.2.1 mRNA expression of SNARE complex and accessory protein genes by 
primary murine megakaryocytes 
R'I'-PCR analysis was used to determine expression of SNARE complex and 
associated proteins by primary murine megakaryocytes, derived from the bone marrow 
froin the femora and tibiae of mice, followed by exposure to TPO conditioned media 
for ') days and separation on a BSA gradient. Gene-specific primers to mouse brain 
VAMP2, VAMP3 (cellubrevin), syntaxin la, syntaxin 4. SNAP-25, SNAP-233, NSF. 
Rab ')a, Rab 3b, Rabphillin 3a, Munc-13, Munc-18-1, a-SNAP and 7-SNAP were 
designed and specific PCR programmes were used (Primer details are listed in Table 
'). 1). The RT-PCR amplification products for SNARE complex and associated proteins 
fi-oin priniai-y inurine megakaryocytes NN, -ere identical in size to those found in the 
\\1101C mouse brain positive control and sequencing identified the products as the 
ocncs of interest (Fil-ILII"C ). 5 and Figure 3.6). No product was observed for SNAP-25. Z71 - C"N 
ýis observed in the NI FG-O I cell line, nor for syntaxin I a. 
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MoMK MoB 
Figure 3.5: mRNA expression of SNARE complex protein genes by primary 
murine megakaryocytes. RT-PCR was used to demonstrate the mRNA expression of 
SNARE complex proteins Cellubrevin. SNAP-23, Syntaxin 4 and VAMP by primary 
niurine rnegakaryocytes (MoMKs). Whole mouse brain (MoB) was used as a positive 
control and expressed all SNARE complex cornponents. Control reactions (no RT) were 
pci-formed in parallel, in the absence of cDNA. 
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Figure 3.6: mRNA expression of SNARE complex accessory protein genes b", 
primary murine megakaryocytes. RT-PCR was used to demonstrate the mRNA 
v proteins NSF. Rab 3a, Rab 3b, Rabphilin 3a, expression ot'SNARF complex accessor. I 
t INC- 13. NIUNC- 18. (x-SNAP and y-SNAP by primary murine megakaryocytes 
(MoMKs). Whole mouse brain (MoB) was used as a positive control and expressed all 
SNARF complex accessory proteins. Control reactions (no RT) were performed In 
parallel. in the absence of cDNA. 
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3.3.3 Expression of SNARE complex and associated proteins by primary 
human megakaryocytes from CD34' umbilical cord blood (UCB) 
cells 
3.3.3.1 mRNA expression of SNARE complex and accessoill, protein genes ki, 
primary human megakaryocytesftom CD34+ umbilical cord blood 
cells 
R'I--PCR analysis was used to determine expression of SNARE complex and 
TC B CD 4+ associated proteins by primary human megakaryocytes. derived from II 
cells, following exposure to 25ng/ml TPO for 14 days. Gene-specific primers to 
human brain VAMP2, VAMP3 (cellubrevin). s\, iitaxin la, syntaxin 4. SNAP-25, 
SNAP-23, NSF, Rab 3a, Rab 3b. Rabphillin 33a. syntaphilin, Munc-131. Munc-18-1, 
u-SNAP, and 7-SNAP and RT-PCR programmes used in these experiments %\-cl-c 
identical to those previously descri II -) _1 II 
'bed in section 3.3.1.1 and listed in Table 1. The 
RT-PCR amplification products for the SNARE complex and associated proteins from 
pi-Imary human megakaryocytes were identical in size to those found in human foetal 
cerebellums (Figure 3.7 and Figure 3.8). No product was observed for SNAP-2-5 as 
seen previously with MEG-01 cells and primary murine megakaryocytes. No products 
wci-c observed for Rab3b or Rabphillin 3a in primary human megakaryocytes. Human 
foetal cerebellum was used as a positive control for all RT-PCR reactions. 
3.3.3.2 Protein expression of SNARE complex and accessorl, proteins in 
primary human megakaryocytes derivedftom CD34 
;_ 
umbilical cord 
blood cells 
SN,, \Rl: complex proteins. SNAP-23. VAMP and syiitaxin 4, were showil to be 
expressed at the proteiri level in priiiiary human megakarvocytes by western blot 
aiialvsis (1`1(_, ure _33.9). N': \%1lP expression in primary 
human me(_, akaryocytes identified 
a molecular species at approximately 68kDa, instead of the expected size of 
3 approximately l8kDa. ., \s stated in section -1.3.1.21, previous experiments have 
identified a 68 kDa barid. probably correspondiii(-, to a VANIP/synaptophysin 
licterodimer. suggesting this isoform is present in primary human megakarýocytes. 
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HMK HB 
Figure 3.7: mRNA expression of SNARE complex protein genes by primary 
human megakaryocytes derived from UCB CD34+ cells. RT-PCR was used to 
demonstrate the n1RNA expression of SNARE complex proteins SNAP-23. Syntaxin 
I a, Syntaxin 4 and VAMP by primary human megakaryocytes (hMKs)- Human foetal 
forebrain (1113) was used as a positive control and expressed all SNARE complex 
components. Control reactions (no RT) were performed in parallel, in the absence of 
cDNA. 
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Figure 3.8: mRNA expression of SNARE complex accessory protein genes by 
v human megakarvocytes derived from UCB CD34+ cells. RT-PCR was used primar. 
to demonstrate the rnRNA expression of SNARE complex accessory proteins NSF. Rab 
3a. UNC-13. MUNC-18. (x-SNAP, y-SNAPand sNntaphilin by priman, hurnan 
rilegakarvocytes (hMKs). Hurnan foetal forebrain 
ýHB) was used as a positive control 
and expressed all SNARE complex accessorý- proteins. Control reactions (no RT) ývere 
performed in parallel. in the absence of cDNA. 
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Figure 3.9: Western blot analysis of SNARE complex proteins in primary human 
megakaryocytes (VIK). Protein expression of SNARE complex proteins SNAP-2D. 
Syntaxin 4 and VAMP was deten-nined by western blot analysis in primary human 
niegakarvocytes. Human brain lysate (HB) was used as a positi i ive control and expressed 
all SNARF complex components. GAPDFI loadino controls were carried out. r-I 
90 
Chapter 'ý 
The 68kda band vvas also identified in the human brain lysate control (Calak-os and 
Scheller. 1994a; Washbourne et al., 1995a; Edelmann et al.. 1995b: Rov et al.. 2004a). 
3.3.4 In vivo expression of SNARE complex and accessory proteins in rat 
bone marrow megakaryocytes 
Expression of CD61. a megakaryocytic cell surface marker. was used to identit'N' the 
megakaryocytes within the rat bone marrow sections. shown by the brown staining in 
Figure 3.10. Immunohistochernical staining of rat bone marrow sections was used to 
identify core SNARE complex and accessory proteins in bone marroxv. The t-SN,, ýR]Hs 
SNAP-23 and syntaxin 4 were identified in a cytoplasmic location with in the 
megakaryocytes. The v-SNARIý. VAMP however \\as not identified in rat bone 
marrow. The accessory protein Munc-18-1 was also identified in the in vivo rat bone 
marrow megakaryocytes (Figure 33.10). Munc-18-1 was observed throughout the 
cytoplasm as well as at the plasina membrane. Control samples, in \\ hich non-speci 1-ic 
mouse and rabbit IgGs were used as opposed to the primary antibody exhibits the level 
ol'background staining. 
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Figure 3.10: Rat megakaryocyte expression of SNARE complex proteins in vivo. 
Protein expression of SNARE complex proteins SNAP-23 and Syntaxin 4, and associated 
protein Munc- 18 were determined by irnmunohistochermstry in ex vivo rat bone marrow 
sections. The megakaryocytic cell surface marker CD61 was used to identify 
niegakaryocytes within the bone marrow. Brown DAB staining indicates the proteins of 
interest. 
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3.4 Discussion 
Glutamate signalling was once thought to ha\ c been restricted to the mammalian C. VS. 
where it is involved in aspects of normal brain function including learning. cognition 
and memory (Ottersen and Storm-Mathisen, 1984b: Fonnum, 1984b: CollinErridgc and 
Lester, 1989b; Headley and Grillner. 1990b). Flo\\ever. the binding of glutarnate to 
glutamate receptors has been identified in non-neuronal tissues such as bone, spleen, 
lung, liver pancreas, heart, stomach. testis and intestine (Hosli and Hosli Q9') .I 'b, 
Vernadakis, 1996b; Steinhauser and Gallo, 1996b, Shelton and McCarthy. 1999a: 
Conti and Weinberg, 1999b; Bergles et al., 2000a, Skerry and Genever, 2001c: Hinoi 
et al., 2004b). The finding that bone marrow megakaryocytcs express open channel 
forming N-methyl-D-aspartate (NMDA) - type (Ylutamate receptors suggests that 
glutamate signalling mechanisms are important in these cells (Gcnc\'cr et al., 1999f, 
Hitchcock et al., 2003g). This was the first evidence of glutamate signalling in 
megakaryocytes and identified a potentially novel mechanism for regulatino 
megakaryocytopoiesis and platelet release. To further investigate the role of glutamate 
signalling in i-negakaryocytopolesis, this chapter addresses the megakaryocytic 
expression of the SNARE complex and key accessory proteins required for SNARE- 
dependent glutamate release in the CNS, for the first time. 
RT-PCR, western blot analysis and immuno local i sati ons have identified of several 
components of the core exocytotic complex in megakaryocytic cells, including t7 
sN-iltaxin la, syntaxin 4, VAMP2, cellubevin/VAMP'). which are the same as those 
identified and characterised in the CNS as mediators for glutamate exocytosis (Sollner 
ct al., 199')c; Chapman et al., 1994b; Bennett, 1995b, Hanson et al., 1997a; Betz et al., 
1997c, Robinson and Mal-tin, 1998b, Sassa et al., 1999a; Zinsmaier and Bronk, 2001 a-, 
Chen and Scheller, 21001a; Richmond and Broadie, 2002b). Expression of the 
t-SN,, \IZF SNAP-25, which is normally present in the SNARE complex in neuronal 
cells. N\as found to be absent from both i-negakaryocytic cell lines and primLII'\ 
nicoakarvocytes at the inRN,, \ level. liowcN-cr its homologue SN. -\P--"I was shown to 
be exj)rcsscd. Despite arnino acid sequence similarities, SNAP-2233 and SN., \P-25 have 
becii shown to be expressed in different tissues. is expressed predominantly 
in the bi-Lim. NOci-cas Ubiquitously expressed iii other human tISSLIC') SUCII 
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as heart, placenta. kidney. muscle. lung. liver and pancreas where it has been shown to 
be vital for membrane fusion and vesicle docking (Ravichandran et al., 1996b). 
Western blot analysis of VAMP expression in MEG-01 cells and HEL cells identified 
a molecular species at approximately 36kDa, instead of the expected size of 
approximately l8kDa. In previous experiments monomeric VAMP (18kDa). VANIP 
homodimers (')6kDa), and 68 kDa bands probably corresponding to a 
VAMP/synaptophysin heterodimers have been observed (Calakos and Schellel-, 
1994b, Edelmann et al., 1995a; Washbourne et al.. 1995b: Roy et al.. 2004b). 
Therefore it is likely that the molecular species identified in this study are \1 AMP 
homodimers. The monomer, homodimer and heterodimer can all be observed in the 
human brain lysate control. 
The identification of genes encoding multiple accessory proteins involved in targeted 
vesicular glutamate release, NSF, a-SNAP, 7-SNAP, Muncl8-1, Muncl3, and 
syntaphilin, by megakaryocytic cells, indicates that the essential components required 
for neurotransmitter release in the CNS were present in these cells. For example in 
lininc 18-1 null mice there is a lack of neurotransmitter release, suggesting Munc 18 has 
an important role in vesicle docking and fusion (Verhage et al., 2000b), therefore it is 
sioiiificant that megakaryocytic cells express this protein and other regulatory proteins 
stich as Munc13 which aids the disassembly of the SNARE complex after exocytosis 
has occurred. 
Megakarvocylic cells also expressed genes encoding key regulatory proteins, 
synaptotaginin, Rab3a, Rab3b, and the Rab3a binding protein rabphilin 3a, providim, 
cvideiice for Ca -dependent glutamate exocytosis from megakaryocytes. In 
inegakaryocytes Rab')a, a neuronal rab protein, and Rab3b, a non-neuronal rab, ý\Cre 
identified in both the MEG-01 cell line and the primary murine megakaryocvtes, 
lio\\cvcr only Rab')a was identified in primary human megakaryocytes. The 
cxprcssion of these Rab proteins and the Rab-33 binding protein rabphilin-3a, provide 
evidence that the SNARE-dependent olutamate release pathway in megakarvocytes is 
rc(pilýitcd In a sinii1ar fasluon to that obsci-ved in the CNS. 
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In neuronal cells, voltage-gated Ca channels are required for the rapid Influx of Ca-+ 
to mediate a fast response to an incoming stimulus. leading to neurotransmitter release. 
Voltage-gated Ca-'+ channels contain a long intracellular linker which associates with 
synaptic proteins such as synaptotagmin. a tight interaction between presynaptic Ca 2- 
channels and the SNARE complex is essential for stabilising neurotransmitter release 
(Zamponi, 2003). The identification of synaptotagmin 1. the putative Ca2_ sensor that 
drives SNARE complex formation in neuronal cells in the megakaryocý tic cell line. 
MEG-01. further supports the evidence for Ca 2- -dependent glutamate exocytosis by 
megakaryocytes. However, megakaryocytes are classified as non-excitablc cells and 
are not believed to express voltage-gated Ca2+ channels (Mahaut-Smith et al., 1999. 
Thomas et al., 2001 -, Mason and Mahaut-Smith. 2004). Therefore, these observations 
suggest that glutamate release mechanisms in megakaryocytes although similar, are 
different to those described for neurons. ) or that alternative 
Ca2+ trafficking pathwavs 
are involved. 
This chapter providcs the first evidence that megakaryocytes possess the relevant 
ri-iachinery to carry out SNARE-dependent glutamate release mechanisms. similar to 
those observed in the CNS at glutarnatergic synapses. These data support the previous 
findings that glutarnate signalling occurs in megakaryocytic cells (Genever et al.. 
1999e, Hitchcock et al., 2003f), and stig(,, ests a re ulatory role for glutamate in 9 
autocrine sumaling and signaling within the bone marrow microenvironment. 
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Evidence of vesicular glutamate 
00 
signalling and release in 
0 
megakaryocytic cells 
Identification of acidic vesicles usin- acridine orange staining in primar\ human meoakar'ýoc)tes, green 
fluorescence and red fluorescence co-localised in a nuclear region within the cell, and red fluorescence 
observed in the cytoplasin and periphery of the cells. 
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Chapter 4: 
4.1 Introduction 
Evidence of vesicular glutarnate signalling 
and release in megakaryocytic cells 
The identification of a megakaryocytic SNARE-complex and other vesicular proteins 
associated with glutamate release in neuronal cells. described in Chapter 31, provides 
the first evidence for SNARE-dependent glutamate release from megakaryocytic cells. 
These Findings and the characterisation of the megakaryocytic NMDA receptor 
suggest an important role for glutamate signalling in megakaryocyte maturation and 
platelet production and paracrine signalling within the bone marrox, ý- (Genever et al., 
1999d; Hitchcock et al., 2003e). Previous studies have also identified olutamate 
signalling in other cells of the bone marrow including osteoblasts and osteoclasts (see 
section 1.4). Osteoblasts have beeii shown to express SNARE and other vesicular 
proteins associated with glutaniate release in the CNS (Bhangu et al., 2001a, Bhangu 
et al., 2001e), and the functional glutamate transporter molecule EAATI (GLAST), 
which has been implicated in glutamate uptake in neuronal cells. has been identified in 
osteoblasts and osteoclasts (Mason et al., 1997c). From these findings it is possible to 
hypothesise that megakaryocytes, osteoblasts and osteoclasts may be responsible for 
()Iutamate release and recycling within the bone marrow aiding bone resorption and 
remodellino, and regulating megakaryocylopoiesis. L- 
Vesicular exocytosis is a fundamental process leading to the release of 
iieurotransmitter by the fusion of the vesicle and plasma membrane (as discussed in 
section 1.3.1 and section 3.1). Exocytosis occurs through distinct mechanisms, two of 
which havc been investigated are full fusion of the vesicular and plasma membranes 
leading to the collapse of the vesicle releasing the neurotransmitter (Heuser and Reese. L_ 
19733, SUdhof, 1995), and "kiss aiid run" exocytosis where the a transient fusion pore 
temporarily connects the lumen of the vesicle and the extracellular space releasilig, the 
neurotransrnitter without the collapse of the N, csicle which is then recycled (Ceccarelli 
et al., 1973): IIN Ic ct al.. 2000. Stevens and Williams, 2000. SUdhof. 2000). 
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Previously an enz%, me-linked fluorimetric glutamate release assay has been eillploN-ed 
in the study of neuronal glutamate release (Nicholls et al.. 1987a; Bezzi et al.. 2004) 
and has been modified for the study of glutamate release from osteoblastic cells 
((jenever and Skerry, 2001d). The assay is based on the principle that addition of 
glutamate dehydrogenase (GDH) and P-mcotinamide adenine dinucleotide phosphate 
(NADP -+ ) %vIII result in released glutamate being oxidised to u--ketoglutarate. resulting 
in the formation NADPH that can subsequently be determined fluorimetricallý. This 
assay was used in this chapter to determine the glutamate release capacity of 
megakaryocytic cells. 
Until recently, technical limitations prevented the investigation of exocytotic events in 
small synaptic vesicles, however the development of optical techniques to track 
vesicle recycling has allowed more extensive studies of small synaptic vesicle 
exocytosis and endocytosis broadening our knowledge of this subject (Betz et al., 
1992, Ryan et al., 1993; Sankaranarayanan and Ryan, 2000; Gandhi and Steveiis. 
2003, Aravanis et al., 2003c). In particular, the development of styryl clyes as 
fluorcscent molecules that label recycling vesicles have revolutionised the \\ýay in 
which synaptic vesicle recycling can be investigated. FM 1 -43 is one of the styryl dycs 
which have been used to investigate exocytosis and endocytosis from indi\, idual 
\, csicles (Aravanis et al., 2003a; Aravanis et al.. 2003b). Investigations carried out by 
Richards et al. (Richards et al., 2005a) using this technique suggest that two modes of 
c\ocytosis occur at the hippocampal synapses. The first a slow event, where a 
population of vesicles lose their dye with slow kinetics, mediated by "kiss and run" 
c\ocN, tosis, and the second a larger eN, eiit, where a population of vesicles lose their d%, c 
\\-Ith faster kinetics. mediated by the full collapse of the vesicle into the plasma 
niciiibrane (Richards et al., 2005b). These styryl dyes can therefore give a vital insight 
into c\ocytosis kinetics at the synapse. 
DLIrIII(I normal synaptic transmission, the excitatory action of released (, Iutamate is 
rapidly terminated due to its efficient removal from the synapse by glutarnate uptake 
systerns in (-, Iia and nci-vc terminals (Nicholls and Attwell, 1990, Clements et al.. 
1992). ', Ncuronal cells contain approximately 51-nM uflutamate in their cytoplasm. with 
tracellular glutaniate IcN c\ -cls of' approximately I to -'pM being reported (Beriveniste 
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et al.. 1984; Anderson and Swanson, 2000). It is crucial that extracellular glutarnate 
concentrations within the CNS are kept low, as excess glutamate Is highly neurotoxIc 
causing neuronal damage (Olney, 1971 - McCall et al.. 1979; Choi. 1988a). To reduce 
the risks of neurotoxicity within the C\S the metabolism of glutamate is 
compartmented by the blood-brain barrier. This essentially pi-e\-Cnts olutarnate from 
the blood plasma (where it is present in a higher concentration) entering the ("Ns. 
\\Iiere is at a lower concentration, therefore the majority of all glutamate \\-ithin the 
CNS is synthesised within its own boarders (Gruetter et al., 1994). Glial cells play an 
important role in the correct functioning of glutamatergic neurotransmission at the 
synapse (Hamberger et al., 1981, Erecinska and Silver, 1990). In particular, astrocytes 
are responsible for maintaining extracellular concentrations of glutamate at a low 
level. Astrocytes are non-excitable cells that are involved in the recycling and 
synthesis of glutamate with in the CNS. The levels of glutamate found in cultured 
astrocytes are much lower than those found in neuronal cells, due to conversion of 
glutamate to glutamine during recycling of the synaptically released glutamate by 
glutamine synthase during the glutamate-glutamine cycle (for reviews see Hertz et al., 
1999-, Nedergaard et al., 2002). The synthesised glutamine is released back into the 
extracellular space from the astrocyte into the synaptic cleft, where it is then taken up 
by nerve terminals and reconverted into glutamate by the enzyme glutaminase. This 
extracellular glutamine has no neurotransmitter action and cannot therefore activate 
cxcitatory amino acid receptors. The newly resynthesised glutamate is then ready to be 
released in a new round of synaptic transmission. 
Astrocytes and neuronal cells express high affinity, sodium-dependent excitatorv- 
arnino-acid transporters (EAATs), v, -hich as discussed in section 1.3.3 enable excess 
cxtracellular glutamate to be retrieved from the synaptic cleft after synaptic 
transmission has taken place leading to the termination of synaptic transmission. The 
rcrnovýil of glutarriate by these transporters prevents neurotoxicity and is Nrital in 
maintainino the integrity of the synapse and neurotransmission (Marcaggi and Attwell, 
'1004h). The identification of EA. ATs within the bone marrow suggests that ulutamate 
recycling rnaý- occur in a similar manner to that observed in the CNS. Here we 
inN cstigate the expression of these transporters in rnegakarvoc\lic cells, hypothesising 
that rnegakarvoc yfic cells rnaý- haNc a functional role 'ývith In the bone i-narro\\. 
recycling and relcýisino glutarnate maintainim-, the bone microenvironnient. 
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An important stage of the synaptic \-esicle cycle Is the regeneration of the synaptC 
%'esicies with in the nerve terminal, where vesicles are reloaded xvith neurotransmitter 
via specific vesicle transporters. for glutamate these are the VGLUTs (for a review ot, 
vesicular glutamate transporters please see section 1.3.4) (Maycox et al.. 1990). These 
transporters require a proton electrochemical gradient, ApH' for active transport of the 
neurotransmitter into the vesicle. This gradient is generated by proton ., \TPase,, of tile 
vacuolar type that electrogenically pump protons into the vesicle interior (MoriN Lima et 
al.. 1992-, Nelson, 1992; Schuldiner et al.. 199-5). In the absence of membrane- 
permeable anions. v-ATPases are able to generate an inside-positive rnernbrane 
potential (AT), which leads the accumulation of Cl- ions and an increase of anions 
entering the vesicle via chloride channels, decreasing the AT, and increasing ApH dLIC t-- 
to the net accumulation of HCL The ApH component of the Aýffl+ can drivc tile 
uptake of most neurotransmitters apart from glutarnatc. which sliows little or no 
sensitivity to ApH. A common property of all synaptic vesicles appears to be their 
acidification coincides with the loading of the neurotransmitter. 
The pl-l-sensitive dye acridine orange was used by Zoccarato et al. (Zoccarato et al., 
1999h) to monitor exocytosis and endocytosis in synaptosomes (Tabb et al., 1992a: 
Zoccarato et al., 1999g). It had been used in previous studies to detect acidification of 
syiiaptic vesicles, lysosomes, endocytotic granules and whole cells (Gluck et al., 1982; 
Bowman et al., 1988-, Tabb et al., 1992b, Hartinger and Jahn, 1993, Dell'Antone ct al., 
1995). Acridine orange is a weak metachromatic base, which is freely permeable due 
to unprotonated amine hoN\, -e\, ei- once it has entered an acidic synaptic \'csiclc it 
[)ccornes protonated and trapped with in the acidic compartments %\Ilere its 
accumulation and dimerisation leads to a change in its optical parameters ('Zoccarato et 
al., 19990. l, xocytosis of the neurotransmitter leads to vesicular alkalisation and the 
iieutralisation of acridine orange allowing it to cross the vesicle membrane, and a 
dccrcasc in acridine orange fluorescence. The study by Zoccarato et al. (Zoccarato et 
al., 1999e) indicated that the rates of synaptic retricval measured using acridine orange 
ere slightly faster than those observed usin(-, I-A 11 -43) dye (Ryan. 1996, Ryan ct al.. 
1996), Atliotioli acridinc orange does nionitor postendocytotic acidification of tlic 
vesicle during neurotransi-nitter loadiiio. indicating that the response to acridine ()ran(-, c 
Is as fast as that of the F\11-41 and' or that neurotransmitter loadiiig takes placcý s 
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immediately following synaptic vesicle retrieval (Zoccarato et al., 1999d). In this 
chapter acridine orange was used to visualise acidic vesicles within megakaryoc,, Iic 
cells supporting our evidence for SNARE-dependent glutamate release in these cells 
similar to that observed in neuronal cells. We also investigated the expression of 
VGLUT proteins with in megakaryocytic cells, these transporters as discussed 
previously were once considered brain-specific markers of glutamatergic neurons, 
their expression by these cells is important in investigating their glutamatergic 
phenotype. 
The aim of this chapter is to investigate whether functional glutamate signalling occurs 
with in megakaryocytic cells, focusing on release and recycling mechanisms within 
both megakaryocytic cell lines and primary megakaryocytes using the wel I-establ i shed 
methods discussed above. 
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4.2 Methods 
4.2.1 Acridine Orange Staining 
The acidic vesicles were stained with acridine orange (Sigma) at a filial concentratiorl 
of 5ýLg/ml in culture medium. After 15 min at 37C. the stain was removcý] by 
centrifugation at 1500rprn for 5 minutes and the cell pellet washed threc timcs Nvith 
I xPBS, and the cells were imaged by confocal microscopy using a Zeiss LS',,, \ 15 10 
meta on an Axiovert 200M. This experiment was repeated 3 times to ensure 
consistency of results (n=3). 
4.2.2 FMI-43 staining 
4.2.2.1 Preparation offibronectin coated coverslips 
l31-ni-n glass coverslips were first sterilised by immersion in 100% ethanol for 
30seconds, washed in sterile distilled water (dH20) and allowed to air dry. The 
coverslips were then placed in 24-well culture plates and coated with 200ý11 of 
"5ng/i-nl fibronectin (Sigma Aldrich), diluted in dH20overnight at 4'('. Fibronectin 
solution was then removed and the coverslips washed 33 times in dH20- 
4.2.2.2 FMI-43 labelling of megakaryocytic cells 
MFG-01 cells in the presence of lOOnM PMA and primary murine megakaryoc-N, tcs 
werc plated at 5x 104 CCIIS/CM2 onto sterile fibronecti n- coated coverslips and 
maintained in culture for 72 and 24 hours respectively. Medium was removed and the 
cclls \\, ci-c incubated for 5 minutes in Hank's buffered saline solution (HBSS) 
containino ImM CaCl,. Recycling vesicles were labelled, in ll\, c cells, using FMI-43i 
(NIOICCUlar Probes) ýit a final concentration of 10ýtM and incubated for various periods 
Lip to -)0 minutes. ., \ftci- these Incubation periods cells were washed in 
HBSS, fixed in 
4()o paraforrnaldcliý-de tor 5 minutes, mounted and N-ic\\cd under tAI illumination. For 
. periments. 
F\11-4' x\ýis added to \1F -01 cclis. incubated t'Or 20 dcstaining c\ 
I "' and then incubated for a further -30 to 60 minLites in 1111nutes. N\ashcd n 
1113SS 1 
I-All-43-fi-ce 1113'-, S. The cells \\'Cl'e thCII fi\CýL 111OUnted and \-icý\-ed under UV 
I ()-, 
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illumination. This experiment was repeated -3 times to ensure consistency of results 
(n=3) and a stop watch was used to ensure timings were accurate. 
4.2.3 RNA extraction, cDNA synthesis and PCR 
RNA was cxtracted and cDNA synthesised from MEG-01 cells and primarý- human 
megakaryocytes derived from CD34+ umbilical cord blood cells using, the method, ', ' 
described in section 3.2.1 and 3.2.2 respectively. and run on a specific PCR program 
designed for the individual primer set (see table 4.1 for primer sequences). The PCR 
products were then analysed by 1% TAE agarose gel electrophoresis, as described in 
section 3.2.3. 
4.2.4 Immunolocalisations 
Cytospin preparations and immunocytochernistry were carried out as described in 
section 3.2.4.1 and 3.2.4.2 respectively, using the MEG-01 cell line cultured in the 
presence and absence of lOOnM PMA, and primary human megakaryocytes derived 
1'rorn CD34' umbilical cord blood cells. See table 4.2 for primary and secondary 
antibodies used and concentrations. 
4.2-5 Western blot analysis 
Protein extraction, polvacrylamide gel electrophoresis and immunodetection were 
carried out as described in section -33.2.5, using the megakaryocytic cell 
line MEG-01 
ctiltured in the presciicc and absence of lOOnM PMA. See table 4.3 for primary and 
sccondarv antibodies used and concentrations. 
4.2.6 1 in munohistochem ist ry 
I-ssuc collection. cr\osectioning, mid pci-oxidasc sat i MII-I ions NN'crc carried out 
as clesci -'. 
". 6 LISIM, the tibiae and femora from adult nats. -ibcd in scction Table 4.4 
"I 10. ) 
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Protein Species Accession Forward Primer Product 
number Reverse Primer Size 
V(jl, [J'Fl I luman NM020309 F-5*-CiCCTC CCTCGCCGCTACATTATCG--, 718 
R-5'-C'GCCG, CCAGGGAGTGCTA-3' 
VOLUT2 I luman/Mouse AB032435 F-5'-TGGACATGGTCAACAACAGCA-3' -)8-5 
R-5'-GCATAGGAACCACAAAAGGAGGT-3' 
FAATI Human U03504 F-5'-GCiAAGGGCACAAACTGAAAACA-3' 431 
R-S'-CCACGGGGCATACCACAT-FA-3' 
FAA'F2 Human U03505 F-5'-AGGGCTTCTTCCGCT-FGGCATCTC-3' 489 
R-5'-CTCCGGCACCTCAGTCAGTCACAGTCCA-3' 
Table 4.1: Primer sequences, and product sizes for RT-PCR reactions 
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Primary Antibody Supplier Dilution Secondary Antibody Supplier Dilution 
Rabbit anti VGLUTI Synaptic 1.1000 Donke-v anti rabbit - Santa 1.200 
systems FITC Cruz 
Rabbit anti VGLUT2 Synaptic 1.500 Donkey anti rabbit - Santa 1-200 
systems FITC I 
Cruz 
Table 4.2: Immunocytochemistry primary and secondary antibody suppliers and 
concentrations 
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Primary Antibody Supplier Dilution Supplier Secondary Antibody Dilution 
Rabbit anti G L"I -I abcam 1: 500 Goat anti Rabbit - Vector 1: 1000 
HRP laboratories 
ý 
Mouse anti GAPDH Advanced 1: 800 Goat anti mouse - Santa Cruz 1: 1000 
Immunoche- HRP 
mical Inc I I I 
Table 4.3: Western blot analysis primary and secondary antibody suppliers and 
concentrations 
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Primary Antibody Supplier Dilution Secondar-, Antibod-, Supplier Dilution 
ýýabbit 
anti VGLUTI Syria 1: 1000 Goat anti Rabbit - Ptic I Vector I 
systems Biotinylated laboratories 
Rabbit anti VGLUT2 Synaptic 1: 500 Goat anti Rabbit - Vector 1: 200 
systems Biotinylated laboratories 
Goat anti EAAT- I Santa Cruz 1: 250 Horse anti Goat - Vector 1: 200 
Biotinylated laboratories 
Rabbit anti EAAT-2 Santa Cruz 1: 200 Goat anti Rabbit - Vector 1: 200 
Biotinylated laboratories 
Table 4.4: Immunohistochemistry primary and secondary antibody suppliers and 
concentrations 
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provides information on the primary and secondary antibod, es used and 
concentrations. 
4.2.7 Glutamate Release Assay 
Glutamate release was determined using an enzyme-linked fluorimetric assay based on 
previously published protocols (Nicholls and Sihra, 1986: Nicholls et al., 1987b) with 
some modifications (Genever and Skerry, 2001c). Cells were cultured prior to tile 
experiment as described in section 2.1.1. Before the assay MEG-01 cells, primary 
human megakaryocytes or primary murine megakaryocytes were plated at 5x1W 
cells/ml (100ýtl per well) in blackened 96-well plates (ýtclear. Greiner Labortechnik 
Ltd., Stonehouse, U. K. ) in release buffer pre-warmed to 37'C, containing NaCI (120 
i-nM), KCI Q mM), NaH2PO4 (1.25 mM), HEPES-Na (25 mM). Glucose (4 mM), 
W'('12 0 mM), Ca('12 (2mM). pH 7.4. The reaction was initiated bv the addition or 
release buffer containing GDH (40 U/ml, Sigma) and NADP+ (ImM), and tile plate 
was transferred to a Dynex MFX fluorescent plate reader equipped with a 
therillostated incubation chamber (370C). Fluorescence was monitored using excitation 
and emission wavelengths of 355 nm and 460 11111, respectively. For each assay. a 
standard curve was produced using known concentrations of exogenous glutamate. 
Test compounds were added to cell suspension 30 min before the addition of GDH and 
\\ecre maintained throughout the assay period. Glutamate release was normallsed to 
cell number. 
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4.3 Results 
4.3.1 Identification of acidic vesicles in megakaryocytic cells 
The pH sensitive dye acridine orange was used to determine whether syiiaptic vesicles 
were present in megakaryocytic cells. Acridine orange is an optical probe \\11ich has 
been shown to be trapped in acidic vesicles (Barasch et al.. 1991 ) wlicrc it exhibits 
different absorption and fluorescence properties depending on the form present. (Trecil 
fluorescence is observed when the dye is in its monomeric form in solution and when 
it is bound to double-stranded nucleic acids, and a red emission can be observed when 
acridine orange molecules accumulate with in the vesicles, either in the presence of 
single-stranded nucleic acids, or as crystals (Kapuscinski et al., 1982). Acidic \resicles 
were identified in the MEG-01 cell line, with red fluorescence observed around the 
periphery of the cells, and green fluorescence observed with in the nucleus of the cell 
(Figure 4.1 A). Acidic vesicles were also observed in primary human mepkaryocytcs, 
where green fluorescence and red fluorescence co-localised in a nuclear region within 
the cell, and red fluorescence observed in the cytoplasm and peripherý' of the cells 
(I 'i o Lirc 4.1 B). 
4.3.2 Identification of vesicular recycling in megakaryocytic cells 
FM 1 -43 staining and destaining has become an important method for studying 
\, cslcular turnover in neuronal cells. To determine whether vesicle recycling could take 
place in nicoakaryocytic cells, FMI-433 staining xvas carried out as described in section 
using the MEG-01 cell line treated with IOOnM PMA and primary murine 
meoakaryocytcs. The FMI-43 dye is incorporated into the ý'esicle membrane and acts 
ýis a fluorescent reporter of \, csicle recycling. The results sllow an accumulati\ýe 
iiici-casc in the aniowit of fluoi-csccnt dyc within the cells over a 20 minute incubation 
period. I'ollomiig reiiioN'al of FNII-4' dye froni the culture media cclis showed 
Ithin 60 IIIIIILItCS (Fi(-, Lire 4.21). 
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4.3.3 Identification of vesicular glutamate transporters (N'GLUTs) and 
glutamate transporters (EAATs) in mega ka ryocytic cells 
RT-PCR was used to determine i-nRNA transcription of vesicular glutainatc 
transporters (VGLUTs). responsible for packaging (Ylutamate into N-csicles. and 
glutamate transporters responsible for recycling glutamate (EAATs) in the 
megakaryocytic cell line MEG-01 and primary human megakaryocytes derived from 
(-'D34+ umbilical cord blood cells. VGLUTI was shoýý-n to be expressed at the nIRNA 
level by MEG-01 cells, treated in the presence or absence of IOOnM PMA for 72 
hours, and primary human megakaryocytes (Figure 4.3). however no transcription at 
the mRNA level was observed for VGLUT2 in these cells. 
Immunocytochernistry of MFG-01 cell cytospin preparations waS used to determine 
the localisation of the VGLUT proteins in MEG-01 cells cultured in the presence or 
absence of lOOnM PMA for 72 hours (Figure 4.4A). Primary antibodies recognising 
VGLUTI and VGLUT2 were used in conjunction with a FITC conjugated sccoliclary 
antibody to localise the expression of these proteins in MEG-01 cells (green positive 
staining). The location of the nucleus was identified by counterstaining with the nuclei 
dye DAPI (blue). Control samples, in which non-specific mouse 1(., Gs were used in 
place of the primary antibody exhibits the level of background staining. 
The glutarnate transporter protein EAAT-2 (GLT-1) was shown to be expressed in 
MFG-01 cells and HEL cells cultured in the presence or absence of IOOnM PMA for 
72 hours by \vcstern blot analysis, the anti-EAAT-2 antibody recognised a protein with 
the molecular weight of approximately 70 kDa (Figure 4.4B). consistent witil the 
kiiomi molecular \\-ci(., Iit of neuronal EAAT-2 (Pines et al., 1992b). 
Ii-niminol-iistochei-nical staining of rat bone marrow sections was used to identify 
VGLUTI. VOLUT-2. FAAT-l and Ey\., \T--' proteins in megakaryocytes in vivo- 
VOLt immunoreacti%ity was observed at the periphery of the cell, at the plasma 
membrane. vdici-c as VGLUTI. FAAT-1 (GLAST) and Ey\., \T-'- (GLT-1 ) were 
observed throughout the cell and at the periphery (Figure 4-5). Control samples. in 
112 
Chapter 4 
c 
-PMA +PMA HB 
hMK HB 
a) < ý- < F- < F- s- -ýe 
< w z < ()f z 
M z 0 z 0 z 0 m 
m C) 0 0 C) z Z C) Z z z 
VGLUT1 
VGLUT2 
GAPDH 
B 
+PMA -PMA HB 
I. - w 
-NC < 0ý < 01 1 < Oý a) z 
Q0 
- 
z 
00 
z 
C) 0 
oZ oZ 0 Z 
EAAT-1 
EAAT-2 
GAPDH 
VGLUT1 
VGLUT2 
EAAT-2 
GAPDH 
Figure 4.3: mRNA expression of vesicular glutamate transporter (VGLUIT) and 
glutarnate transporter (EAAT) protein genes by mega ka r. voc. vtic cell line, MEG-01, 
in the presence and absence of PMA (A, B) and primary human megakaryocytes 
(hNIKs) derived from CD34+ cord blood (C). RT-PC R was used to demonstrate ill RNA 
expression of VGLUTs- and EAATs in megakan, ocytic cells. Human foetal forebrain 
(11B) was used as a positive control and control reactions (no RT) were performed in 
parallel. 
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Figure 4.4: Protein expression of vesicular glutarnate transporter (VGLIJT) and 
glutarnate transporter (EAAT) proteins by megakaryocytic cell lines, MEG-01 and 
another megakaryocytic cell line, HEL, in the presence and absence of PMA. (A) 
Protein expression ofVGLUT I and VGLUT2vvere determined by immunocytochemistry 
in the niegakaryoblastic cell line NIEG-01. in the presence and abscence of PMA (green 
fluorescence (FITC) indicates the protein of interest. blue fluorescence is a DAPI nuclear 
stain). Bar indicates 30pni (B) Western blot analysis,, vas used to determine the expression 
of'l--'AAI'--" in NIEG-01 and HEL cells, in the presence and absence of PMA. Human brain 
Ivsate was used as a positive control and GAPDH loading controls are shown. 
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which non-specific goat and rabbit IgGs were used in place of the primary antibody 
exhibit the level of background staining 
The identification of the vesicular glutarnate transporters (VGLUTs) and the glutamate 
transporter proteins EAAT-1 and EAAT-2 in megakaryocytic cells indicates that 
megakaryocytes may participate in a release and recycle mechanisms with similarities 
to those observed in the CNS, this data is supports our observations that glutamate 
recycling occurs in megakaryocytic cells. 
4.3.4 Glutamate release by megakaryocytic cells 
An enzyme-linked fluorometric glutamate release assay was used to determine 
whether megakaryocytic cells had glutamate release activity. We demonstrated that 
primary murine megakaryocytes, primary human megakaryocytes and the MEG-01 
cell line spontaneously released glutamate. MEG-01 cells, differentiated with the 
phorbol ester PMA, were shown to release significantly more glutamate than cells 
without PMA (P<0.001) (Figure 4.6). Primary murine megakaryocytes released 23.4% 
significantly more glutamate than MEG-01 cells differentiated with IOOnM PMA for 
72 hours (P<0.001), and 13.5% more compared to human megakaryocytes (P<0.05). 
The levels of glutamate released by the MEG-01 cells and the primary human 
megakaryocytes were similar and differences in release were not significant (P>0.05) 
(Figure 4.7). To determine the effects of calcium and potassium on glutamate release 
from megakaryocytic cells, MEG-01 cells cultured in the presence and absence of 
IOOnM PMA were treated with or without 2mM CaC12 and/ or 60mM KCI (Figure 
4.8). There was shown to be no significant difference in the amount of glutamate 
released by MEG-01 cells, which had not been exposed to PMA, when treated or 
untreated with 2mM CaC12 and/ or 60mM KCI. MEG-01 cells treated with IOOnM 
PMA for 72 hours released 29% significantly less glutamate in the presence of 2mM 
CaCl-, than untreated controls (P<0.001). Exposure to a depolarizing concentration of 
KCI (60mM) in the absence of 2mM CaC12 lead to a 13% reduction in the amount of 
glutarnate released by PMA treated MEG-01 cells, however there was no significant 
difference in the glutamate released from cells exposed to 60mM KCI in the presence 
116 
Chapter 4 
m (0) 
-IC 
-IC 
-IC 
LO LO Lr) 
N T- CD C) 
C) C) 
,, 
ýxý /poseelej ejeweInIB solowu silaO f0 
4 
IL 
C) 
6 
ui 2 
n 
C) 6 
ui 
2 
.2 --p 
> 
0"Z: 
V) aQC o3 
ct 
--o t ýý -Zý 
..! ý 0 .2 
03 a) 
ai 
lcý 
03 
40 C,, j m 
03 
E 
C'4 
I'- 
a 
117 
-- -: 
Chapter 4 
N. S 
0.25 
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E 
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Figure 4.7: Glutamate release from the megakaryocytic cell line, MEG-01, primary 
mouse megakarvocytes (MKs) and primary human MKs derived from CD34+ cord 
blood cells. MEG-0 I cells. treated with PMA, released significantly more glutamate than 
cells treated without PMA. The primary murine MKs released 23.4% significantly more 
glutaniate than MEG-01 cells differentiated . N-ith lOOnM PMA for 72 hours 
(***=-P, 0.00l), and 13.5% more compared to human MKs (**=P<0.05). The levels of 
glutaniate released by the MEG-01 cells and the primary human Mks were similar and 
differcilces in release were non signiticant (N. S at P>0.05). The statistical test used was a 
one-Ný, -ay ANOVA. n=3, error bars indicate standard deviation. 
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of 2mM CaC12 (P<0.001 and P<0.05 respectively). Real-time glutamate release assays, 
supported these findings and showed that exposure to depolarising concentrations of 
KCI (60mM) reduced the amount of glutarnate released from PMA treated MEG-01 
cells by approximately 20% compared to controls in the absence of 2mM CaCl-, 
(Figure 4.9). Similar results were observed when primary human megakaryocytes 
were treated with or without CaC12 in the presence or absence of a depolarising 
concentration of KCI (Figure 4.10). There was shown to be no significant difference in 
the amount of glutamate released by primary human megakaryocytes when exposed to 
2mM CaC12 in the presence or absence of a depolarising concentration of KCI 
(60mM) (P<0.05). However, primary human megakaryocytes released 23% 
significantly less glutamate in the presence of 2mM CaC12 compared to untreated 
samples (P<0.001), and exposure to a depolarising concentration of KCI (60mM) in 
the absence of 2mM CaC12 lead to a 9% reduction in the amount of glutamate released 
by primary human megakaryocytes (P<0.05). 
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Figure 4.9: Real-time glutamate release from the megakar. yoc. ytic cell line, MEG-01 
in the presence of a depolarising concentration of KCI. Real-time glutamate release 
assays indicated a 2WIo reduction in glutamate release after exposure to potassium chloride 
(60n1M) compared to controls (n= 
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4.4 Discussion 
The pH-sensitive dye acridine orange has previously been used by Zoccarato et al. 
(1999) to monitor exocytosis and endocytosis of acidic neurotransmitter-containino 
vesicles in synaptosomes (Zoccarato et al., 1999c). as syi-iaptic \csicles appear to 
become acidified in response to neurotransmitter loading. After exocytosis. it has been 
demonstrated that accumulated acridine orange (red emission) is released from 
synaptosomes, leading to a prompt decrease in acridine orange fluorescence 0, reen 
emission) (Zoccarato et al., 1999b). Then in response to neurotransmitter loading there 
is a large uptake of acridine orange as the recycling synaptic vesicles become acidified 
(red emission) (Zoccarato et al.. 1999a). In both MEG-01 cells and primary human 
megakaryocytes we identified abundant cytoplasmic and peripheral vesicle 
populations, both green and red emissions of acridine orange were obscl-\, cd 
simultaneously in acidic vesicles, with red emissions predominantly at the cell 
periphery, indicating that both monomeric (green emission) and accumulated acridine 
orange (red emission) coexist with in megakaryocytic cells. These results indicate that 
acidic neurotransmitter-containing vesicles are present in megakaryocytic cells, and 
the presence of both red and green acridine orange fluorescence strongly suggest that 
vesicle recycling is occurring in i-negakaryocytic cells. 
IN 1-43, a styrylpyridinium dye. was first employcd by Betz et al. (1997) (Betz and 
Angleson, 1997b) to observe vesicle recN'clino in li\, ing nerve terminals, and has also 
becii used to investigate synaptosomal recycling in a range of species includino 
rnotisc. frog, and rat (Betz and Angleson. 1997a: Betz et al., 1997d; Kavalali et al.. 
1999, Fergestad and Broadie, -1001; 
Rheuben et al., 2004). The incorporation of the 
FNI 1-4-")' dvc into meoakarvocN-tic cells over the 20 minute time-course indicates that 
vcsicular endocytosis takes place within megakarvocytes. In destainuig, experiments 
N\1icn the dye is i-cmoved from the culture medium, the reduction Of fluorescence 
provides evidericc for vesicular cxocytosis. These data strongly indicate vcsicular 
i-ccvclin(,, in nic(-, akarvocytic cells. 
Vesicular olutaniatc transporters (VOLUTs) are reqUired for the storm-uc of -olutamate t, 
into sVnaptic vcsicIcs in glutaniate releasing ncurons. In MFG-01 cells and human 
I2 
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megakaryocytes the expression of VGLUTI was observed at the mRNA level bý- 
RT-PCR, whereas VGLUT2 expression appeared to be absent. However. both 
VGLUTI and VGLUT 2 were shown to be expressed at the protein level bý- 
immunocytochernistry in MEG-01 cells. VGLUTI and VGLUT2 were also observed 
in megakaryocytes in rat bone marrow sections. These results suggest that VGLUTI 
and VGLUT2 may play a similar role in megakaryocytes to that seen in the CNS, 
facilitating glutarnate packaging into vesicles prior to SNARE-dependent exocytosis 
(Morimoto et al., 2003b). Expression of the VGLUTI and VGLUT2 proteins was 
more prominent in differentiated MEG-01 cells, undifferentiated cells (cells not 
treated with PMA) showed weaker expression of the VGLUT proteins. This suggests a 
differentiation dependent VGLUT expression in these cells. It was also noticeable that 
the expression of the VGLUT proteins in both the primary and MEG-01 cells was 
prominent at the plasma membrane where the red acridine orange staining was 
observed, consistent with vesicular release activity identified in specialised zones in 
neuronal cells (Bellocchio et al., 1998b; Hisano et al., 2002a). The identification of 
'brain-specific' vesicular glutamate transporters (VGLUTs) in megakaryocytes 
highlights the glutarnatergic phenotype of megakaryocytic cells, as it has been shown 
in the CNS that no other component is required by neuronal cells to store and release 
of glutamate by exocytosis (Takamori et al., 2001 b; Herzog et al., 2001 b; Fremeau, Jr. 
et al., 2001 b; Varoqui et al., 2002e). 
The identification of the glutamate/aspartate transporter, EAAT-I (GLAST) and 
EAAT-2 (GLT-1) (Mason et al. 1997) within the bone marrow suggest a role for 
glutamate signalling in paracrine intracellular communications within the bone 
marrow microenviroriment. The identification of EAAT-I and EAAT-2 by RT-RCR, 
western blot analysis and immunohistochemistry in megakaryocytic cells strongly 
suggests that these cells may also play an important role in glutamate recycling with in 
the bone marrow microenviroriment, and further supports the evidence for glutamate 
sionalling from megakaryocytes similar to that observed in neuronal cells. L- 
Studies in cortical neurons and chrornaffin cells (neurosecretory cells) have shown that 
these cells release glutamate when stimulated by KCL a depolarising agent (Romero et 
al., 2003). To determine glutamate release actiNity in mep-akaryocytes a real-time 
olutarnate release assay was carried out. The results demonstrate that MEG-01 cells 
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released glutarnate in the presence of Ca2+. but that unlike neuronal cells. there was a 
decrease in glutamate release when the cells were depolarised with 60mM KCL These 
results suggest that in comparison to neuronal cells, megakaryocý-tes spontaneously 
released glutarnate and that glutamate release is negatively regulated by depolarisation 
with 60mM KCL The results from glutamate release assays indicate that MEG-01 cells 
differentiated with PMA release significantly more glutamate than untreated cells, 
suggesting that more mature megakaryocytes have the ability of releasing more 
glutamate. These findings are supported by the higher expression patterns of 
exocytotic proteins in PMA treated MEG-01 cells. The results also indicated that 
release of glutamate from megakaryocytic cells can occur in a calcium-independent 
manner, unlike neuronal cells where calcium influx in response to pre-synaptic cell 
depolarisation leads to the release of the neurotransmitter. Spontaneous release of 
glutamate was also identified in primary murine megakaryocytes and human 
megakaryocytes. Similar observations have been seen in osteoblastic cells which were 
also shown to spontaneously release glutamate at concentrations similar to those 
observed from neuronal cells (Genever and Skerry, 2001b). During differentiation, the 
concentration of glutamate released by osteoblastic cells was shown to be significantly 
increased, and unlike neuronal cells, osteoblastic K+-mediated depolarisation was also 
shown to inhibit glutamate release, as seen in the megakaryocytic cells suggesting that 
voltage-mediated megakaryocytic and osteoblastic calcium entry reduced the level of 
glutamate exocytosis. These findings suggest that glutamate signalling within the bone 
marrow may be similar yet distinct from that observed in neuronal cells. 
This chapter provides the evidence for functional glutamate recycling in 
megakaryocytic cells. Expression of glutamate transporters EAATs and VGLUTs 
strongly suggest that glutamate signalling pathways similar to those identified in the L- 
CNS occur in i-negakaryocytes. The release of glutamate by these cells also supports 
evidence for vesicular glutamate release mechanisms in megakaryocytic cells, and the 
findings that other bone marrow cells release glutamate indicates that glutamate may 
have an important role within the bone marrow microenvironment for 
i-negakaryocytopoiesis and bone remodelling via autocrine/paracrine interactions. 
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Manipulation of glutamate release 
from megakaryocytic cells 
1: 1 Tl b\ NIIEG-01 cells 48 hour,, after transformation. Green fluorescence , xpression of 
the pEGI--I'-\'('I, Ll - 
indicates EGFP fluorescence ot'VGLUTI and blue fluorescence indicates the nuclei of the cell. 
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Chapter 5: Manipulation of glutamate release from 
megakaryocytic cells 
5.1 Introduction 
The characterisation of the megakaryocytic SNARE complex (described in chapter 3) 
and the identification of vesicle recycling and glutamate release (described in chapter 
4) confirms the existence of components required for SNARE-dependent olutarnate 
release in megakaryocytes. These findings provoke intriguing questions regarding the 
function of glutamate release in megakaryocytes. Previous studies, as discussed in 
section 1.5.2,, have shown that antagonism of megakaryocytic NMDA-typc glutamate 
receptors leads to impaired megakaryocyte maturation and platelet production 
indicating an important role for glutamate signalling in megakaryocytopoiesis. In this 
chapter we used the glutamate release inhibitor, riluzole (discussed beloxv). to 
determine the functional role of glutamate release in megakaryocyte proliferation and 
differentiation. To further investigate the molecular mechanisms involved in 
rnegakaryocytic glutamate release and establish that megakaryocytic glutamate release 
occurs via a SNARE-dependent mechanism we transiently overexpressed the vesicular 
glutarnate transport protein (VGLUTI) 
(discussed previously in section 1.3.4 and 4.1) 
and clostridrial tetanus and botulinurn neurotoxins (discussed below) to determine 
their effects on glutarnate release from these cells. 
Glutarnatc. as discussed in section 1.3 is the major excitatory neurotransmitter in the 
CNS. cxisting at VCFV high concentrations in the brain. Normal (Tlutamate release is 
physioloolcally important for maintaining neuronal functions including learning and 
n1ei-nory formation or plasticity of the brain (Malgaroli and Tsien, 1992: Bliss and 
Coll ingridg, e. 1993b). A number of neuropatholoolcal conditions includii-ig, strokes and L- - C7 - 
chronic neurodcocnerative disorders such as HuntIng), ton's disease, Alzheimer's 
discýise. and anivotrophic lateral sclerosis (ALS) havc becn linked to abnormal 
olutainate i-clease in the CNS fliel-cfore iiiaintaining, low levels of presynaptically 
i-clcascd (iflutaniate is an important neuroprotective mechanism (Choi. 1988b. Meldrum 
Lind Garthwaitc. 1990. Choi and Rothman. 1990: Lipton and Rosenberg,. 1994). 
12, 
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Riluzole (2 - amino -6- [tr-ifluoromethoxy] - benzothiazole) is a neuroprotective agent 
with anticonvulsant, sedative and anti-ischaernic properties (Malgouris et al.. 1989b. 
Bensimon et al.,, 1994b; Doble, 1996; Wokke, 1996). Clinical trials have shown that 
riluzole prolongs the life of patients with ALS, a rapidly progressive and fatal disease 
characterised by the degeneration of both upper and lower motoneurons (Bensimon et 
al., 1994a; Lacomblez et al., 1996; Louvel et al., 1997; Dengler, 1999). As a result of 
these studies riluzole has been approved and is marketed for the treatment for patients 
with ALS. In addition,, it has also proved effective in animal models of Parkinson's 
disease, Chorea Huntington and cerebral and retinal ischaernia (Malgouris et al., 
1989a; Pratt et al., 1992; Mary et al., 1995; Barneoud et al., 1996; Lagreze et al., 
1999). 
The precise mechanisms by which riluzole produces its neuroprotective effects in ALS 
are unknown, however it is hypothesised that riluzole acts to limit glutamate 
excitotoxicity by inhibiting the release of glutamate from presynaptic terminals 
(Malgouris et al., 1989c; Martin et al., 1993a; Shaw and Ince, 1997; Centonze et al., 
1998). Several studies have shown that riluzole inhibits the release of glutamate from 
cultured cerebellar granule and hippocampal cells (Doble et al., 1992; Prakriya and 
Mennerick, 2000), and from slices of hippocampal area CAI (Martin et al., 1993b), 
and from cat caudate nucleus in vivo (Cheramy et al., 1992). Riluzole has also been 
shown to reduce currents through a wide variety of ion channels, including voltage 
dependent sodium channels (Stefani et al., 1997b; Zona et al., 1998a; Urbani and 
Belluzzi, 2000), high-voltage-activated calcium channels (Siniscalchi et al., 1997; 
Huang et al., 1997; Stefani et al., 1997a), potassium channels (Zona et al., 1998b; 
Duprat et al., 2000; Xu et al., 2001), and NMDA receptor-gated channels (Hubert et 
al., 1994). In this chapter we used riluzole to inhibit glutamate release from 
megakaryocytic cells to determine the functional effects of glutamate release on 
megakaryocyte proliferation and differentiation. 
As discussed previously in sections 1.3.1 and 1.3, regulated synaptic vesicle 
exocytosis at mature synapses involves the interaction of v-SNAREs VAMP- I and -2 
(Trimble et al., 1988b, Baumert et al., 1989a) and t-SNARES SNAP-25 (Oyler et al., 
1989b) and syntaxin (Bennett et al., 1992b). forming the SNARE-complex. Direct 
evidence for the involvement of the SNARE-complex proteins syntaxin and VAMP in 
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neurotransmission came from genetic studies carried out in DrosolAila and Cxle, (,, aii-ý 
(Broadie et al.. 1995: Schulze et al.. 1995: Deitcher et al.. 1998: OgaNA-a et al.. 1998: 
Salfee et al.. 1998). which identified SNARE-complex proteins as targets for the 
proteolytic action of clostridial tetanus and botulinum neurotoxins. blocking 
neurotransmitter release in the nerve terminal (Schlax-o et al.. 1992b; Montecucco and 
Schiavo, 1994a; Niemann et al.. 1994d). 
The clostridial neurotoxins are a family of structurally and functioiially related toxills. 
To date seven distinct botulinum serotypes have been identified BoNT/A. 11.1('. /D. 
+1', /F and /G. The various BoNTs are produced by distinct strains of Closti-itfiIIIII 
hotulinum, where as the tetanus neurotoxin (TeNT) is produced by a uniform group of 
Cletani (for reviews see Schantz and Johnson, 1992: Humeau et al.. 2000). These 
neurotoxins are composed of two di sulphide-I inked polypeptide chains (Helting et al.. 
1979; Weller et al., 1989; Weller et al.. 1991. Montecucco and ScliMvo, 1994b. 
Niemann et al., 1994b). The heavy chain (100kDa) mediates the specific bindillo of 
the toxin to the neuronal presynaptic membrane and the internalisation of the light 
chain (LC; 50kDa), which is responsible for the intracellular proteolytic activity and 
subsequent blockage of neurotransmitter release (Niemann et al., 1994a). 
Only three of the SNARE-complex proteins have been identified as targets of the 
closridial neurotoxins (for reviews see Niemann et al., 1994c; Montecucco and 
Schiavo, 1995). In mammals VAMP-1 and VAMP-2 are cleaved by TeNT, BoNT/B, 
/D, /F and /G. SNAP-25 by BoNT/A. IC and /E and syntaxin only by BoNTX (Blasi 
ct al., 199_33a, Rossetto et al.. 1994. Schiavo et al., 1995, Pellizzari et al., 1996; Foran ct 
al.. 1996c, Pellizzari et al., 1997. Cornille et al., 1997: Washbourne et al.. 1997b: 
Vaidyanathan ct al., 1999b). Previous studies have used targeted expression of TeNT 
and BoNT neurotoxins to investigate synaptic function and exocytosis in neuronal 
cells, providing useful tools for im-estigating SNARE-dependent neurotransmission in 
vitro and in vivo. Prcsyiiaptic expression of TcNT-LC in DI-osol)hil(I was shown to 
abolish c\ okcd ncurornuscular synaptic transmission, indicatinu, that Di-osoj)hihi 
\,,, \mp (11-. sN b) is susceptible to clcavaue by the TeNT-1-C, however spontaneous 
releasc still occurred in these TeNt-l-C expressing synapses. although at a reduced 
i-ate, indicating fliat is liot csscmial for spontaneous release (Swceiiev ct al.. 
1995). . \nothcr studý exaniined 
the effect on c\ocýtosis in PC12) endocrine cells 
I -)() 
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transienfly transfected with the Bo\T/Cl LC. which cleaves syntaxin and SN. AP-_" 
(Blasi et aL 1993b: Williamson et al.. 1996a. Foran et al., 1996b. Fisher and 
l3urgoyne, 1999c). The expression of the BoNT CI LC in PC12 cells resulted in a 
marked inhibition of both basal and evoked exocytosis providnig, a useful method for 
analysing the function of components of the exocytotic machinei-y (Fisllei- and 
Burgoyne, 1999b). These methods are used in this chapter to investigate the role of the 
SNARE-complex in megakaryocytic glutarnate release. 
-1 ' Megakaryocytopolesis, as discussed previously in section 1. . 1. 
is regulated bý- 
numerous cytokines, (Kaushansky et al.. 1986: Ikebuchi et al., 1987: Bruno and 
Iloffman, 1989; Bruno et al., 1989-, Avraham et al., 19921; Burstein et al., 199 
Kaushansky, 1995b), chemokines (Keller et al.. 1994), prowth factors (Han ct al., 
1992) and extra cellular matrix molecules (Mossuz et al., 1997), many of x\lilch are 
produced by the stromal cells within the bone marrow microenvironment (Dorshkind, 
1990; Eaves et al., 1991, Deryugina and Muller-Sleburg, 19931). The primary regulator 
controlling megakaryocytic differentiation and platelet production. as discussed in 
section 1.2.3, is thrombopoietin (TPO) (Kaushansky, 1995a). However. studies have 
shown that TPO ki-lockout mice produce normal megakaryocytes and platelets 
indicatino that other cytokines have an important role and are sufficient to support 
n1coakaryocytopoiesis in the absence of TPO (Bunting et al., 1997b). L- 
Hie establishment of co-culture systems with defined stromal cells and haernatopoietic 
progenitor cells has been vital in broadening our understanding of the role of stromal 
cells in the regulation ol'i-negakaryocytopoiesis. Haernatopoietic progenitor cells have 
been characterised and stromal cells have been shown to be derived from 
nic, sencliviiial stern cells (MSCs)- MSCs are pluripotent and have the abilitv to 
*fferentiate into a raii, -, c of mesenchymal tissues, ""Clf-renc\\ and di I includino bone. 
adipose. cartila, (-,. e. muscle, marrow stroma. tendon. and ligament. Isolation and CLIltLll*C 
of N1, S('s from human bone iiiarrow aspirates have demonstrated that these cells 
I ipotent potential follovving, display ýi fibroblastic i-norpholoov and retain their pluri I 
c. \tc, isivc culture expansion (Haynesworth et al.. 1996b. Majun-idar ct al.. 1998a: 
pitmiger et al., 1999b). 
I lie incage , Stticllc,, -; 
by Pittenger ct al. (Pitteii-gci- ct al.. 1999a) establis d the multil, 
l-)()tcntiaI of human '\I',, ('s (h'\1S('s) isolated fi-orn adult marrow in vitro. and it has 
13 0 
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been further demonstrated that these cells express various haernatopoietic cýlokines 
including IL-6, IL-1 1, LIF. SCF. and Flt'; /Flk2 ligand (FL) (Haynesworth et al.. 
1996a: Majumdar et al.. 1998b; Mbalaviele et al.. 1999): cell adhesion molecules such 
as WAM-1. F-selectin. and activated leukocyte cell adhesion molecule (ALCAM): 
and ECM proteins such as collagen I and fibronectin (Haynes"vorth et al.. 1992: 
Mosca et al.. 1996: Bruder et al.. 1997). These hMSCs also have the abilitv to 
maintain long-term culture-initiating cells (LTC-IC) in long-term bone marroXV Culture 
with (I'D34+ haernatopoietic progenitor cells and support both myelold and crythrold 
differentiation (Majumdar et al., 1998c). In the absence of exogenous cytokines, 
hMSCs have been shown to support megakaryocyte and pro-platelet formation (Cheng 
et al., 2000a), suggesting that the cytokines and other molecules produced by hMSCs 
are sufficient for sustaining megakaryocytopolesis and platelet formation, or 
alternatively MSCs may produce small quantities of TPO, which work with the MSC- 
produced cytokines to enable thrombopolesis to occur (Cheng et al., 2000b). Howcvcr 
the latter hypothesis is based on the idea that TPO is essential for this process to take 
place, a notion that is inconsistent with the observations that TPO knockout mice 
produce normal megakaryocytes and platelets (Bunting et al., 1997a; Cheng et al., 
2000c). 
Studies from our laboratory (personal communications, Dr Gary Spencer) provide 
cv1dence for glutamate signalling in MSCs. MSCs have been shown to release 
(, lutarriate into their extracellular environment and express the necessary molecular 
machinery required for vesicular glutamate exocytosis, including v-SNARE VAMP. 
t-SNARE SNAP-23, key accessory proteins Munc-18, Rab3A, Rab 3B and NSF, and 
\, csicular glutamate transporters VGLUTI and VGLUT2. They have also been shown 
to express functional glutamate receptors, AMPA and NMDA-type glutamate 
receptors (NMDARL 213, I-C and 2D), and antagonism of these receptors inhibits 
ostcooctiic dii'lerentiation of MSCs. These findings suggest that glutamate signalling t, 
has an important role iii NISCs and that the release of glutamate by these cells with Ili 
the bone i-narro\\ providcs a Source of agonist ((-flutamate) for receptor activation and 
p, II-acrine communications N\itliln the bone marrow. In this chapter we usc 
NISC-nic, -, akaryocN tic ccll co-cultUres to investigate the role of olutamate sionalling, 
\\. Itll In the bone marrow microenvirorlment. and to determine the cffects of glutamate 
on ostcoblast diflercntiation in \ itro. 
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5.2 Methods 
5.2.1 MTT viability assay 
To determine the effects of a glutamate release inhibitor. riluzole (Tocris). on 
megakaryocyte viability, MEG-01 cells (2 x 10ý' cells/ml) were cultured in 96 %\-ell 
plates with and without PMA for 72 hours in the presence of varying concentrations (0 
to 100ýtM) of the glutamate release inhibitor riluzole (dissolved in DMSO (Sigma)). 
For non-riluzole treated samples, an equivalent volume of DMSO was added. The 
niethylthiotetrazole (MTT) assay was then used to determine cell viability. After 72 
hours,, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Thiazol 
blue; Sigma) solution was added directly to the wells to give a final concentration of I 
mg/ml and the plates were incubated for a further 3 hours. The cells were lysed with 
acidic isopropanol (0.1 M HCI) and absorbances read at 570 nm. 
5.2.2 Annexin V-FITC Apoptosis detection kit (Sigma) 
To determine the effects of riluzole, on megakaryocyte apoptosis, MEG-01 cells (I x 
106 cells/nil) were cultured in 96 well plates with and without PMA for 72 hours in the 
presence of N'arying concentrations (0 to 100[iM) of riluzole (dissolved in DMSO 
(Sionia)). For non-riluzole treated samples an equivalent volume of DMSO was added. 
After 7_2 hours incubation. the cell suspension was washed twice with I xPBS. Cells 
\\-cre then resuspended in I xbinding, buffer at a concentration of approximately IX 106 
cclisl nil. 500jd of the cell suspension was transferred to a 1.5ml microcentrifuge tube. 
and 500j, Ll of the non-treated cell suspension to a second 1.5ml microcentrifuge tube 
(control). To each cell suspension 5ýd of annexin V-FITC and l0lLl of propidium 
iodide Nvas added. The tubes Nvcre incubated at room temperature for exactl-\ 10 
minutes in the dark. I'luot-escciice of the cells was determined immediately \\ ith a flow 
c\, tojj, ctc, -. Cells in early apoptosis stain Nvith the annexin V-FITC alone. ll\-c cells 
12 
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sho%% no staining by either propidium iodide or annexin V-FITC. and necrotic cells are 
stained by both propidium iodide and annexin V-FITC. 
5.2.3 Transmission electron microscopy 
MEG-01 cells were treated with and without IOOnM PMA. in the presence of 25PNI 
Riluzole for 72 hours. Cells were washed twice in IxPBS before bein(-, fixed ill 4"o 
paraformaldehyde/ 2.5% glutaraldehyde in IOOmM phosphate buffer (pH7.0) at rooill 
temperature for 90 minutes. Cells were then washed 3 times for 10 minutes in IxPBS 
and fixed for a second time in I% osmium. tetroxide for I hour on ice and washed 
twice for 10 minutes in IxPBS. The cells were dehydrated through graded ethanols. 
dried over a molecular sieve and washed twice in epoxypropane for 5 minutes. The 
cells were embedded in 60% epoxypropane/ 40% epon araldite for '10 minutes and 
were desiccated overnight in silica gel. Fresh epon araldite was added the next daý'. 
and was allowed to polymerise for 48 hours at 60'C. Sections were cut and stained 
with saturated uranyl acetate in 50% ethanol with Reynolds lead citrate and viewed 
using a transmission electron microscope (TEM, Tecnai 12 BioTwin. FEI). Samples 
were prepared by the Technology facility, University of York, for use on the TEM. 
5.2.4 Plasmid constructs and transfections 
5.2.4.1 Plasmid constructs 
pcDNA3.1- and pcDNA3.1/V5-HIS B were obtained from Invitrogen. and pEGFP-N2 
\vas obtained from Clontech. The expression construct pTNT, carrying actove tetanus 
toxin light chain (TeNTLC) gene, Nvas a kind gift from Dr S. Sweeney, Universlt\ of 
York. UK. This gene was directionally cloned into pcDNA3.1/V5-HIS B using EcoRl 
and Aliol restriction sites for use in mammalian cells. VGLUTI was directionallý- 
cloned into pEGFP-N-1 using the Bglll and Still restriction sites. Primers used to 
ociierate the VGLUTI constructs Nvere: 5'-ttagcagatctca o ()a(, cc(-, ccac cat- 31' and 
ý'-(lattac(, tc(, Lic,,,, (, a(, (lcacatgotct(-, tag-'i" and the rc%'crse primer contained a one base 
pair mismatch to mutate the translational stop codon and created an open reading 
t'l-allic In which EOFP protein is ftised to the C-terminus of VOLUTI to allow 
. pi-cssion of 
FGFP N\ thin tile transfectcý] cells. VGLUTI N\a.,, so directionally ex al, II 
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cloned into pcDNA3.1- using the Bg1I1 and KpnI restriction sites. In this case the 
primers used to generate the VGLUT I constructs Were: 
5'-ttagcagatctacaggagccgccaccat-3' and 5'-gattacggtacc(-, (-, (-Ya(-, gcacatg(-, tca(ita(-, -'ý". The 
botulinurn toxin construct pBoNT/C1 was a kind gift from R. D. Burgoyne and NNas- 
constructed as described previously by Fisher and Burgoyne, 1999 (Fisher and 
Burgoyne. 1999a). In brief, DNA encoding the botulinum toxin light chain was 
amplified by PCR using the following forward (5") and re\, erse (3)") primers 
d(ataggtaccatgccaataacaattaacaac) and d(tgcagggcccagtoat(, (lt(-, at(, (, t(-, at(icc 
respectively. These primers incorporated a Kpnl restriction site in the forward primer 
and an Apal site in the reverse primer to facilitate subcIoning in to the pcDNA') N'ector 
(Invitrogen), producing the pBoNT/C I construct. 
5.2.4.2 Trans rming Chemically One Shoig TOPIO Competent Cells I ofo 
(In vitrogen) 
Vials containing the ligation reactions were centrifuged briefly and placed on ice. One 
50ýtl vial of One ShoW cells for each ligation/transformation \N'as thawed on ice. Fach 
ligation reaction (I to 5ýtl) was pipetted directly into the vial of competent cells and 
mixed by tapping gently. The remaining ligation mixtures were stored at -20'C. The 
viAs were incubated on ice for 30 minutes before heat shocking cells at 37'C in a 
water bath for exactly 45 seconds. The vials were then immediately placed on ice and 
250[LI of pre-warmed S. O. C medium (Invitrogen) was added to each vial. The vials 
\\, ere then incubated at 37'C for exactly I hour with shaking at 225 rpm in a shakino 
incubator. From each transformation vial 50ýd and 100ýd was plated on separate, 
labeled LB-agar plates containing the appropriate antibiotic 100[tg/ ml ampicillin or 
ýOpo, ml kanamvc1n. The remaining transformation were stored at +4'C. Plates '\, ýCre 
incubated at 37'C overnioht. 
5.2.4.3 Growth of bacterial cultures in tubes 
, siliole colonics Nverc pickcd 
from Creshl% streaked selective plates and \\ci-c used to 
moculatc 5 nil of I. B medium containin-g, the appropriatc select*,, c -hese I antiblotic. I 
cultures NNcre then incubated o\ Ait at 7 Ith vigorous shaking at '2251-pill. 
1 '14 
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5.2-4.4 QIAprep@ Miniprep (Qiagen) 
The kit was used according to the manufacturer's instructions. In brief. bacterial cells 
were harvested by centrifugation at > 8000 rpm (6800 x g) in a table-top 
microcentrifuge for 3 min at room temperature. The bacterial cell pellet was resuspend 
250gl of Buffer PI and transferred to a microcentrifuge tube. 250gI of Buffer P2 Nvas 
added and mixed thoroughly by inverting the tube 4-6 times. 350gl of Buffer N3 was 
then added and mixed immediately and thoroughly by inverting the tube 4-6 times. 
The microcentrifuge tube(s) were centrifuged at 13,000 rpm (-] 7,900 x g) in a table- 
top microcentrifuge for 10 minutes. The supernatants were then added to a QlAprep 
spin column by decanting or pipetting, before centrifugation at top speed for 60 
seconds and the flow-through discarded. The QlAprep spin column was then washed 
by addition of 0.75 ml of Buffer PE and centrifuging for 60 seconds. The flow-through 
was discarded, and the tube centrifuged for an additional I minute to remove residual 
wash buffer. The QlAprep column was then placed into a clean 1.5 ml microcentrifuge 
tube and the DNA eluted by the addition of 50ýtl Buffer EB (10 mM Tris-Cl, pH 8.5) 
or water to the center of each QlAprep spin column, letting it stand for I minute 
before centrifugation for I minute. 
5.24.5 Plasmid DNA Transfection using Lipofectamine 2000 reagents 
(Invitrogen) 
MEG-01 cells were transiently transfected in 6-well plates using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer's instructions. The pGL3-luciferase 
plasmid (Promega) was used in transfection reactions to determine transfection 
efficiency. Prior to preparing DNA: Lipofectamine complexes, suspension cells were 
plated at 1.5xl 06 cells in 500ýtl of growth medium without antibiotics. For each 
transfection reaction, complexes were prepared as as follows: 4.7gg of sample DNA 
and 0.3ýtg of pGL3-luciferase plasmid were diluted in a total volume of 250PI of Opti- 
MEM`(' I Medium (Invitrogen) without serum and mixed gently; 20ýd of 
Lipofectamine TM 2000 were then added to 230gl of Opti-MEMS I Medium and 
incubated for 5 minutes at room temperature. After the 5 minute incubation, diluted 
135 
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DNA was added to the diluted LipofectamineT%l 21000 (total volume = 500 ýth. Tile 
complexes were mixed gently and incubated for 20 minutes at room temperature. 
After 20 minutes incubation 500 ýLl of complexes were added to each Nvell containin., Zý. 
cells and medium and mix gently. Cells were incubated at 37-C in a 5'o CO-) incubator 
for 48 hours prior to testing for transgene expression. 
5.2.5 Glutamate release assay for transiently transfected MEG-01 cells 
Glutamate release was determined using the enzyme-linked fluorimetric assay 
previously described in section 4.2.7. Before the assay MFG-01 cells transiently 
transfected with VGLUTL botulinum C or the tetanus toxin light chain were plated at 
5x 105 cells/ml (100ýd per well) in blackened 96-,, N-ell plates (pclear, Greiner 
Labortechnik Ltd., Stonehouse, U. K. ) in release buffer pre-warmed to 37"C. 
containing NaCl (120 mM), KCI Q mM), NaH2PO4 (1.25 mM), HEPES-Na (25 nIM), 
Glucose (4 mM), MgC12 0 MM), CIC12 (2mM), pH 7.4. The reaction xN, -as initiated by 
the addition of release buffer containing GDH (40 U/ml, Sigma) and NADP+ (I niM), 
and the plate was transferred to a Dynex MFX fluorescent plate reader equipped with a 
ffiermostated incubation chamber (37'C). Fluorescence was monitored using excitation 
and emission wavelengths of 355 nm and 460 nrn, respectively. For each assay, a 
standard curve was produced using known concentrations of exogenous glutamate. 
Intracellular glutamate concentrations were determined by the addition of 0.1% 
triton-X (Sigma), incubating the plate at room temperature for 20 minutes and 
monitoring fluorescence as previously in a Dynex MFX fluorescent plate reader. 
Glutaniate release was normallsed luciferase activity. 
5.2.5.1 Bright-Glo. Luciferase Assay System (Promega) 
I Flie BrIpht-Glo Iticilcrase assay \\as carried out accordino to tile ill all ufiact urer's t, - t7 
inStRICtIOlls. In white 96-\\cll plates 100[il of i-cagent was added to 100ýtl of the 
olutamate i-cleasc ýissav cell culture and incubated for illi I 
inutes at room tenlPeraturc 
to all()\\ complete cell 1ý sis and measured in a luminorrictcr. 
I 
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5.2.6 MEG-01 cell - Mesenchymal stem cell (MSC) co-cultures 
5.2.6.1 Isolation and Culture of Primary B. 11SCs 
Tissue culture plasticware and reagents were purchased from Invitrogen (Paisley. 
U. K.. http: //www. invitrogen. com) unless otherwise stated. Primary human hone 
marrow stromal cells (BMSCs) were isolated from femoral heads following informed 
consent (with kind authority from Harrogate District Hospital. Harrogate. 
removed during hip-replacement operations. The marrow surrounding the trabccular 
bone fragments was collected and grown in control medium (alpha minimum essential 
medium (a- MEM) containing 2 mM glutamax, 100 U/ml penicillin, 100 ýtg, iiil 
streptomycin, and 15% fetal bovine serum (FBS)) in 7 ý_CM2 flasks at --)'7'C 
in 5'o CO-, 
at 95% air atmosphere. After 7 days of incubation, the nonadherent cells were 
removed and medium was replaced every 3 days. On reaching confluency, the cells 
were subcultivated at a 1: 3 ratio and then cultured up to passage 15. For co-culture 
X 105 CM2 24 \N experiments MSCs were plated at I cells per in - -ell plates, and left 24 
hours to adhere to the cell culture plastic forming a monolayer. 
5.2.6.2 VGIMK-MSC Co-cultures 
To determine the influence of glutamate on the osteogenic differentiation of human 
inesenchymal stem cells (MSCs) VGLUTI over-expressing MEG-01 cells (VGIMK) 
and empty vector controls were parachuted onto MSC monolayers and allowed to 
form heterotypic contacts. MEG-01 cells were cultured and transiently transfected 
with the pEGFP-N2/VGLUTI and pEGFP-N2 vector (empty vector control) as 
prcN-iously described in section 5.2.4. After 48 hours the transiently transfected 
MFG-01 cells were adjusted to a cell concentration of 5x 104 cells/ml in control 
(, ciiic medium (control medium, supplemented vvith 10 nM medium or in osteo,., I 
dexamethasone, 50 [tg/nil L-ascorbic acid phosphate, and 5 mM B-Olycerophosphatc 
(Sig, iiia-Aldrich)) to induce osteogenic differentiation of the MSCs. 11111 of the cell 
Suspension was parachuted onto the MSC monolaýcrs and \\-ci-c incubated at '37C in 
0 CO, at 95ý o air atmosphere for 4 days. 
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5.2.6.3 Quantitative pNPP Alkaline Phosphatase Assay 
After 4 days of incubation the media was removed from the monola\ci- of \ISC-.,, - and 
MEG-01 cells was washed with 0.2M carbonate buffer (2: 1 vol: vol of O_'NI '. \a, CO-, 
and 0.2M NaHCO-,. pH 10.2). Cells were then lysed in 150ýtl of 0.1% triton in 0.22\1 
carbonate buffer and cells subjected to 3 cycles of fi-eeze'tha,, N-in(_, (-8(-)--C/ 'i'TC). 50pl 
of the cell lysates were transferred to a clear 96-well plate to measure alkaline 
phosphatase activity and 50ýtl were transferred to white-bottomed 96-well plates to 
calculate DNA content by pico green assay. 
5.2.6.3.1 Alkaline Phosphatase activity 
The cell lysates in each well were incubated with 50ýtl of 33mM p-nitrophenol (pNP) 
substrate (Sigma) in 3mM MgCl, in 60mM carbonate buffer at 37'C for up to 15 
minutes. The pNP standards were prepared as described in Table 5.1. and 100[11 added 
in triplicate to wells of the clear 96-well plate. The absorbance of tile samples and the 
standard curve was measured at 405nm on a Dynex MFX plate readcr. 
5.2.6.3.2 Quant-iVm Pico Green (Invilrogen) Assay 
DNA standards were prepared as described in Table 5.2 using I 00vtg/ml Salmon 
sperm DNA (I Omg/ml, Sigma) diluted in 0.1% Triton-X in 0.2M carbonate buffer and 
50ýtl added in triplicate to wells of the white-bottomed 96-well plate. The Quant-iTT"11 
Pico Green dsDNA reagent (Invitrogen) was diluted 1: 50 in TE buffer (10mM 
Tris-I ICL ImM EDTA, pH 7.5) and 50ýtl added to each sample/ standard. The plate 
\vas then incubated in the dark at room temperature with gentle agitation for 2 minutes 
before fluorescence was measured at 485nm excitation and 583nm emission on a 
Dviicx MFX fluorescent plate reader. The DNA content of the samples , vas 
determined using the DNA standard curve and alkaline phosphatase acti\-ity 
normallsed against DNA content. 
I8 
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Concentration pNP 
(RMOI/Ml) 
pNP (gl) 0.2M carbonate buffer 
0.5 20 380 
0.3 12 
-388 0.2 8 33 92 
0.1 4 196 
0.05 2 398 
0.025 1 '1199 
0.0125 0.5 3' 9 9.5 
0 0 400 
Table 5.1: Alkaline phosphatase assay pNP standard curve 
I -, () 
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DNA cone Volume of DNA Volume of 0.1% 1 
(Rg/mI) ([LI) Triton (tfl) 
Total 
4d) 
8 80 (ýd of I 00ýtg/ml stock) 920 1000 (A) 
4 500 of A 500 1000 (B) 
2 500 of B 500 1000 (C) 
1 500 of C 500 1000 (D) 
0.5 500 of D 500 1000 (E) 
0.25 500 of E 500 1000 
0 0 500 500 
Table 5.2: Pico green assay DNA standard curve 
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5.3 Results 
5.3.1 Functional effects of inhibiting glutamate release in mega ka ryocytes 
To determine the functional effects of inhibiting glutamate release on megakarýocý-tic 
proliferation and differentiation primary murine megakaryocý-tes and MEG-01 cells 
(treated with and without lOOnM PMA) were cultured in the presence of riluzole 
(glutamate release inhibitor) for 48 and 72 hours respectively. Figure 5.1 shows the 
morphological changes in the cells, and Figure 5.2 shows the results of an MTT assaý. 
used to determine the viable number of MEG-01 cells followin(2 riluzole exposure. A 
dose-dependent decrease in the numbers of viable cells , vas observed followill" 
riluzole exposure (P<0.001). As expected there Nvcre fewer cells in the cultures treated 
with PMA due to the inhibition of cell proliferation and promotion of cell 
differentiation (at the beginning of the experiment 2x 10 5 cells/ml Nvere added to each 
well for both PMA treated and untreated samples). These results \\-crc supported by 
the results of the Annexin V apoptosis assay. which indicated that there was an 
increase in apoptosis and necrosis on exposure to increasing concentrations of riluzole 
(Figure 5.3). 
I I'o further investigate the effects of inhibiting glutamate release on the morpholoply of 
the MEG-01 cell line, transmission electron microscopy (TEM) was carried out on 
cells treated with 215pM riluzole 
for 72 hours (Figure 5.4). The results from TEM 
show an increased number of cell N, "aCLIOles and fewer, smaller mitochondria in the 
cells treated with riluzole compared to the un-treated control cells (Figure 5.4). There 
\vas also evidence of platelet shedding in the control cells. which was not observed in 
riluzole-treated MI, G-01 cells (Figure 5.4). 
To determine the inhibition of glutamate release from megakaryocytic cells on 
exposure to riluzole, orlutarnate relcase assays were performed (as described previousk 
iri section 4.2.7) on '\11-'G-Ol cells (treated with and without lOOnM PMA) cultured in 
the prcsciice of a raiigc of riluzole concentrations (OpM to I 00ýM) for 72 hours. The 
I-C', UltS from glutarriate relcasc assays showed a dosc-dependent increase in the amount 
Of (-IlUtarnate released from MEG-01 cells treated x\Ith and without PNIA on exposure 
to I-IIII/Ole (Fi. 'ILII-C 
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Figure 5.1: Morphological changes in MEG-01 cells observed using light microscopy 
after exposure to riluzole. (A -Q cells treated with I OOnM PMA in the presence of 
I-IILIZOle (0.50 and I OOpM) after 72 hours incubation. (D - F) MEG-0 I cells treated without 
PMA in the presence riluzole (0,50 and 100pM) after 72 hours incubation, and (G-1) 
primary murinc nicoakarvocytes treated with 0 and 50pM riluzole after 24 and 48 hours 
shown in II and I respectively. 
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Figure 5.4: Morphological changes in MEG-01 cells visualised byTEM after exposure 
to riluzole. (A) Control M EG-0 I treated with PMA for 72 hours, showing distinct nuclear 
lobes (N). large mitochondria (arrows) and possible platelet formation (magnified area). 
(B) MEG-01 cell treated with PMA in the presence of 25pM riluzole for 72 hours, the cell 
appears to have a more distorted periphery than the control. contains many large vacuoles 
(astricks). and smaller mitochondria (arro\N- head). 
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5.3.2 Overexpression of VGLUT1 in megakaryocytic cells 
In the MEG-01 cell line overexpressing EGFP tagged VGLUTL the localisation of the 
protein was prominent at the plasma membrane of the cells. in a specific area as shown 
in Figure 5.6A, suggesting a potential 'synaptic zone' with in megakar\ocytic cells 
similar to that observed in neuronal cells. Glutamate release assays demonstrated that 
MEG-01 cells overexpressing the VGLUTI protein released 41% more (P<0.001) 
glutamate compared to empty vector controls (Figure 5.613). These cells XNCI-C also 
shown to contain 36% more (P<0.001) intracellular (Ylutamate. L- 
5.3.3 Overexpression of the tetanus toxin light chain (TeNTLC) and 
botulinurn toxin C (BoNT/Cl) in megakaryocytic cells 
To determine whether the SNARE complex is responsible for glutamate release from 
megakaryocytes, MEG-01 cells were transiently transfected with the TCNTLC and 
BoNT/C I which cleave VAMP and SNAP-25 respectively to disable vesicle i-ecycling 
by preventing the formation of the SNARE complex. The results of glutamate release 
assays indicated that the overexpression of the TeNTLC induced a 30% decrease 
(P<0.001) in released glutamate compared to empty vector controls (Figure 5.7A), 
whereas overexpression of BoNT/CI in MEG-01 cells showed no significant 
difference in the levels of glutamate released (P<0.001) compared to empty vector 
controls (Figure 5.7B). Western blot analysis of MEG-01 cells treated with and 
without lOnM tetanus toxin (Sigma) in the presence or absence of lOOnM PMA 
(1ý'i('Ure 5.8) showed that tetanus toxin significantly decreases VAMP expression in 
MEG-01 cells in the absence and presence of PMA (P<0.001), suo(, )estin, (y the 
reduction of' olutamate release from these cells is due to the proteolytic cleavaoc of 
VAMP. 
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Figure 5.6: Overexpression of VGLUTI in the MEG-01 cell line. (A) Expression of 
l, -CjFP-VGLUTl 
fusion construct in MEG-01 cells. EGFP-VGLUTI accumulated at the 
cell periphery (arrow head) and in discrete zones (asterisk) compared to empty vector 
controls. Bar indicates I Opm. 
(13) Usino olutaniate release assays ,a significant increase in the amount of glutamate 
released by MFG-01 cells overexpressing VGLUTI was observed compared to vector 
controls (***P<0.001). The statistical test used was a one-xvay ANOVA, n=3, error bars 
indicate standard deviation. 
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Figure 5.7: Glutamate release from MEG-01 cells overexpressing the tetanus toxin 
light chain (TeNTLQ and botulium toxin C (pBoNT/CI). (A) Overexpression of the 
TeNTLC in megakarvocytic cells significantly reduced glutarnate release by 30% compared 
to empty vector controls (***P<0.001). (B) Megakaryocytic cells overexpressing 
pBoNT/CI showed no significant difference in glutamate released compared to emptN 
vectorcontrols (N. S at P>O-001). The statistical test used wasaone-NA'avANOVA, n=3. error 
bars indicatc standard deviation. 
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Figure 5.8: Inhibition of SNARE-complex formation in megakaryocytic cells using 
tetanus toxin. (A) Western blot analysis of VAMP expression in the megakaryocytic cell 
line, MEG-0 1. in the presence and alýsence of I OOnM PMA following exposure to tetanus 
toxin (I 011M). 
(B) Densitonietry was used to quantify VAMP expression against GAPDH controls 
(* ** Pý, 0.00 1). The statistical test used was a one-way ANOVA. 
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5.3.4 Effect of MEG-01 cells overexpressing VGLUTI on the osteocrenic t! o 
differentiation of MSCs in co-cultures 
Previous studies in our laboratory (personal communication. Dr Gary Spencer) have 
shown, as discussed in section 5.1. that \ISGs express Components invol'kcd in 
regulated glutamate exocytosis and glutamate receptors AMPA and NMDA-type 
glutamate receptors. Here, co-cultures were used to investigate the influence of 
glutamate on the osteogenic differentiation of human mesenchynial stem cells 
(MSCs). Prior to co-culture, synaptic vesicle recycling was determined in MS('s usino 
FM 1 -43 staining, carried out as described previouslý- in section 4.2.2. The results show 
an accumulative increase in the amount of fluorescent dye within the cells over a 20 
minute incubation period. Following removal of FM 1 -43 dye from the culture media 
cells showed destaining within 30 minutes (Figure 5.9). In co-cLilture experiments 
VGLUTI overexpressing MEG-01 cells (VGIMK) and empty vector controls xvcrc 
parachuted onto MSC monolayers and allowed to form heterotypic contacts. After 
fours days of culture under osteogenic conditions, alkaline phosphatase acti\'ities wel-c 
shown to be 26% greater (P<0.05) in VGIMK-MSC co-cultures compared to MSCs 
co-cultured with empty vector MEG-0 I controls (Figure 5.10). 
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Figure 5.10: Osteogenic differentiation of human MSCs co-cultured with VGLUTI 
overexpressing MEC-01 cells. MSCs cultured in osteogenic medium showed a 
significant increase (***P<0.001) in alkaline phosphatase activity after 4 days incubation in 
CO-CUltUre with VGLUTI over expressing MEG-01 cells (VGIMK) compared to empty 
vector controls (EGFPMK). There was a significant difference in alkaline phosphatase 
activity observed bet, -\, een the osteogenic MSC-EGFPMK cocultures and the non- 
osteogenic controls (***P<0.001). However, no significant difference in the amount of 
alkaline phospliatase activity observed in NISCs cultured in non-osteogenic conditions (N. S. 
at p-0.005). The statistical test used was a one-way ANOVA. n=3, error bars indicate 
standard dcviation. 
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5.4 Discussion 
To determine the functional effects of inhibiting glutamate release on megakaryocytic 
proliferation and differentiation, the cells were observed after 72 hours of treatment 
with riluzole for morphological changes using light microscopy (I-M) and 
transmission electron microscopy (TEM), and viable cell numbers were determined 
using the MTT assay. In neurons riluzole inhibits glutamate release by blocking ionic 
influx via NMDA channels, voltage-sensitive Na 2+ channels, calcium influx and 
possibly interaction with G-proteins (Estevez et al., 1995d; Wang et al., 2004). It has 
been demonstrated that glutamate has a direct neurotoxic effect on isolated 
motorneurons, and that low concentrations of riluzole prevent cell damage induced by 
such glutarnate toxicity (Estevez et al., 1995c). 
After treatment with riluzole it was observed by LM that the number and size of 
MEG-Ols and primary murine megakaryocytes was reduced, these findings suggest 
that riluzole is toxic to megakaryocytes. The appearance of the cells from TEM 
suggests that riluzole also alters the morphology of the cells. The MEG-01 cells 
treated with 25pM riluzole for 72 hours displayed significant cytoplasmic 
abnormalities, in the form of large open vacuoles and smaller mitochondria. The 
presence of an abnormal cytoplasm and numerous large vacuoles is also seen in 
Bernard-Soulier Syndrome, a severe bleeding disorder, where the lack of GPIb-lX 
complexes results in thrombocytopenia and giant platelets (Nurden et al., 1997b). 
GPIb-IX complexes therefore have an important role in normal megakaryocyte 
maturation and DMS production. The data presented here suggests that glutamate may 
also play an important role in cell development and differentiation, and indicates that 
there is a possibility that the inhibition of glutamate release in megakaryocytes, may 
have an effect on megakaryocyte differentiation and platelet size and function. 
However this has yet to be determined in future studies. 
The observations made from TEM and LM are supported by the results from the MTT 
assay and the Annexin-V apoptosis assay, which suggest that glutamate release may 
be involved in megakaryocyte proliferation and/ or viability, as inhibition of glutamate 
release with riluzole leads to a significant reduction in viable cell numbers with an 
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increase in programmed cell death. However, this hypothesis presumes that the 
dose-dependent increase in glutarnate release observed from megakaryocy-tic cells 
exposed to riluzole was due to leakage of intracellular glutamate from cells 
undergoing apoptosis and the breakdown of the cell membrane, not that riluzole exerts 
its effects on megakaryocytes via another mechanism. Further investigations are 
required to determine whether riluzole inhibits glutamate release from megakaryocytes 
as seen in neuronal cells or acts via alternative pathways to affect cell viability. These 
results are interesting as the effect of riluzole on megakaryocytes appears to be toxic, 
the opposite effect to what is observed in neuronal cells, where it is neuroprotective 
(Estevez et al., 1995b; Wang et al., 2004). Similar observations were made when 
osteoblastic cells were treated with riluzole. Exposure to low concentrations of riluzole 
(I - 10ýM) lead to a reduction in osteogenic differentiation without affecting viability, 
however,, the addition of higher concentrations (ý! 25ýM) of riluzole, which usually 
have no effect on neuronal viability, resulted in high levels of osteoblastic cell death 
and apoptotic characteristics, including increased Bax/Bcl-2 ratio, membrane 
blebbing, chromatin condensation and DNA fragmentation (Genever and Skerry, 
2001a). Together these findings suggest that although glutamate is released by 
megakaryocytes and osteoblasts that the mechanisms of glutamate release in the bone 
marrow may be different to those seen in the CNS. Further work is required to 
investigate the role of glutamate on megakaryocyte survival. 
The localisation of EGFP-tagged VGLUTI in MEG-01 cells mirrored the 
immunolocalisation of the endogenous protein and the acridine orange staining of 
acidic vesicles (see section 4.3) again suggesting that there may be a 'synaptic zone' 
within megakaryocytes similar to that observed in pre-synaptic neurons. 
Overexpression of VGLUTI in the megakaryocytic cell line MEG-01 showed a 
significant increase in the amount of glutamate released compared to empty vector 
controls. These findings are supported by previous studies which have shown that 
over-expression of VGLUTI in cultured glutamatergic neurons increases the amount 
of glutarnate released at synapses (Wojcik et al., 2004). Also, overexpression of the 
Drosophila VGLUT. DVGLUT. in motoneurons was shown to increase vesicular 
glutamate release, leading to an increase in synaptic vesicle volume and a decrease in 
the number of synaptic vesicles released, to maintain normal levels of excitation at the 
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synapses (Daniels et al.. 2004b). These data confirm the specificity and importance of 
VGLUFY-clepenclent glutamate signalling in megakarvocytes. 
The light chain of the tetanus toxin (TeNT) neurotoxin, an exotoxin of Closti-idiuni 
tefuni. inhibits neurotransmitter release by proteolytically cleaving VANIP-2 bet,, veen 
Gln-76 and Phe-77. impairing synaptic vesicle exocytosis from neuronal cells (Link et 
al., 1992-, Schiavo et al., 1992a). Treatment of the megakaryocytic cell line MEG-01 
with TeNT lead to a marked reduction in the expression of VAMP-2. indicatnig, that in 
megakaryocytic cells TeNT is also able to cleave VAMP2, therefore preventing the 
formation of the SNARE complex. Transient transfection of the TeNT light chain in 
the megakaryocytic cell line MEG-01 significantly reduced the amount of glutarnate 
released from these cells compared to empty vector controls, confirmincy that 
proteolyic cleavage of VAMP2 in megakaryocytic cells inhibits glutamate exocytosis 
through SNARE-dependent mechanisms. 
The botulinum neurotoxin serotype C (BoNT/C) cleaves both syi1taxin I and 
SNAP-25 (Blasi et al., 1993c; Foran et al., 1996a, Williamson et al., 1996b). In this 
study we transiently transfected MEG-01 cells with the BotNT/CI light chain to 
determine its effects on exocytosis. The results indicated that unlike cells treated with 
the TeNTLC there was no significant reduction in glutamate released from cells 
overexpressing the BoNT/Cl compared to empty vector controls. These results 
support the findings from RT-PCR that megakaryocytic cells do not express one of the 
main targets of BoNT/C SNAP-25. expressing only its homologue SNAP-23. Previous 
studies have shown that SNAP-23 is either resistant to cleavage or is cleaved to a 
reduced exmit by the different BoNT serotypes (Washbourne et al.. 1997a, 
Vaidyanathan et al., 1999a), suggesting the megakaryocytic SNARE-complex is 
composed of SN.,; \I)--") and the other exocy-totic proteins, not SNAP-25. 
Mcoakarvocytic cclls N\ci-e also shown to express the other BoNT/C target syntaxin I 
hN R'I'-PCR and its hoinolopic syMaxin 4, ho\\cvci- studies have shown that syntaxin 
4 can not be clcaN-ed bv BoNT C (Hansen et al.. 1999). As glutamate exocvtosis was 
not diminished in niegakaryocytic cells using BoNT, "Cl it suggests that 
jjjc,, akar\oc\6c s\ntaxin I can not be cleaved or is cleaved to a reduced extent by 
13oN'I-, '('. or that syntaxin 4 which is also expressed by rnegakaryocytes and is resistant 
to clea\ agc by BoNl C replaces syntaxin I in the complex. 
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Co-culture studies using MSCs and NIEG-01 cells overexpressing VGLUTI have 
implicated megakarvocytic glutamate release in the regulation of bone marrow stem 
cell activity. The increase of glutarnate released from the VGLý_'_F] overexpressing 
MEG-01 cells was shown to increase the osteogenic differentiation of NISCS 
compared to the empty vector controls. These findings support observations from our 
laboratory (personal communication. Dr Gary Spencer) that osteogenic differentiation 
of MSCs is significantly inhibited by exposure to glutamate receptor antagonists 
(-'FM-2 and MK-801, which inhibit AMPA and NMDA receptors respectively. Also 
prolonged exposure of MSCs to AMPA agonists, glutamate or NMDA. has been 
shown to lead to an increase in viable cell numbers, indicating that olutamate 
signalling is vital to the differentiation and \'lability of MSCs. As \\-ell as expressing 
glutamate receptors, MSCs express the necessary machinery required for N-esicular 
glutamate exocytosis and ha\, e also been shown to release (-llutamate into theil, 
extracellular environment, these data are supported by findings in this study that 
functional synaptic vesicle recycling occurs in MSCs and suggest communication 
between the cells occurs via paracrine glutamate signalling. These results collectiN'ely 
sLiggest that glutamate signalling and communication between stem cells, bone cells 
and i-negakaryocytes in a paracrine and autocrine manner has a vital role within the 
bone marrow microenvironment in cell differentiation and cell viability. 
This chapter confirins the importance of glutamate release in megakaryocytic 
differentiation and cell viability, and confirms via the use of tetanus toxin that 
SNARE-dependent glutamate release takes place in megakaryocytic cells. Also the 
observations that modified megakaryocytic glutamate release activity is sufficient to 
Influence MSC differentiation through heterotypic cell interactions, indicates an 
important role for olutaniate sioiiallincy from these cells in paracrine interactions within 
the bone marrow microciivironnicnt. 
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Chapter 6: General discussion 
Megakaryocytes, as discussed previously in section 1.23. are derived from HSCs via a 
tightly regulated process involving numerous cytokines and haernatopoietic oroNN-th 
factors, ensuring the number of platelets released in to the circulation is adequate to 
meet physiological needs. Since the identification of TPO as a major I-C(-TLilator of 
megakaryocytopoiesis, the majority of research in this field has focused oil this 
hormone (Wendling et al.. 1994a; Lok et al., 1994a: Kaushansky et al.. 1994a, de 
Sauvage et al., 1994a). However, studies by Bunting , and colleagues 
have showii that 
normal platelets and megakaryocytes are produced in 0i, o in the absence of TPO 
(Bunting et al., 1997c), and other studies using transgenic mice deficient in the TPO 
gene and the c-mpl receptor indicated although these mice showed an 85',, 'o reduction 
iii peripheral platelet, marrow and spleen megakaryocytes, the iilcoakaryocytes and 
platelets that were present remained functionally normal (Gurney et al., 1994b; 
Kaushansky, 1995d; de Sauvage et al., 1996a), strongly suggesting that although TPO 
is important in the development of an adequate number of megakaryocytes and 
platelets, other factors must also be involved in platelet production. The data presented 
in this thesis presents additional evidence for a novel olutarnate signalling system that 
rcolulates i-negakaryocyte differentiation and platelet production, enhancing our 
knowledge of peripheral glutamatergic signalling. 
I Me main aim of this work was to further investigate and broaden our knowledge 
rcgardnio olutamate signalling in megakaryocytes as a potential novel regulator of 
ineoakarvocytopolesis and platelet production. Previous studies have sho""'ri that 
mcoakaryocytcs cxpress functional NMDA-type receptors, and antagonism of these 
i-cceptors leads to impaired megakaryocytopolesis and platelet production in 111'o 
indicatnig, an important role for glutamate signalling in these cells (Genever et al., 
1999c, Hitchcock et al., 2003d). The findings described in this thesis support this 
c\, idciice for neuronal-like olutamate signalling in megakaryocytic cells by identifying 
components required for regnilated vesicular exocytosis, vesicle recycling and 
endocvtosis. 
I; () 
Chapter 6 
6.1 Evidence for Pre-synaptic glutamate release mechanisms in 
megakaryocytes 
The data presented in this thesis has shown that niegakarvocytes express coiv 
exocytotic SNARE proteins identical to those identified and characterised in neuronal 
cells as effectors of regulated vesicular glutamate exocytosis. Identification of the 
v-SNARE isoforms VAMP-1 and Cellubrevin (VAMP-3) and the t-SNAIZEs 
SNAP-23 and syntaxins I and 4 in megakaryocytes confirmed the components 
required to form the ternary core exocytotic complex exist in megakaryocytic cells. 
In the CNS, out of the eight identified VAMP isoforms (VAMP 1-8) it is only 
VAMP- I and VAMP-2 which are thought to be exclusively associated with trafficking, 
events that involve regulated exocytosis (for review see Gerst, 1999a), whereas the 
other VAMP isoforms such as cellubrevin (VAMP3) appear to function in both 
constitutive and re ulated trafficking pathways in a variety of systems. Neuronal cells 91 
also express numerous t-SNAREs, to date, 16 syntaxin isoforms have been identified 
(excluding alternative spliceoforms) in mammalian cells, however only syntaxins IA, 
B and, possibly, C, as well as syntaxins 2 through 4 have been shown to localise to the 
plasma membrane and are thought to participate in exocytosis (Inoue et al., 1992a; 
Bennett ct al., 1992a; Bennett et al., 1993a; Jagadish et al., 1997b). In the CNS, 
syntaxin I is most cornmonly found to be associated within the SNARE complex 
involved in regulated glutamate release (Gerst, 1999b). SNAP-25 which exists in two 
%-ariants (SNAP-25 A and B) is the only synaptosomal protein to be associated with 
VAMP and syntaxin in the mammalian CNS (Oyler et al., 1989a; Chapman et al.. 
1994a: Bark et al., 1995a), howe\'er, a constitutively expressed form of SNAP-25, 
SNAP-_1') (Ra\'ichandran et al., 1996a), which is present in nonneuronal tissues is 
predicted to participate in both constitutive and stimulus-coupled exocytic e%'C11ts 
(Ra,., 'Ichandran et al., 1996d: Chen et al.. 1997, Sadoul et al., 1997: Leung et al.. 1998: 
Guo ct al.. 1999: Rea et al.. 1998). 
I'lic rcason for the difference between the number ot'symaxin and VANIP or SNAP-225 
isofornis is unclear. but suggcsts some promiscuitv in the , --SN., \RE-t-SN., \Rl-' 
ilitcr, ictions of the latter two families. Differential expression of these v-SNAREs and 
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t-SNAREs in megakarvoc\Ies SLH-Igests that N, -S\ARE-t-S\'--\RE promiscuity or 
functional redundancy may also function in this system and indicates that the 
trafficking and formation of the exocytotic SNARE complex relies on other 
mechanisms to enerate specificity as seen in neuronal cells within the CNS (Yan, -, et 9 
al., 1999; Brunger, 2001b). 
Evidence for SNARE-dependent glutamate release mechanisms in megakaryocvtes. 
similar to those observed in the CNS, is further supported by findings in this study that 
cells transiently overexpressing the tetanus toxin light chain (TeNTLC) (discussed iii 
Chapter 5) release significantly less glutarnate compared to empty vector controls, 
confirming that proteolyic cleavage of VAMP2 in megakaryocytic cells inhibits 
glutamate exocytosis through SNARE-dependent mechanisms. 
Furthermore, the identification of numerous accessory proteins ilivolved iii targeted 
vesicular glutamate exocytosis and endocytosis. NSF, a-SNAP, Y-SNAP, Munc 18-1, 
Munc 13, and syntaphilin, by megakaryocytic cells, indicates that the essential 
components required for neurotransmitter release in the CNS were present in these 
cells. These proteins are essential for neurotransmitter release throughout the CNS, for 
example in inuncIS-1 null mice there is a lack of neurotransmitter release resulting in 
complete paralysis at birth, suggesting Muncl8-1 has an important role in vesicle 
docking and fusion (Verhage et al., 2000c). The expression of Munc-18-1 expression 
is considered to be neuron- specific and it is therefore significant that megakaryocytes 
express not only this protein but also other regulatory proteins such as Munc 13 which 
aid the disassembly of the SNARE complex after exocytosis has occurred (Gerst. 
1999c, Verhage et al., 2000d). In addition, this work has also shown that 
mcoakaryocytic cells express key regulatory proteins, synaptotagmin. Rab3a, Rab3b, 
and the Rab3a bindino protein rabphilin 33a, providing evidence for Ca 2+ -dependent 
olutainatc exocytosis from megakarvocytes similar to that observed in the CNS. 
Identification of the 'braiii-specific' vesicular glutarnate transport proteins (VGI-t-'T-1 
and -2) in i-negakarvocytic cells. has provided evidence for uptake and packaging of' 
olutaniatc into synaptic N-csicles by megakaryocytes. These data have emphasised the 
udutaniatcroic plienotype' ol' inegakarvocytic cells highlighting the similarities in Ztý -- --- 
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exocytotic mechanisms for both intracellular vesicular packaging and glutarnatergic 
signalling between the CNS and megakaryocytes. The significance of these findings 
are supported by recent studies in the CNS which have shown that no other component 
is required to make a neuron store or release glutarnate by exocytosis upon stimulation 
(Brunger, 2001a; Varoqui et al., 2002f), a selectivity setting glutamate-releasing 
neurons apart from other neurotransmitting neurons and provides compelling evidence 
for a similar mode in megakaryocytes (Ni et al., 1994a; Bellocchio et al., 1998a; 
Takamori et al., 2000a; Bellocchio et al. 9 2000a; Fremeau, Jr. et al., 2001a). 
Modulation of vesicular glutarnate uptake in megakaryocytes by transiently 
overexpressing VGLUT-I was shown to have a profound effect on the magnitude of 
glutamate signalling by regulating the quantity of glutamate available for release. As 
observed previously in neuronal cells (Daniels et al., 2004a), overexpression of the 
VGLUTI protein lead to a significant increase in both packaged (intracellular) and 
released glutamate. This manipulation of glutamate signalling represents a possible 
target for drug development via the specific control of the megakaryocytic glutamate 
signalling pathway. 
The work presented above, provides compelling evidence for possible 'pre-synaptic' 
glutamate release mechanisms in megakaryocytes, these observations were supported 
by findings in this study that megakaryocytes release glutamate at similar or even 
greater levels than those released by depolarised neurons at glutarnatergic synapses. 
Elevated levels of glutamate release were observed in the megakaryoblastic cell line 
MEG-01 with a more differentiated megakaryocytic phenotype, after exposure to 
PMA, than undifferentiated cells. These results are supported by findings from 
RT-PCR and immunolocalisation experiments (see Chapter 3 and Chapter 4) which 
showed an increased expression of the SNARE complex and accessory proteins 
including the VGLUTs in differentiated cells compared to undifferentiated cells, and 
suggest that the glutamatergic phenotype is more prevalent in differentiated cells. 
However, unlike neuronal cells, glutamate release from megakaryocytes is 
spontaneous and is negatively regulated by depolarisation with 60mM KCI. 
Furthermore, the treatment of megakaryocytic cells with the glutamate release 
inhibitor riluzole lead to a significant reduction in viable cell numbers and an increase 
in apoptosis, suggest that glutamate release may be involved in megakaryocyte 
proliferation and/ or viability. These results are interesting as the effect of riluzole on 
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megakaryocytes appears to be toxic. the opposite effect to what is observed in 
neuronal cells. where it is neuroprotective (Estevez et al., 1995a: Wang et al., '004). 
The reason for the differences in the release mechanisms between me2akarvocytes and 
CNS system is unclear at this time. 
In addition to this evidence for \,, esicular exocytosis, it has also been observed that 
megakaryocytes participate in vesicular glutamate recycling mechanisms similar to 
those described in the CNS. Expression of excitatory amino acid transporters (1.. AATs) 
by megakaryocytes and observations of megakaryocN-tic vesicular recycling t-)\- 
I'MI-43 staining strongly suggests that these cells may also play an important role in 
glutamate recycling with in the bone marrow microenvironment, and further supports 
the evidence for glutamate release from megakaryocytes similar to that observed in 
neuronal cells. 
6.2 Implications of megakaryocytic glutamate signalling mechanisms 
Glutamatergic signalling, as discussed previously in section 1.4, has been identified in 
a variety of non-neuronal tissues including heart, intestine, kidney, pancreas, placenta. 
and inammary gland and bone (for reviews see Skerry and Genever, 2001a; Hinoi et 
al.. 2004c). Unlike the majority of these other pheripheral tissues, which consist of a 
Iloi-nogenous population of cells. the bone marrow where megakaryocytes are located 
consists of a heterogeneous cell population of both stem cells and mature cells. 
Therefore it is difficult to predict the precise impact that the data presented in this 
fliesis and in previous studies (Genever et al., 1999b. Hitchcock et al., 20033c) will 
lia\, c on the current understanding of peripheral glutarnatergic signalling, 
megakaryoc ytopoiesis and platelet production with in the bone marro%\ 
inicrociivironment. Ho\N-ever. the fact that glutamate release and active vesicle 
i-ccyclino has been observed in inegakaryocytes, as discussed above and in chapter 4, 
suooests that glutarnatc signalling from these cells could have significant implications 
on the modulation of NNIDA receptor-mediated megakarvocytopolesis (Ilitchcock ct 
al.. 2OWN and in establishing interactions between the rnegakaryoc\tes and 
(C, 1,1, - 1) positr\ e cells iii the 
bone marrow microeiivironment including osteoblasts 
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(Mason et al.. 1997b). Due to the ranty of megakarvoc%tes within the bone marroxv. it 
is possible with this current data to hypothesise that released (-Ylutamate would Lict 
predominantly on the cell from which it was released, in an autocrine fashion. helping 
to regulate megakaryocytopolesis via NMDA-type glutamate receptor activation. and 
recycling the released glutamate through the megakarvocytic EAAT-1 (GLAST) and 
EAAT-2 (GLT-1) receptors. These findings and the fact that bone marrow cells also 
release and recycle glutamate (Mason et al.. 1997a; Bhangu et al.. 2001a. Bhangu et 
al., 2001f) suggests that there is always a constant source of olutamate within the 
vicinity of the megakaryocytes for NMDA receptor activation and paracrine 
interactions with other bone marrow cells (Figure 6.1). Observations duriniý this study 
also suggest that glutamate signalling from megakaryocytes is sufficient to influence 
MSC differentiation through heterotypic cell interactions. providing further cNidence 
for the importance of glutamate signalling from these cells in paracrine interactions 
within the bone marrow microenvironment. 
The hypothesised autocrine glutamate signalling pathway in megakaryocytcs suggest 
that glutamate signalling may be a potential target for anti-platelet therapies for 
treatment of CVD as manipulation of megakaryocytic glutamate release preventing 
autocrine glutamate receptor activation and/or blockage of the mcgakaryocý'te 
NMDA-type v,; ould lead to impaired megakaryocytopoiesis and platelet production, as 
seen in previous studies (Hitchcock et al.. 2003a). However further work is required in 
this area, including the use of siRNAs and \'iral transfection to knock down 
components of the SNARF apparatus and accessory proteins to determine the 
functional effects of glutamate release on megakaryocytopolesis and platelet 
production, and the meoakaryocyte NMDA-tN, pe olutamate receptor signalling. 
6.3 Megakatyocytic 'prekvnaptic' glutamate release: 
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Figure 6.1: Hypothesised role of megakaryocytic glutarnate release in the bone 
marro-w microenvironment. Hypothesised autocrine glutamate signalling i I in 
meoakaryocytic cells (NIKs) and the possible regulation of megakaryocyte 
differci-itiation via interactions between gl utarnate-re leasing megakaryoctyes and 
olutamatc-releasing bone marrow cells expressing the glutarnate transporter EAAT-2 C" 
(GlA'- I) and glutaniate receptors (Modified from Spencer et al., 2006). 
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(1-onnum. 1984c) there have been numerous studies demonstrating the importance of 
glutamatergic signalling in aspects of normal brain function including learnin, _,. 
cognition and memory (Ottersen and Storm-N lathisen. 1984a. Forinum. 1984d: 
Collinjidge and Lester, 1989a; Headley and Grillner. 1990a). 
In comparison to our understanding and knowledge about glutamate signalling ill the 
CNS. our understanding of glutamate signalling in peripheral tISSLICS IS Still ill Its 
infancy, with the signalling mechanism in megakaryocýles less well characterised than 
that in other cell types. This thesis significantly advances our understanding and 
supports the previous findings. namely the identification of the megakaryocyýtic 
NMDA-type glutamate receptor, for megakaryocNle glutarnatergic signalling and 
suggests glutamate release from these cells may have an important role in paracrille 
interactions within the bone marrow microenvironment. 
To conclude, it is clear that megakaryocytes are an important source of glutamate in 
the bone marrow microenvironment and operate similar molecular mechanisms to 
those observed in the CNS to ensure regulated vesicular glutamate exocytosis. This is 
the first evidence for glutamatergic exocN*totic mechanisms iii megakaryocytes and 
suggests an autocrine activation mechanism for the megakaryocytic NMDA-type 
glutamate receptors influencing megakaryocytopoiesis and platelet production; and 
paracrine interactions with other cells within the bone marrow. 
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Abbreviations 
AA arachidonic acid (not the first time this is used) 
ADP adenosine diphosphate 
AMPA ct-amino-3-liN, droxN--5-meth,,,, 1-4-isoxazole propionate 
ANOVA analysis of variance 
BFU-MK burst forming unit megakaryocyte 
BFU-E/MK burst forming unit-erythrold / megakaryocyte 
BMSC bone marrow stromal cells 
BNPI brain-specific Na+-dependent inorganic 
transporter I 
BSA bovine serum albumin 
cAMP cyclic adenosine monophosphate 
cDNA complementary DNA 
CFU-GM CFU-granulocyte-macrophage 
CFU-MK Colony forming unit megakaryocyte 
CHD coronary heart disease 
CHO Chinese hamster ovary 
CML chronic myeloid leukaemia 
CNS central nervous system 
CVD cardiovascular disease 
DAB 3,3'-diaminobenzidine 
DAG diacylglycerol 
D-AP5 D+) -2 -amino -5 -pho sphonopentano ic acid 
dH20 distilled H20 
DMS demarcation membrane system 
DNISO dimethyl sulphoxide 
DN, k deoxý-ribonucleic acid 
Mase deo xv ri bonLic I case 
1) N PI differentiation-associated BNPI 
(INTP deoxyriborILICleotide triphosphate 
DTT dithiothreitol 
EAAT cxcitatory amino acid transporter 
phosphate 
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Abbreviations 
EDTA ethylenediaminetetraacetic acid 
ETB Ets binding sequence 
FBS foetal bovine serum 
FGFP fibroblastic growth factor P 
FITC fluorescein isothiocyanate I 
FN fibronectin 
FOG friend of GATA 
GAP GTPase activating protein 
G-CSF granulocyte colony stimulating factor 
GAPDH glyceraldehyde-3 -phosphate dehydrogenase 
GDH glutamate dehydrogenase 
GLAST glutamate/aspartate transporter 
GLT-I glutamate transporter- I 
GNI-CSF granulocyte macrophage colony-stimulating factor 
GP glycoprotein 
GSH glutathione synthase 
GTPase guanosine triphosphatase 
HBSS Hank's buffered salt solution 
HEL human erythroleukaernia 
"IV human immunodeficiency virus 
HSC haernatopoietic stem cell 
IgG immunoglobulins G 
IL interleukin 
INIDNI Iscove's Modified Dulbecco's Medium 
IP3 inositol triphosphate 
KA kainate 
kainate [21 S- (2 a. _3b, 
4b)]-2-carboxyl-4-(l -methy1ct1-iciiyl)-3- 
pyrrolidinaecetic acid 
k1) kilobases 
kDa kilodalton 
LPIS liposaccharide 
LIF 1CLikaemia inliibitory factor 
LT C- IC lon, --terril culturc-initlatino cells 
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Abbreviations 
LTP long-term potentiation 
m meter 
ýL micro 
M molar 
MACS magnetic activated cell sorting 
mGIuR metabotropic glutamate receptors 
min minute 
MK-801 5-Methyl-10, ll-dihydro-5H-dibenzo-[cc, 6] cyclohepten-5,10- 
imine 
ml millilitre 
mRNA messenger-ribonucleic acid 
MTT methylthiotetrazole 
n nano 
NADP+ P-nicotinamide adenine dinucleotide phosphate 
NADPH P-nicotinamide adenine dinucleotide hydrogen phosphate 
NF-E2 nuclear factor-erythrocyte 2 
NMDA N-methyl-D-aspartate 
NR NMDA receptor 
PAF platelet-activating factor 
PBS phosphate buffered saline 
PDGF platelet-derived growth factor 
PF4 platelet factor 4 
PI propidium iodide 
P13-K phosphatidylinositol--' 3 -kinase 
PKC protein kinase C 
PLC phospholipase C 
I'MA phorbol myristate acetate 
13SD-95 postsynaptic density-95 
RANK figand receptor activator of NF-kB 
RNA ribonucleic acid 
RNase nbonucleasc 
rpm rcN olutions per minutes 
RT-PCR i-c\ erse transcriptase polymerase chain reaction 
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Abbreviations 
SCF stem cell tactor 
'., ý'D S sodium dodecyl sulphate 
ARNAs small interfering RNAs 
SNARE soluble N-ethyl maleimide-sensitive factor attachment protein 
receptors 
v-SNARE vesicle-SNARE protein 
t-SNARE target-SNARE protein 
TBE Tris-borate EDTA 
TEM transmission electron microscopy 
TGFP1 transforming growth factor PI 
TPO thrombopoietin 
TRIS tri (hydroxy) methyl aminomethane 
UCB umbilical cord blood 
U. V. Ultraviolet 
VGLUTI vesicular glutamate transporter I 
VGLUT2 vesicular (, Iutamate transporter 2 
VWf von-Willebrand factor 
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